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Abstract of the Dissertation
Defining Gastric Epithelial Cell Population Dynamics at Homeostasis and Following Injury
by
Joseph Burclaff
Doctor of Philosophy in Biology and Biomedical Sciences
Developmental, Regenerative, and Stem Cell Biology
Washington University in St. Louis, 2019
Professor Jason C Mills, Chair

Gastric diseases affect many people around the world, yet surprisingly little is known
about the basic dynamics of gastric epithelial cells. Loss of acid-secreting parietal cells has long
been observed to precede pre-cancerous gastric metaplasias like Spasmolytic PolypeptideExpressing Metaplasia (SPEM), yet no signaling component from dying parietal cells has yet
been implicated in initiating the metaplastic responses. Also, experiments pulsing 3H-thymidine
and or examining intracellular components suggest that gastric mucous neck cells are short-lived
transient intermediates between the gastric stem cell and mature zymogenic “chief” cells, yet
specifics about this transition remain elusive. Here, we develop a novel mouse line and new
techniques for tracing gastric cell lines to further probe these interactions.
To identify the changes in parietal cell signaling upon injury which lead to chief cell
dedifferentiation and the appearance of SPEM, we bred mice expressing the human diphtheria
toxin receptor solely in parietal cells. Injection of diphtheria toxin specifically kills parietal cells
through apoptosis. Surprisingly, while the parietal cells died in similar numbers to those in mice
x

treated with tamoxifen, no SPEM or chief cell dedifferentiation was observed, and proliferation
only increased through the neck, with minimal proliferation in the base. We also showed that
SPEM can still arise if we inject tamoxifen or DMP-777 after the parietal cells are already killed
via diphtheria toxin. These experiments indicate that chief cell dedifferentiation is not simply
triggered by the loss of parietal cells, nor are dying parietal cells necessary for acute drugs to
initiate metaplasia. However, the signal which initiates the metaplasia remains unknown.
Furthermore, we studied the dynamics of long-lived cells in the mouse stomach using a
modified BrdU pulse-chase protocol. Published reports describing gastric epithelial cell
population dynamics have relied on continuous infusion or relatively short pulse-chases of DNA
markers such as 3H-thymidine. Here, we pioneer a new technique, pulsing BrdU throughout our
normal tamoxifen injury regimen to label nearly all cells in the unit, allowing us to chase for
months and track long-lived label-retaining cells. Following our pulse of tamoxifen and BrdU,
we find that nearly two thirds of chief cells retain label even through a 9-month chase, indicating
that they are either longer-lived than expected or that chief cells slowly divide to maintain their
own population without being replaced by newer cells from higher in the unit. We also find
subpopulations of label-retaining neck cells and parietal cells exist after a 9-month chase,
shedding more light on their population dynamics. To further test whether neck cells give rise to
chief cells, as others have reported, we administered a short BrdU pulse followed by various
chase lengths and found that most neck cells do not directly give rise to chief cells, indicating
that neck cells likely have a functional, as yet unidentified purpose, other than acting as a
precursor to chief cells. Finally, we show through additional tamoxifen and Helicobacter pylori
injury that long-lived chief cells give rise to acute and chronic SPEM cells and find that SPEM
cells can directly redifferentiate back into chief cells upon recovery from injury. Altogether, we
xi

suggest for the first time that chief cells may be a stable population in the gastric unit, largely
maintaining their own census at homeostasis and in injury independently of neck cell transitions
or parietal cell status.

xii

Chapter 1: Introduction

The following section is modified from a review published in Disease Models & Mechanisms
Burclaff, Joseph, and Jason C. Mills. "Plasticity of differentiated cells in wound repair and
tumorigenesis, part I: stomach and pancreas." Disease models & mechanisms 11, no. 7 (2018):
dmm033373.
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1.1

Introduction to plasticity

The series of sequential cell fate choices governing how normal, adult differentiated cells arise
from their precursors has been well delineated over the last decades. The opposite process, in
which cells dedifferentiate to reacquire progenitor properties, though noted by pathologists over
a century ago (Adami, 1900) and demonstrated by occasional, pioneering studies only reentered
the scientific mainstream with the demonstration a decade ago by Yamanaka and others that
multiple adult cell types can be induced to return to pluripotency (Takahashi and Yamanaka,
2006). Since then, research has expanded to also examine the native capacity of mature cells in
vivo to reverse their differentiated state in nearly all tissues (Mills and Sansom, 2015; Tata and
Rajagopal, 2016). The plasticity of cells in a tissue manifests in multiple ways: stem cells (SCs)
can interconvert to other SC populations, mature cells can dedifferentiate to recapitulate the
earlier stages of their ontogeny, and mature cells can transdifferentiate to mature cell types of
different lineages (Jopling et al., 2011).
Cellular plasticity may be key to regeneration following large-scale injury, yet a tissue’s capacity
for plasticity may also carry an inherent potential for adverse consequences like cancer. Here, we
will discuss how plasticity may help refine a long-standing model for how cancer begins. The
well-established ‘multi-hit model’ postulates that tumors arise as long-lived SCs accrue
mutations necessary for tumorigenesis (Fearon and Vogelstein, 1990). Recently, though, it has
become clear that individual stem cells in mice may not be as long-lived as traditionally believed
(Lopez-Garcia et al., 2010; Snippert et al., 2010; Baker et al., 2014), raising the question of how
a single SC could accumulate multiple mutations over the course of years (Mills and Sansom,
2015). Even if the SC population remains stable over time, intestinal SCs are relatively shortlived, as SCs divide frequently and stochastically, commonly jostling each other out of the niche
2

in mice (Lopez-Garcia et al., 2010; Snippert et al., 2010) and in humans (Baker et al., 2014).
Although some intestinal SCs tend to be longer-lived (Ritsma et al., 2014) and SCs with
oncogenic mutations hold a competitive advantage over wild-type SCs in the intestinal crypt
(Snippert et al., 2014), the question remains whether SCs are the sole population that
accumulates tumor-inducing mutations over the lifetime of an organism. Moreover, in organs
such as the pancreas that lack a constitutive SC, other cell types must accumulate such
mutations.
Increasing evidence shows that plasticity can be involved in the origin of cancers in numerous
epithelial tissues (Giroux and Rustgi, 2017) and even astrocytes (Friedmann-Morvinski and
Verma, 2014). This dissertation examines the gastric chief cells, which undergo plasticity
following injury and may accrue the ‘multiple hits’ defined by Kinzler and Vogelstein
(Vogelstein and Kinzler, 1993) and initiate tumor formation. Similar events in the intestine,
pancreas, and skin are further reviewed in the following works (Burclaff and Mills, 2018a;
Burclaff and Mills, 2018b). A more complete understanding of the process of mutation
accumulation may further our understanding of how every organ produces tumors with a
multitude of phenotypes that vary not only from person to person but even within a single
person: tumors initiated by cells stem cells or cells at various stage of differentiation or
dedifferentiation may contribute to this diversity (Visvader, 2011; Song and Balmain, 2015).
Plasticity can allow post-mitotic cells to re-enter the cell cycle, and we have proposed that cycles
of proliferation and quiescence can favor tumorigenesis as accumulated mutations can become
fixed in long-lived differentiated cell populations. We have termed this the ‘cyclical hit’ model
in which cell lineages cycle through phases of dedifferentiation and redifferentiation, allowing
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for the accumulation and unmasking of mutations in long-lived cells (Figure 1) (Mills and
Sansom, 2015; Saenz and Mills, 2018b).
Before discussing the work done for this dissertation, we survey the current state of plasticity
research in the stomach which experiences the recruitment of long-lived, mature secretory cells
back into the cell cycle upon certain types of physiological injury. We discuss how recent
advances in our knowledge of these events and their governing mechanisms address how mature
cells might initiate or be involved in tumorigenesis, challenging the idea that adult SCs are the
sole cell type responsible for both accumulating mutations and spawning cancers (White and
Lowry, 2015). We end by postulating how the changes undergone in gastric plasticity might be
governed by conserved cellular programs, which hold important implications for cancer
initiation.

Figure 1.1 Proposed models of mature cells acting as cancer cells of origin.
We propose that long-lived mature cells may accumulate and store mutations, eventually acting
as – or giving rise to cells that can act as – cells of origin for tumors in diverse tissues. This
4

mutational accumulation may occur in two main ways: A) Mature cells (dark blue) may
accumulate mutations (orange triangles) as they maintain their mature functioning cell fate over
time. The mutations themselves or outside stressors may cause dedifferentiation (teal cell). If the
acquired mutations are sufficiently carcinogenic, they may then block the cell in the
dedifferentiated state, causing it to expand as a clone that can give rise to cancer (red). B) The
‘cyclical hit’ model describes mature cells which dedifferentiate and redifferentiate multiple
times in response to injury/inflammation. Each time cells are called back into the cell cycle,
replicative stress can promote mutation accumulation. Differentiated cells can store such
mutations indefinitely. Eventually, a mutation or combination of mutations is sufficient to block
the cell in one of its replicative phases and lead to clonal expansion and potential tumorigenesis.

1.2

Introduction to the stomach

The stomach body (corpus) is lined by an epithelium that is flat on the luminal surface but
invaginates into glands descending towards the musculature. The gland and its surface epithelial
cells form the gastric unit, containing mucus-secreting surface pit foveolar cells at the surface,
mucous neck cells interspersed between acid secreting parietal cells in the neck region
(Bredemeyer et al., 2009), and zymogenic chief cells at the base (Karam, 1993; Karam and
Leblond, 1993b; Karam and Leblond, 1993a; Karam and Leblond, 1993c) (Figure 2A).
Proliferation in the healthy gastric epithelium is overwhelmingly confined to morphologically
undifferentiated cells located above the neck cells at the isthmus of the unit. Based on their
ultrastructure and on nucleotide tracing studies (Hattori and Fujita, 1976b; Mills and Shivdasani,
2011), these isthmal cells have long been assumed to be multipotent SCs that fuel replacement of
all mature cells in the gastric unit, though the extant data do not rule out other self-renewal
mechanisms (Bjerknes and Cheng, 2002; Quante et al., 2010; Willet and Mills, 2016; Wright,
2016).
Although several candidate markers have been identified in cells that populate the gastric unit
(Phesse and Sansom, 2017), none of these have been shown to be enriched exclusively in the
5

isthmal cells. This means that a verified marker of gastric epithelial SCs in the body of the
stomach remains to be identified.

Figure 1.2: The gastric unit and its response to injury.
A) The healthy gastric unit, with pit cells at the opening to the gastric lumen, stem cells at the
isthmus, parietal cells and neck cells in the middle of the unit, and chief cells at the base. Not
pictured: endocrine and tuft cells. Proliferation (red nuclei) is confined to the isthmus, with new
pit cells migrating up and parietal and mucous neck cells migrating down. Neck cells transition
to chief cells at the zone between neck and base. Colored arrows mark the direction of cell
changes. B) A metaplastic gastric unit following injury such as Helicobacter pylori infection or
acute pharmacological agents. Parietal cells quickly die and mature chief cells become
metaplastic cells co-expressing chief and neck cell markers. Proliferation occurs from the
isthmus through the base, with paligenotic chief cells re-entering the cell cycle.

6

1.3

Gastric Plasticity

Chief cells are large, long-lived, and non-proliferating cells that devote their energies to
producing digestive enzymes. However, surprisingly, chief cells in both mice and humans are
plastic; they can disassemble their complex secretory apparatus (Capoccia et al., 2013; Lo et al.,
2017) to re-enter the cell cycle and, potentially in some cases, act as reserve SCs upon injury
(Stange et al., 2013b). In humans, Helicobacter pylori infection can cause chronic atrophic
gastritis. In this condition, parietal cells die (atrophy), and increased proliferation is observed
among the remaining cells in the gastric unit. In mouse models, both H. pylori and various drugs
can be used to kill the parietal cells and force the recruitment of other cells as additional reserve
SCs (Sigal et al., 2015; Petersen et al., 2017b). Drugs that mimic the H. pylori-induced cellular
changes include high doses of the selective estrogen receptor modulator tamoxifen (Huh et al.,
2012b; Saenz et al., 2016), the neutrophil elastase inhibitor DMP-777 (Goldenring et al., 2000;
Nomura et al., 2005), and its ortholog L635 (Weis et al., 2013). In all cases, the observed
changes include loss of parietal cells, loss of mature chief cells, and the emergence of
metaplastic cells. In the stomach, the metaplastic cells that emerge upon parietal cell death
express large amounts of trefoil factor 2 (TFF2, also Spasmolytic Polypeptide), so the cell
lineage shifts in chronic atrophic gastritis have been called Spasmolytic Polypeptide Expressing
Metaplasia (SPEM).
SPEM cells were originally thought to arise via proliferation from the isthmal SCs undergoing an
alternate differentiation path, and some continue to believe that to be the case (Hayakawa et al.,
2015; Hayakawa et al., 2017; Kinoshita et al., 2018a), yet lineage tracing studies with multiple
genetic drivers from the base and isthmus of the gastric unit in mice, with corroboration in
human tissues, indicate that the majority of SPEM cells, at least in the acute setting, likely arise
7

from chief cells that reprogram to express TFF2 and re-enter the cell cycle (Lennerz et al., 2010;
Nam et al., 2010; Goldenring et al., 2011a; Capoccia et al., 2013; Leushacke et al., 2017; Matsuo
et al., 2017; Mills and Goldenring, 2017) (Figure 2B). Gene promoters that have been used to
lineage trace chief cell reprogramming into progenitor cells include: Tumor necrosis factor
receptor superfamily, member 19, (Tnfrsf19, known as Troy), which is mostly expressed in
mature chief cells; basic helix loop helix family member A15 (Bhlha15, known as Mist1), which
is almost exclusively expressed in chief cells; and Leucine Rich Repeat Containing G ProteinCoupled Receptor 5 (Lgr5) mRNA, which is likewise almost exclusively expressed in chief cells.
Recent work further supports the interpretation that mature chief cells are the predominant
source of acute SPEM cells, showing that SPEM can arise even when any potential proliferative
contribution from the SC or progenitor cells is abrogated (Radyk et al., 2018). Interestingly,
SPEM cells recapitulate many aspects of immature cells in the early developing stomach where
there are abundant proliferating cells that co-express TFF2 and markers of chief cell
differentiation (Keeley and Samuelson, 2010). The SPEM cells are not characteristic of the adult
isthmal SCs, which lack granules or other ultrastructural characteristics of any specific
differentiated cell lineage (Karam and Leblond, 1993a).
While parietal cell loss is nearly always correlated with SPEM, a recent study demonstrated that
highly targeted parietal cell apoptosis alone is insufficient to induce metaplasia (Burclaff et al.,
2017). The cause and mechanism of SPEM initiation remain enigmatic, though several players
have been implicated, such as requirement for a signaling cascade including Extracellular Signalregulated Kinase (ERK), Cluster of Differentiation 44 (CD44), and Signal transducer and
activator of transcription 3 (STAT3) (Khurana et al., 2013), macrophages, and interactions
between interleukins (IL) IL-33 and IL-13 (Petersen et al., 2014; Petersen et al., 2017a). Our
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recent work also showed that a sequential, stepwise process of 1) autodegradation, 2) induction
of metaplastic gene expression like SRY-box 9 (SOX9) and TFF2, and 3) cell cycle re-entry
characterized the process chief cells used to reprogram (Willet et al., 2018a). Each step has
checkpoints that cells must traverse to complete proper tissue regeneration. For example,
blocking lysosomal functioning stopped cells from inducing SOX9/TFF2, and inhibiting
mTORC1 stopped cell cycle re-entry. The stages and checkpoints were preserved in pancreatic
regeneration, and additional experiments as well as other literature indicated that kidney and
liver regeneration follow the same sequence. Thus, there is support for a conserved cellular
regenerative/dedifferentiation program that has been called ‘paligenosis’, suggesting that cells, in
addition, to programs for cell death (apoptosis) have programs to regain regenerative ability
(Messal et al., 2018).

1.4

Gastric Tumorigensis

Since Pelayo Correa’s early work mapping the histological stages of gastric cancer progression
(Correa, 1988), it has been known that patients with metaplasia/chronic atrophic gastritis have an
increased risk for gastric cancer (Hattori, 1986; Kakinoki et al., 2009; Goldenring et al., 2010)
and that gastric cancer seems to arise in a stepwise fashion. The stages of gastric tumorigenesis
cannot be fully studied in mice, as no mouse models of gastric cancer faithfully replicate latestage human disease (Petersen et al., 2017b). Humans with extensive metaplasia and SPEM
nearly invariably also get intestinal metaplasia, but intestinal metaplasia does not seem to be a
common feature of injury response in mice. In some mouse models, however, SPEM can
progress to proliferative lesions with histological abnormalities resembling human dysplasia
(Nomura et al., 2004; Petersen et al., 2017b). The architecture of the gastric unit is useful to
consider, as the spatial separation between the normal isthmal and basal proliferation zones via
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chief cell dedifferentiation allows for inferences to be made about the cells of origin for
metaplasias and dysplasias (Radyk and Mills, 2017). Multiple recent studies have shown how
proliferative dysplasia can be induced solely by expressing activated Kirsten Rat Sarcoma
(KRAS) using multiple promoters found in chief cells (Choi et al., 2016; Leushacke et al., 2017;
Matsuo et al., 2017). Such studies show that chief cells are able to act as cells of origin for
tumorigenesis. As there is no known promoter reliably specific to the isthmal SC in the stomach,
similar direct evidence does not exist for the SC acting as another potential cell of origin, though
of course this is certainly a possibility awaiting better genetic tools in future work. The ability of
the chief cells to act as cells of origin for gastric cancer is consistent with the ‘cyclical hit’ model
of tumorigenesis, whereby long-lived chief cells may accumulate and store mutations in rounds
of dedifferentiation and redifferentiation in chronic inflammation or metaplasia, possibly leading
to tumorigenesis (Figure 1) (Mills and Sansom, 2015; Saenz and Mills, 2018b).

1.5

Conclusion

In the search for the cell of origin for epithelial cancers, investigators have long favored stem and
progenitor cells as the likely culprits owing to their constitutive proliferative capacity and
supposed longevity (Fearon and Vogelstein, 1990; Vogelstein and Kinzler, 1993). However,
interestingly, before the rise of the specific field of Developmental Biology, pathologists had
considered three possible cancer cells of origin with relatively equal potential: 1) stem cells (or
‘mother cells’, as they were known over a century ago) (Adami, 1900); 2) ‘rests’ or cryptic
embryonic cells that never really differentiated in the adult; and 3) differentiated cells that can
become proliferative again after potentially accumulating deleterious phenotypes. We are in the
process of shifting our understanding of how tissues renew towards accepting that the more
fluid/plastic notions of a century ago might describe reality more comprehensively than the rigid
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stem-cell-based, unidirectional differentiation theories that predominated the latter half of the
Twentieth Century. A more nuanced understanding of stem and differentiated cells and tissue
repair, now with molecular underpinnings of the underlying cellular processes, may help refine
models of tumorigenesis. For example, intestinal SCs live shorter than had been expected
(Lopez-Garcia et al., 2010; Snippert et al., 2010). Thus, the longest-lived cells in many adult
solid organs may actually be the differentiated populations. Thus, while many types of tumors
may still arise ultimately from SCs (Visvader, 2011), the studies presented in this review give
cause to re-imagine the multi-hit model to include the potential contribution of fully
differentiated post-mitotic cells such as gastric chief cells (Choi et al., 2016; Leushacke et al.,
2017) either as direct cells of origin for tumors or as sources for the stem/progenitor cells that go
on to spawn cancer.
Opportunities to inhibit tumor initiation at the cell of origin may arise in multiple tissues if
common pathways can be identified and manipulated to block their dedifferentiation. As a start,
we can look at the many similarities between the stomach and the pancreas, in which mature
secretory acinar cells undergo a similar plastic event following injury (Burclaff and Mills,
2018a). Both systems begin with large, long-lived secretory cells that undergo paligenosis to
give rise to smaller, simpler cells reminiscent of embryonic cell types. Both systems also lose
similar maturity markers and share many signal-transducing and metaplastic genes, and both
involve a role for inflammation. Recent evidence indicates that paligenosis may be the process
used during dedifferentiation of mature non-secretory cells in other organs as well, including
liver and kidney (Willet et al., 2018a), and evidence for proliferative dedifferentiation is also
being delineated in diverse tissues such as glia, warranting investigation into further mechanistic
conservation (Friedmann-Morvinski and Verma, 2014). Our scope is expanded to describe
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plasticity in the skin and intestine in published work (Burclaff and Mills, 2018b) to continue to
discuss its implications for tumorigenesis and further highlight the conservation of plasticityrelated genes and processes across tissues.
Data from the stomach and pancreas support a model wherein mutations are acquired and stored
through cycles of differentiation and dedifferentiation until a neoplastic mutation such as Kras
activation inhibits a paligenotic cell’s ability to redifferentiate, which we describe as the cyclical
hit model (Figure 1). This model also might help answer longstanding questions about tumor
development. So-called ‘oncofetal’ gene expression in adult tumors has long puzzled oncologists
(Uriel, 1979), with genes that are normally expressed only in early development becoming reexpressed in many tumors (Ahrlund-Richter and Hendrix, 2014). Metaplastic gene re-expression
is the second stage of paligenosis (Willet et al., 2018a), consistent with the expression of
embryonic genes being observed in ADM (Jensen et al., 2005), and the metaplastic stomach
establishes morphology and cell types similar to the developing fetal gastric epithelium (Keeley
and Samuelson, 2010; Osaki et al., 2010). It is thus likely that tumor cells express these
embryonic genes because the genes were reintroduced via a paligenosis event that occurred at
some point in one of their cellular ancestors.
Clearly, we are at only the beginning of the beginning of understanding how cell plasticity plays
a role in tumorigenesis and even in how tumors can adapt to chemotherapy and radiation therapy.
The following dissertation presents many projects describing the dynamics of this plasticity, and
all indications are that there may be an explosion of new ideas and potential therapeutic
approaches as the concepts of cell plasticity and dedifferentiation, and the underlying conserved
mechanisms and cellular processes, begin to be more deeply explored.
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Chapter 2: Targeted Parietal Cell Apoptosis
Is Insufficient To Induce Metaplasia In The
Stomach

The following chapter was published in Gastroenterology
Burclaff, Joseph, Luciana H. Osaki, Dengqun Liu, James R. Goldenring, and Jason C. Mills.
"Targeted apoptosis of parietal cells is insufficient to induce metaplasia in stomach."
Gastroenterology 152, no. 4 (2017): 762-766.
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2.1

Abstract

Parietal cell (PC) atrophy is widely considered to cause metaplasia in the stomach. We bred mice
with PC-specific diphtheria toxin receptor expression and found that targeted PC death increased
proliferation in the normal stem cell zone but did not cause metaplastic reprogramming of chief
cells. Furthermore, the metaplasia-inducing agents tamoxifen or DMP-777 still induced
metaplasia even following previous ablation of PCs via diphtheria toxin. Thus, we demonstrate
the surprising finding that PC atrophy alone is not sufficient to induce metaplasia and that
completion of metaplastic reprogramming of chief cells requires further mechanisms beyond PC
injury/death.

2.2

Parietal Cell Death and Metaplasia

Metaplasia in the stomach consistently occurs in the setting of parietal cell (PC) atrophy: in
autoimmune gastritis patients(Adams et al., 1964), in Helicobacter pylori induced atrophic
gastritis(Yoshizawa et al., 2007), and in animal models of acute injury(Nomura et al., 2005; Huh
et al., 2012a). Thus, we and others have proposed that PC death causes metaplasia. For example,
PCs might constitutively elaborate gastric-differentiation-promoting factors whose loss during
PC atrophy might lead to aberrant (metaplastic) differentiation of remaining cells(Mills et al.,
2001). Alternatively, the immune response to PC death could cause metaplasia, or dying PCs
might elaborate specific injury-induced factors or by-products that trigger metaplasia.
Here, to better determine the specific role of PCs, we employed a method to precisely induce PC
apoptosis. We bred PC-specific, Cre-inducible simian Diphtheria Toxin Receptor(Buch et al.,
2005; Zhao et al., 2010) (Atp4b-Cre;LSL-DTR) mice [hereafter called “DTR mice” (Figure 2.1)].
In these mice, PCs are the only cells that can respond to apoptosis-inducing diphtheria toxin. As
a positive control for PC atrophy and Spasmolytic Polypeptide-Expressing Metaplasia (SPEM),
14

the metaplasia seen in direct temporal and spatial correlation with human and mouse PC atrophy
(Lennerz et al., 2010), we used a system previously described by us and others(Huh et al., 2012a;
Sigal et al., 2015; Saenz et al., 2016) involving injections of high-dose (5 mg/20 g mouse body
mass) tamoxifen (“TAM”). Consistent with previous results, TAM caused atrophy of >90% of
PCs and increased cell proliferation throughout the gastric unit. In >75% of gastric units, the
pathognomonic pattern of SPEM was identified: GIF+ chief cells (ZCs) at the base of the units
co-expressing the epitope for the lectin GSII. As previously shown, many SPEM cells were also
proliferative (yellow arrowheads, Figure 2.3A,B). Three daily injections with 225 ng DT also
killed >90% PCs and increased mucosal cell proliferation in the isthmal region deep to the
foveolar cells (Figure 2.3A-C). Both atrophy and proliferation were maintained by daily DT
injection up to 14 days, while cessation of injection at D3 allowed for complete recovery within
the same timeframe (Figure 2.3C).
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Figure 2.1: Atp4b-Cre;LSL-DTR drives iDTR specifically in parietal cells.
Top) Natural fluorescence in Atp4b-Cre;LSL-DTR;ROSAmTmG mice. Cells with Cre driver
express GFP (green), and all cells without Cre driver express mTomato (red). Bottom) IF
staining for GFP (green), driven by Cre driver, and the parietal cell marker VEGFB (red).

To confirm that DT was directly targeting PCs, we grew gastroids from DTR mice crossed with
mTmG reporter mice(Muzumdar et al., 2007). In these mice, PCs express membrane-associated
eGFP (as in Figure 2.1). We cultured these gastroids with vehicle or DT for three days (Figure
2.2) in the absence of Wnt3a, R-Spondin 1 and Noggin. Control gastroids had negligible death.
DT treatment of DTR-derived organoids resulted only in specific extrusion of eGFP+ cells
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without change in overall gastroid size or number. Thus, DT causes specific killing of parietal
cells.

Figure 2.2: DT specifically kills parietal cells.
Top) Gastroids from DTR mice with the Atp4b+ parietal cell lineage fluorescing green (Atp4bCre;LSL-DTR;ROSAmTmG mice) and all other lineages in red. The same gastroids were
monitored over 3 days of control or DT treatment. Note DT treatment does not affect gastroid
survival, but PCs are specifically extruded into lumen of gastroids by Day 1 (arrowheads in
inset) and then are largely gone by Day 3. PC extrusion – which is consistent with cell death in
these cultures – does not occur in controls. Bottom) Immunofluorescence co-staining with anti17

GFP (green) and anti-PC-marker H+/K+ATPase (red) antibodies.

In marked contrast to the TAM atrophy model, the DT treatment never caused substantial SPEM
at any timepoint (n>40 total mice examined to date), and proliferation was almost entirely
excluded from the base of the unit, localizing instead to the upper isthmus and neck regions
(Figure 2.3A, B). SPEM is thought to arise from reprogramming of ZCs and reentry into the cell
cycle (Goldenring et al., 2011b; Mills and Sansom, 2015), so we examined the morphology of
the basal cells carefully. Whereas ZCs after TAM treatment had the expected simple columnar
morphology with scant GIF that occurs in SPEM cells, the ZCs in DT-treated DTR mice
maintained largely normal morphology with apical GIF granules still apparent (Figure 2.3D).
CD44v9, a marker upregulated during proliferative metaplasia, was increased only in the
proliferating neck of DT treated mice, but not in the base, contrasting with TAM treatment,
which caused CD44v9 expression in neck and base (Figure 2.4). Clusterin, a secreted protein
increased in SPEM(Weis et al., 2013), also labeled cells in the base of the gastric unit in TAM
mice, while in DT mice, it marked only rare basal cells (Figure 2.4). Thus, apoptosis of PCs
alone, even for as long as two weeks, was not sufficient to cause metaplasia.
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Figure 2.3: Diphtheria toxin-mediated parietal cell ablation does not cause metaplasia
A) Stomachs following three days of vehicle, DT, or TAM injections (top: green: GSII, red:
anti-GIF, magenta: anti-BrdU); arrowheads = representative proliferating SPEM cells (yellow
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cytoplasm+magenta nucleus). Bottom: red:anti-VEGFB (parietal cells). B,C) Quantification of
immunofluorescence staining. D) Bases of units with anti-E-Cadherin (green) and anti-GIF (red).
E) Stomachs as for panel A (red: anti-CD44v9, green: GSII, magenta: anti-BrdU; bottoms of
units traced in white). F) qRT-PCR from whole corpus at D3. For all data: “*”, “**”, “***” =
p<0.05, 0.01, 001; n≥3 mice per group.
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Figure 2.4: Changes in protein localization for markers of SPEM and chief cell
differentiation following TAM and DT.
A) Base of D14 DT treated unit with anti-E-Cadherin (green) and anti-GIF (red). (B-D)
Immunofluorescence of stomachs following three days of vehicle, DT, or TAM injections. B)
Red CD44v, Green: GSII, magenta: BrdU. C) Red: GIF, Green: Tff2. D) Red: GIF, Green:
Clusterin.

We next examined expression of transcripts associated with normal gastric differentiation and
metaplasia (Weis et al., 2013). We observed a significant decrease in GIF mRNA expression
across the whole corpus of the stomach in DT mice and a trend towards a decrease in the critical
chief cell differentiation factor MIST1 (BHLHA15); however, both markers were far more
substantially reduced in TAM mice (Figure 2.3F). Further corroborating histological findings,
Clusterin and another commonly used SPEM marker HE4 (Wfdc2)(Nozaki et al., 2008) were
significantly increased following TAM, but were unaffected by DT treatment (Figure 2.3F). Of
eight other transcripts that showed statistically significant changes, TAM – but not DT –
treatment caused significantly increased expression of genes involved in metaplasia and the
immune response (Cd14, Ceacam10, Cftr, Ctss, Dmbt1, Vil1). Consistent with the histology,
both TAM and DT increased proliferation-related transcripts (Ccnb2, Chek2) (Figure 2.5).
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Figure 2.5: Quantitative Real-Time PCR of selected transcripts implicated in SPEM.
Transcripts were analyzed from RNA isolated from the whole gastric corpus of mice treated with
vehicle, DT or TAM for three days. 12 transcripts with significant changes in experimental
groups compared to control (* indicates p≤0.05, ** indicates p≤0.01) are shown.
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The results described thus far argued against the model wherein PCs constitutively elaborate
factors that promote differentiation, as non-metaplastic ZCs can clearly be maintained in the
absence of PCs. However, it was still possible PC atrophy caused metaplasia, but the manner of
death was critical. Perhaps PCs dying in H pylori infection or TAM – but not DT – treatment
release metaplasia-inducing signals when they are injured. If true, metaplasia should not occur in
DTR mice once PCs were already dead. Thus, we injected DTR mice with DT to kill PCs first
and then co-injected DT and TAM for three days (DT+TAM). Mice injected with DT for 5 days
showed increased isthmal/neck proliferation without SPEM, as expected; however, mice that
received DT then TAM exhibited proliferative SPEM similar to what occurred with TAM alone
(Figure 2.6A-C). Therefore, SPEM can occur even without substances released from injured
PCs. Similar results were obtained with another atrophy/SPEM-inducing agent, DMP777(Nomura et al., 2005), with DMP-777 treatment causing SPEM just as effectively even if
PCs were already pre-killed by DT (Figure 2.6D-F; Figure 2.7).
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Figure 2.6: SPEM can be induced in the absence of parietal cells
A Stomachs following five days control, DT, or DT then TAM injections (green: GSII, red: antiGIF, magenta: anti-BrdU; arrowheads = representative proliferating SPEM cells (yellow
cytoplasm+magenta nucleus). B) Immunofluorescence data quantified. C) H&E. D) Stomachs
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following 16 days control, DT, or DT then DMP-777, stained as for panel A. E)
Immunofluorescence data quantified. F) H&E. For all data: “*”, “**”, “***” = p<0.05, 0.01, 001
vs. Control in ANOVA with Dunnett; n≥3 mice per group

Figure 2.7: DMP-777 control showing deletion of parietal cells.
IF of stomachs following 16 days control, DT, or DT then DMP-777 for the PC marker VEGFB
(red).

Overall, our results show that PC atrophy may be required but is not sufficient for metaplasia.
Furthermore, signals from injured/dying PCs do not seem to be required for metaplasia
induction. Additionally, we observe that the DTR mice had increased proliferation only in the
normal isthmal progenitor zone, whereas TAM/DMP777 treatment showed both isthmal
proliferation and proliferation of metaplastic cells in the base. Thus, the results are also
consistent with previous findings that the stomach has two distinct cellular sources for
progenitors: 1) constitutive stem cells in the isthmus and 2) ZCs in the base which can be
induced to undergo metaplastic cell cycle reentry. If, as we have shown here, atrophy alone is not
sufficient to induce cell cycle reentry, then ZCs undergoing metaplasia must require additional,
as yet unidentified factors (e.g. cytokines/specific immune cell activation) to undertake this
cellular reprogramming
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2.3

Methods and Materials

Animals and injections
All experiments involving animals were performed according to protocols approved by the
Washington University School of Medicine Animal Studies Committee. Mice were maintained
in a specified-pathogen-free barrier facility under a 12 hour light cycle. Wild type C57BL/6,
Gt(ROSA)26Sortm1(HBEGF)Awai (iDTR)(Buch et al., 2005), and B6.129(Cg)Gt(ROSA)26Sortm4(ACTB-tdTomato,-EGFP)Luo/J (mT/mG)(Muzumdar et al., 2007) mice
were all purchased from Jackson Laboratories. ATP4b-Cre mice(Syder et al., 2004) were crossed
with iDTR mice, which express the inducible simian diphtheria toxin receptor under the control
of the Rosa26 promoter. Littermate controls were housed together when possible to minimize
differences in gastric microflora. To selectively kill parietal cells, Diphtheria Toxin (225
ng/mouse, Sigma) was injected intraperitoneally one or three times per day. Since parietal cells
(PCs) die at a comparable rate to those previously published with D3 TAM, most analysis was
done at D3 DT. Diphtheria Toxin was dissolved in sterile 0.9% sodium chloride saline. To
induce SPEM, Tamoxifen (5 mg/20 g body weight, Toronto Research Chemicals Inc.) was
injected intraperitoneally daily for three days or DMP-777 (7 mg/20 g body weight, gift of
DuPont-Merck Corporation) was gavaged daily for 14 days. Tamoxifen was dissolved in a
vehicle of 10% ethanol and 90% sunflower oil (Sigma), and DMP-777 was suspended in 1%
methylcellulose (Sigma) in distilled H2O.
Immunofluorescence
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Mice were given an intraperitoneal injection containing 5-bromo-2’-deoxyuridine (BrdU, 120
mg/kg) and 5-fluoro-2’-deoxyuridine (12 mg/kg) in sterile water 90 min before sacrifice.
Following sacrifice, stomachs were immediately excised and flushed with PBS, then pinned out
and fixed in freshly prepared methacarn (60% methanol, 30% chloroform, 10% glacial acetic
acid) for 20 minutes and stored overnight in 70% ethanol. Tissues were arranged in 3% agar in a
tissue cassette, underwent routine paraffin processing, and 5μm sections were cut and mounted
on glass slides. Sections underwent a standard deparaffinization and rehydration protocol, were
blocked in 1% BSA, 0.3% Triton-X100, in PBS, left overnight with primary antibodies, washed
in PBS and incubated for one hour with secondary antibodies, washed, incubated 5 minutes in 1
g/ml bisbenzimide (Molecular Probes), washed, then mounted using glycerol:PBS.
Primary Antibodies used in this study: rabbit anti-human gastric intrinsic factor (1:10,000, gift of
Dr. David Alpers, Washington University), goat anti-Brdu (1:20,000, gift of Dr. Jeff Gordon,
Washington University), goat anti-VEGFb (1:100, Santa Cruz), goat anti-Clusterin (1:100, Santa
Cruz), mouse anti-E-Cadherin (1:200, BD Biosciences), rabbit anti-GFP (1:100 Santa Cruz),
mouse anti-TFF2 (1:500, Abcam), rat anti-CD44 v10-e16, ortholog of human v9 (1:200, Cosmo
Bio), or 1 g/ml fluorescently labeled GSII lectin (Alexafluor488, 594, Molecular Probes).
Secondary Antibodies included AlexaFluor (488, 594 or 647) conjugated donkey anti-goat, antirabbit, or anti-mouse (1:500, Molecular Probes).
Immunofluorescence quantification
All timepoints were quantified with at least three mice, with representatives from both genders.
Stomachs were fluorescently stained with bisbenzimide and either anti-BrdU or anti-VEGFb
markers along with the neck cell marker GSII lectin and zymogenic cell marker anti-GIF. Images
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were captured as TIFF files from a Zeiss Axiovert 200 microscope with Axiocam MRM camera
and with Apotome optical sectioning filter. Each stomach had at least 5 images taken containing
10+ well-oriented gastric units each. Units were counted using the neck staining, and total
quantifications of proliferating cells (BrdU+) or PCs (VEGFb+)(Mills et al., 2003) were averaged
over total unit numbers per mouse.
For quantifying units exhibiting SPEM, SPEM was defined exclusively in corpus gastric units as
either 5+ cells per unit co-expressing GSII and GIF or GSII-expressing cells extending to the
base of the unit.
Genotyping
Tissue was lysed with DirectPCR reagent (Viagen Biotech Inc) with added Proteinase K (New
England BioLabs) at 55 ⁰C for 11 hours, then 85 ⁰C for 15 minutes. Genotyping PCR was run
with Redtaq (Sigma). Primers: H+/K+ATPase-Cre Forward: AGGGATCGCCAGGCGTTTTC,
Reverse: GTTTTCTTTTCGGATCCGCC.
Corpus gastroid culture
Gastric glands from the corpus of the stomach were isolated from Atp4b-Cre;LSL-DTR;
ROSAmT/mG mice (Muzumdar et al., 2007) according to (Barker et al., 2010) and (Stange et al.,
2013a). Whole gastric glands were mixed with Matrigel, distributed in 48-well plates and grown
in Advanced DMEM/F12 medium (Invitrogen), 50% Wnt3a conditioned medium, 10% RSpondin1 and Noggin conditioned medium supplemented with 10mM HEPES, 1X N-2, 1X B27,
1X glutamax (Invitrogen), 2.5 mM N-Acetylcysteine (Sigma-Aldrich), 50 ng/mL EGF, 100
ng/mL FGF10 (Peprotech) and 10 nM gastrin (Sigma-Aldrich). 10 µM ROCK inhibitor (Y28

27632, Sigma-Aldrich) was provided for the first 3 days. Three days after initial culturing,
gastroids were treated with 10 ng/mL of diphtheria toxin in the absence of Wnt3a, R-Spondin 1
and Noggin. Fresh medium containing DT was added the following day. Using Cytation 3
(Biotek), all wells were microscopically scanned every 24 hours throughout the whole
experiment, and the number of dead gastroids was scored.
Quantitative RT-PCR
Total RNA was extracted from corpus stomach tissue using the RNeasy Mini Kit (Qiagen). RNA
was treated with DNAse I then cDNA was synthesized with Superscript III (Invitrogen) and
random primers. qRT-PCR was performed using PowerUp SYBR Green Master Mix
(ThermoFisher) and gene specific primers (Figure 2.8) on a QuantStudio 3 PCR System
(ThermoFisher) and data analyzed using QuantStudio Design & Analysis Software. Every run
was standardized to TATA Box Binding Protein (TBP) primers. All primers were exon-spanning
when possible, (i.e. for genes having multiple exons of sufficient length). For full list of primers,
see Supplemental Table. All graphs and statistics were completed in GraphPad Prism, using oneway ANOVA with either Dunnett’s or Tukey’s post-hoc multiple comparison tests to determine
significance.
Gene

Forward Primer 5'→3'

Reverse Primer 3'→5'

TBP

CAAACCCAGAATTGTTCTCCTT

ATGTGGTCTTCCTGAATCCCT

GIF

GAAAAGTGGATCTGTGCTACTTGCT AGACAATAAGGCCCCAGGATG

Mist1

GAGCGAGAGAGGCAGCGGATG

AGTAAGTATGGTGGCGGTCAG

TFF2

TGCTTTGATCTTGGATGCTG

GGAAAAGCAGCAGTTTCGAC

Clusterin

CCAGCCTTTCTTTGAGATGA

CTCCTGGCACTTTTCACACT

Wfdc2/HE4

TGCCTGCCTGTCGCCTCTG

TGTCCGCACAGTCCTTGTCCA

Mal2

GCTTTCGTCTGTCTGGAGATTG

ACACAAACATGACCCATCCTTG

Arhgap9

TGCTGCCTGACTTTCGTGATG

GCGGTCATTCGGTTCTTATCC

Casp1

GAAAGACAAGCCCAAGGTGAT

GGTGTTGAAGAGCAGAAAGCA
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Ccnb2

TGAAGTCCTGGAAGTCATGC

GAGGCCAGGTCTTTGATGAT

CD14

CTCTGTCCTTAAAGCGGCTTAC

GTTGCGGAGGTTCAAGATGTT

Ceacam1

CCTCAGCACATCTCCACAAAG

TATAGCCGTAGTGTTTCCCTTG

Ceacam10

CTCCGATTTCTGTGCGATTTC

GTCCGTGGCAGATTGTGAAC

Cenpk

AATACTGGACACTCTTAACG

GGATCTTAGTTGTCAGTTCAT

CFTR

CTGGACCACACCAATTTTGAGG

GCGTGGATAAGCTGGGGAT

Chek2

TCGGCTATGGGCTCTTCA

CGTCCTTCTCAACAGTGGTC

Ctss

TCTATGACGACCCCTCCTG

TTGCCATCCGAATGTATCCTT

Cxcl17

AGGTGGCTCTTGGAAGGTG

CTCTGGAGGGTCTTTGCGA

Dmbt1

ACCTCCTCACGGTGCTACAG

GCTTCTTCACATCCTCCACTG

ETV5

GCTCTTGGTGCTAAGTAGGA

TCTGATGGGTGGGTGACA

Fignl1

TTATATTCCCCTCCCAGAAGC

GCCAGAAAACCCATCAGACT

Glipr1

CCAGCTTCGGTCAAAAGTGAG

TGGGTGTATCCGTGAATGCAG

Gpx2

CAGGGCTGTGCTGATTGAG

CGGACATACTTGAGGCTGTTC

Ly6a

GACTTCTTGCCCATCAATTACC

TTAGTACCCAGGATCTCCATAC

Lyz2

GCCAGAACTCTGAAAAGGAATG

CTTTGGTCTCCACGGTTGTAG

Mad2l1

TGCTTACAACTACTGACCCCG

ACTGCCATCTTTCAAGGACTTC

Mmp12

CATGAAGCGTGAGGATGTAGAC

CTAGTGTACCACCTTTGCCA

Ms4a6b

TCCCTCCAATCTACACTTTACC

GACTTTGTCTCCGTGACGATG

Ms4a6c

AAAAGACGAGTCCCAGCCTAC

ATGGGACAGGAGGAACAGATG

Muc4

GCTGCCTGTATTCTTGCCT

ATGTTCTGGTGCTGCTGGA

Pigr

GATTTGGGAGGCAATGACAAC

GCTTTCTTGGATTCTTCTGGC

Prom1

TGGATAACACAGGAAGGAAGAG

CAGGGTAGAGGCAAATGTCAG

Slfn9

TCCTTAGTGGTGAAACGGTCT

TCAGGTTGCTCACTCTGGTTG

Tmem48

GCTGCTACAAATGGGAGGAT

CACGGAAGGCGTCTGACTA

Top2a

CGAAATGGCTATGGAGCTAA

TATCTTTGTCCAGGCTTTGC

Traf4

CAGGTGTTAGGCTTGGCTATC

CGATTAGGGCAGGGGACTA

Tyrobp

GGTGTTGACTCTGCTGATTGC

AAGCTCCTGATAAGGCGACTC

Ube2c

CAACATCTGCCTGGACATC

CCTGCTTTGAATAGGTTTCTTGC

Vil1

TCAAAGGCTCTCTCAACATCAC

GGTGCTGGAAGGAACAGG

Figure 2.8: Primers used for quantitative RT-PCR
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Chapter 3: Gastric chief cells self-maintain,
independent of isthmal stem cells, in
homeostasis and injury
3.1 Abstract
Background & Aims
Chief cells are thought to arise from mucous neck cells in the adult mammalian stomach during
homeostasis. The cellular source of injury-induced Spasmolytic Polypeptide-Expressing
Metaplasia (SPEM) is debated and there is no evidence yet of how SPEM resolves upon
recovery from injury. We investigated the dynamics of the chief cell lineage in homeostasis and
following injury to further investigate these topics.
Methods
We used pulse-chase experiments of varying lengths with two nucleotide analogues during
homeostasis and throughout acute tamoxifen injury to track long-lived label-retaining cells.
Results
BrdU-labeling was seen to enter chief cells very slowly with continual pulsing, and the majority
of the labeled chief cells were nonadjacent to the transitional zone. Varying pulse and chase
windows of BrdU showed that BrdU exited the neck but did not enter the chief cell population.
Our label-retention assays showed that the majority of chief cells retain label for over 9 months
at homeostasis. When labeled chief cells are challenged with acute or chronic injury, label is
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retained in metaplastic cells, and this can be following back into healthy chief cells upon
recovery from acute injury.
Conclusions
Our data is consistent with a model wherein chief cells are a self-sufficient cell population at
homeostasis maintained through infrequent self-replication, with neck cells shown not to give
rise to chief cells, as had previously been believed. Chief cells are also able to maintain their own
population following injury through dedifferentiating into metaplastic cells which can then
redifferentiate upon resolution of the insult.

3.2 Introduction
The lineage relationships between the stem cells, progenitors, and differentiated cells of the adult
mammalian stomach have been poorly defined, largely due to the lack of specific markers and
genetic tools to investigate the gastric stem cell. All cells in the healthy stomach are posited to
arise from a multipotent stem cell at the isthmus of the gastric unit (Karam and Leblond, 1993a).
In this model, stem cells give rise to immature progenitors of most mature gastric lineages that
mature as they migrate to their functional location within the gastric unit. This model also posits
a special relationship between mucous neck cells and gastric chief cells. Immature mucous neck
are borne from the isthmal stem cell then migrate down the unit and differentiate into mature
mucous neck cells, a process that takes about two weeks. When mucous neck cells reach top of
the base, they transdifferentiate into zymogenic ‘chief’ cells w are estimated to live for around
half a year (Karam and Leblond, 1993c; Quante et al., 2010; Goldenring et al., 2011a). The
conversion of neck cells to chief cells is supported by the existence of ‘transitional’ cells
between neck and chief cells which express markers of both populations (Suzuki et al., 1983),
experiments showing that labels such as 3H-Thymadine slowly fill into the base after the neck
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cells are labeled in long pulses (Karam and Leblond, 1993c), and experiments showing increased
transitional cells when chief cell maturation is blocked (Ramsey et al., 2007).
Gastric injury induces the loss of mature chief characteristics and the appearance of metaplastic
cells co-expressing chief and neck cell markers termed Spasmolytic Polypeptide-Expressing
Metaplasia (SPEM) (Schmidt et al., 1999). Lineage tracing from the chief cell-marking Mist1
locus indicates that these metaplastic cells arise via dedifferentiation of chief cells (Nam et al.,
2010). However, Mist1 expression has also been shown in rare isthmal cells (Hayakawa et al.,
2015; Kinoshita et al., 2018b), questioning the specificity of the lineage marker, and nearly all
other genetic drivers which mark chief cells have also been shown to have some isthmal activity
as well (Phesse and Sansom, 2017), making further genetic lineage tracing approaches currently
unfeasible. SPEM can arise from pre-existing cells without the need for cellular division (Radyk
et al., 2018), supporting the chief cell origin. SPEM resolves within weeks following acute injury
(Huh et al., 2012b), yet it is not yet known on a cellular level what becomes of the metaplastic
cells.
In this study, we use multiple pulse-chase experiments with 5-bromo-2'-deoxyuridine (BrdU),
including experiments pulsing BrdU during injury, to mark long-lived label-retaining cells
allowing us to track the dynamics of the chief cell population at homeostasis and following
SPEM-inducing injury independently of genetic lineage tracing. We find that chief cells appear
to self-replicate at homeostasis and that the majority of neck cells are not fated to becoming chief
cells, contrary to current belief. We then illustrate the conversion of chief cells to SPEM cells
following acute and chronic injury, and further indicate that metaplastic cells can re-differentiate
back into chief cells. Following our results, we suggest a model wherein chief cells are a largely
self-maintaining population at homeostasis and following injury.
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3.3 Methods and Materials
Animals and Injections
All experiments involving animals were performed following protocols approved by the
Washington University School of Medicine Animal Studies Committee. Mice were maintained
in a specified pathogen-free barrier facility under a 12-hour light cycle. Wild type C57BL/6 mice
were purchased from Jackson Laboratories (Bar Harbor, ME). Littermate controls were housed
together when possible. To induce SPEM, tamoxifen (5 mg/20 g body weight; Toronto Research
Chemicals, Inc, Toronto, Canada) was injected intraperitoneally daily for 3 days. Tamoxifen was
dissolved in 10% ethanol and 90% sunflower oil (Millipore Sigma, MO). 5-bromo-2’deoxyuridine (BrdU; MilliporeSigma) was administered via drinking water (800 mg/L) for up to
8 weeks, changed on the third day. 5-ethynyl-2’-deoxyuridine (EdU; Baseclick, Bavaria,
Germany) was injected intraperitoneally daily for 4 days (30 mg / kg mouse mass, dissolved in
PBS).

Immunofluorescence
Upon sacrifice, stomachs were immediately excised, flushed with phosphate buffered saline
(PBS), inflated, and fixed overnight in cold formalin (3.4% formaldehyde in PBS; Millipore
Sigma, MO). The following day, stomachs were transferred to 70% ethanol then cut into rings,
embedded in 3% agar, and underwent routine paraffin processing. 5 μm sections were mounted
on glass slides. Slides were deparaffinized and rehydrated with xylenes and isopropanol, and
antigen retrieval was done via pressure cooking in a Tris solution. Slides were blocked with 1%
bovine serum albumin and 0.3% Triton X-100 in phosphate-buffered saline for 1 hour, then
primary antibodies were incubated overnight at 4 °C. The following day, secondary antibodies
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were applied for 1 hour then slides were mounted using ProLong Gold antifade reagent with
DAPI (Invitrogen, CA).

Primary antibodies used in this project include: rabbit anti-human gastric intrinsic factor
(1:10,000; a gift from Dr. David Alpers, Washington University, St Louis, MO), goat anti–5bromo-2’-deoxyuridine (1:20,000; a gift from Dr. Jeff Gordon, Washington University, St Louis,
MO), Rabbit anti-Ki67 (1:100; Abcam, Cambridge, UK), Sheep anti-pepsinogen II (1:1000,
Abcam), Rabbit anti-αSMA (1:200, Abcam), goat anti-clusterin (1:200, Santa Cruz), rat antiBrdU (1:200, Abcam), rat anti-CD44 v10-e16, ortholog of human v9 (1:200, Cosmo Bio), AAA
Lectin (1:500, EY Labs), and 1 g/mL fluorescently labeled GSII lectin (Alexa Fluor 488, 594,
and 647; Molecular Probes). Secondary antibodies included AlexaFluor (488, 594, or 647)
conjugated donkey anti-goat, anti-rabbit, anti-sheep, anti-rat, or anti-mouse antibodies (1:500;
Molecular Probes). EdU was imaged using the BCK-EdU488 kit following the manufacturer’s
instructions.

Helicobacter pylori infection
The mouse-adapted, wild-type pre-mouse Sydney strain of Helicobacter pylori, PMSS1, was
kindly provided by Dr. Rick Peek (Vanderbilt University). Growth of the PMSS1 strain prior to
inoculation of mice has been previously described(Saenz et al., In press.). Mice were fasted for
4-6 hours prior to oral gavage with 200 μL of an overnight H pylori culture (~1 x 108
cfu/mouse), then fasted for an additional 1-2 hours after infection. Mice were then allowed to
feed ad libitum and were sacrificed 8-12 weeks after infection. Mouse stomachs were excised
and opened along the lesser curvature. Food was gently scraped away, and the forestomach
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removed. Stomachs were pinned out in cold formalin and fixed overnight at 4°C. The next day,
stomachs were cut in longitudinal sections and underwent routine paraffin processing.

Immunofluorescence Quantification
All quantifications were from at least three mice, with both sexes used. Quantifications were
done on stomachs stained fluorescently for anti–5-bromo-2’-deoxyuridine, neck cell marker GSII
lectin and chief cell marker anti-GIF. Single GIF+ cells were scored as mature chief cells; Single
GSII+ cells as mucous neck cells, and GIF+/GSII+ cells were considered metaplastic. Slides were
imaged on a Zeiss Axiovert 200 microscope with an Axiocam MRM camera. For BrdU-retention
assays, only fully imaged units with >3 label-retaining chief, SPEM, or neck cells were
quantified, and at least 20 label-retaining units were quantified per stomach when possible.
Counts were done using Axiovision LE64 software to selectively overlay color channels to count
label-retaining cells co-staining with GIF and/or GSII, as previously described (Radyk et al.,
2018). Counts were averaged over the total number of units quantified per mouse, then all mice
for a condition were averaged for the final value. Graphs were completed in GraphPad Prism (La
Jolla, CA), using one-tailed student t-tests to determine significance, *P<0.05, **P<0.01, and
***P<0.001.

3.4 Chief cells take up little BrdU upon extended continuous pulsing
To track the cellular dynamics of the corpus unit independent of genetic lineage tracing, we
performed continuous BrdU labeling experiments. We administered BrdU in drinking water
continuously for up to eight weeks, harvested stomachs, then immunostained and quantified the
proportion of each cell lineage labeled with BrdU. All cells that performed DNA-replication
during our labeling window will be BrdU+. Due to the continuous labeling paradigm, once a cell
36

is labeled it will remain labeled during the entire pulse window, allowing us to interpret the
entire proliferative history of the gastric corpus unit during our labeling window. As shown in
Figure 3.1, neck cells readily labeled with BrdU, with 70% labeled at two weeks, 77% at four
weeks, and 88% at eight weeks, with neck cells near the isthmus incorporating label before those
lower in the unit, consistent with data published by Karam for a similar experiment giving
continuous 3H-Thymadine (Karam and Leblond, 1993c). Parietal cells incorporated BrdU as a
lower rate than neck cells, as expected, with 24% labeling at two weeks, 37% by four weeks, and
50% at eight weeks, slightly below the rate reported by Karam yet following a similar trend
(Karam, 1993). However, chief cells remained largely BrdU-negative, with less than 10% BrdU+
at all timepoints (Figure 3.1A-B). Surprisingly, we noticed that the chief cells that did take up
BrdU were often nonadjacent to the transitional zone between the unit neck and base, contrary to
what would be expected if chief cells derive from BrdU+ transitional cells. Less than one quarter
of BrdU+ chief cells were adjacent to the transitional zone, with the rest distributed throughout
the base (Figure 3.1C). BrdU+ chief cell were also often found in pairs regardless of position
(Figure 3.1D), suggesting that chief cells may infrequently divide into additional chief cells at
homeostasis, consistent with other works describing a low level of proliferation at the unit base
(Suzuki et al., 1983; Karam and Leblond, 1993c).
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Figure 3.1: Continuous BrdU marks few chief cells in the healthy stomach
A) Stomachs of mice administered BrdU via drinking water for two or eight weeks. BrdU (white
nuclei) incorporation into the main gastric epithelial cell types was tracked (Top panels: GSII+
neck cells in green, GIF+ chief cells in red, GSII+GIF+ transitional cells seen as yellow. Bottom
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panels: Ezrin-expressing parietal cells in red). B) BrdU uptake quantified from images such as in
panel A for each cell population, counted as percentage of the population per unit positive for
BrdU. C) The location within the base of each BrdU+ chief cell was noted, counted as numbers
of cells below the lowest GSII+ (or GSII+CIF+) cell. D) Representative images of BrdU+ chief
cell pairs, stained as for panel A.

3.5 BrdU administered throughout acute injury marks nearly all epithelial
cells
With less than 10% of chief cells incorporating BrdU within an 8-week pulse, pulsing long
enough to mark all chief cells then still chasing multiple months to deplete label from all nonchief cells would be impractical. To label chief cells in a more feasible time window, we tried
continuous labeling with BrdU throughout acute gastric injury using high doses of the selective
estrogen receptor modulator, tamoxifen (TAM). Three daily injections of TAM causes ablation
of nearly all parietal cells and initiates a proliferative and metaplastic response from the
remaining epithelial cells (Huh et al., 2012b; Saenz et al., 2016). To test whether there is enough
proliferation for BrdU to mark nearly all cells, we continuously labeled with BrdU in the
drinking water one day prior to treating with TAM through two days following TAM treatment.
At the end of the BrdU+TAM labeling period, BrdU marked 98.3±0.2% of neck cells,
96.3±0.7% of SPEM cells, and 77.9±3.5% of chief cells (Figure 3.2A-B). TAM-induced SPEM
resolves within two weeks (Huh et al., 2012b), so we performed the same experiment followed
by a chase with normal drinking water for up to nine months. Over 80% of chief cells were
BrdU+ following one month chase, along with 80% of parietal cells and 65% of neck cells
(Figure 3.2C-D). Parietal and neck cells regularly lost label for the first six months before
leveling out with around 20% of parietal cells (Figure 3.3A) and 8% of neck cells retaining label
from months six through nine. Chief cells maintained label throughout the full chase, with
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65.9±4.7% BrdU+ even after nine months, notably longer than their calculated half-year survival
rate (Karam and Leblond, 1993c; Quante et al., 2010). BrdU was diluted from nearly all isthmal
cells within the first months and nearly all neck cells by five months, indicating that the chief cell
population maintains BrdU with no contributions from the upper unit, either through living much
longer than previously recognized or through infrequent self-replication.
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Figure 3.2: BrdU+TAM pulse chases indicate that chief cells are a self-maintaining
population
A) Stomach of a mouse administered BrdU alongside three daily injection with TAM. BrdU
(white nuclei) incorporated into all main cell types of the damaged gastric epithelium (GSII+
neck cells in green, GIF+ chief cells in red, GSII+GIF+ SPEM cells seen as yellow). Right panel
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shows same gastric units with only DAPI and BrdU for better visualization of BrdU uptake. B)
BrdU uptake for each cell population quantified from images such as in panel A, counted as
percentage of the population per unit positive for BrdU. C) Stomachs of mice given the
BrdU+TAM pulse as in panel A then chased for 1-9 months with normal drinking water. Stained
as for panel A. D) BrdU uptake for each cell population quantified from images of 1-9 months
chased, such as in panel C, counted as percentage of the population per unit positive for BrdU.

Figure 3.3: BrdU retention in parietal cells and other epithelial lineages
A) BrdU (white nuclei) is retained in parietal cells (red, Ezrin) through 9 months of chasing, with
long held label generally seen in the lower-most parietal cells. B) Label is seen in endocrine
cells, tuft cells, and stromal cells following three a month chase, but not in pit cells.
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3.6 Chief cells are not the predominate terminal maturation state for neck
cells
Both continuous labeling with BrdU and the BrdU+TAM pulse-chase experiments suggested that
chief cells maintain their own census in the adult stomach, so we next tested the dynamics of
neck cells, as they have been considered transient intermediate precursors to chief cells. We
administered BrdU for two weeks, by which point six neck cells (69.9±4.2% of total), but less
than one chief cell (4.3±0.9% of total) per unit incorporated label. After the continuous 2 weeks
of BrdU labeling, we then chased with normal water for up to eight weeks to see if chief cells
would gain label as neck cells lost it, as would occur if neck cells transitioned into chief cells.
After the eight-week chase, only two neck cells per unit retained label (net loss of 4) while still
only one chief cell per unit had BrdU (no net gain) (Figure 3.4A-B). To find other mechanisms
by which the neck cells could be losing their label, we stained for cleaved caspase 3 and Ki67 in
uninjured stomachs. As expected, no apoptosis was observed in the neck region, and Ki67 was
generally only expressed in the uppermost neck cells (Figure 3.4C), making it unlikely that BrdU
was lost through programmed cell death or diluted by proliferation. We did notice BrdU+ pit
cells fairly regularly at 4 weeks chase (Figure 3.4D), beyond what would be expected for cells
with a published lifespan of 3-4 days (Karam and Leblond, 1993b), otherwise we observed no
process other than dilution in proliferative isthmal cells for any gastric cells to lose BrdU label.
Regardless of how neck cells lose their BrdU, our experiments indicate that neck cells are not
predominately fated to become chief cells, again consistent with chief cells maintaining their
own population.
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Figure 3.4: Chief cells are not the final fate for neck cells
A) Stomachs of mice administered BrdU for two weeks then chased for 4-8 weeks. BrdU (white
nuclei) retained in all main cell types of the damaged gastric epithelium was tracked (GSII+ neck
cells in green, GIF+ chief cells in red, GSII+GIF+ transitional cells seen as yellow). B) BrdU
retention for neck and chief cells quantified from images such as in panel A for the pulse and for
2, 4, and 8 week chases. C) Healthy stomachs stained with GSII (green), GIF (red), and either
cleaved caspase 3 (white, left panel) or Ki67 (white, right panel) to check for cells undergoing
apoptosis or entering the cell cycle. D) Stomach of mice administered BrdU for two weeks then
chased for 4 weeks often had BrdU+ pit cells (AAA, red).
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3.7 Chief cells give rise to SPEM cells following gastric injury
All of our experiments thus far support a model wherein chief cells self-maintain their population
at homeostasis from self-duplication. We next probed whether the same is true following injury.
We performed previously mentioned experiments with BrdU+TAM injury to drive high labeling
throughout the chief cell population and then chased for 3 months. As noted above, at the end of
the 3 month chase 75±7% of chief cells retain label (Figure 3.5A), while the pit, isthmus, and
upper mucous neck cells are unlabeled. In fact at the 3 month chase stage, we only observe an
average of 0.8 BrdU+ epithelial cells in the pit-isthmus-upper neck region that were not
obviously mature parietal cells based on morphology. Separate staining showed that rare gastric
cell populations like endocrine cells, tuft cells, and stromal cells retained label at 3 months. Pit
cells were never seen retaining label after 3 months chase (Figure 3.3B).
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Figure 3.5: Metaplastic cells arise from chief cells following chronic and acute injury
A) Stomach of mouse given BrdU+TAM pulse then a 3 month chase (BrdU, white; GIF, red;
GSII, green). B) Stomach of mouse given BrdU+TAM pulse, 1 month chase, then infected with
Helicobacter pylori, stained as for panel A. C) Stomach of mouse given BrdU+TAM pulse, 3
month chase, then 3 days TAM, stained as for panel A. D) BrdU retention for neck (green), chief
(red), and SPEM (yellow) cells quantified for panels A-C. E) Stomach of mouse given BrdU
over only two days of TAM (BrdU, white; GIF, red; GSII, green). Right panels: split colors
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showing GIF, GSII, and BrdU separately, arrowheads denote SPEM cells that have not yet
proliferated (GIF+, GSII+, BrdU-). *P<0.05, **P<0.01, and ***P<0.001 in one-tailed Student’s t
tests.

To address whether chief cells sourced SPEM, we combined our TAM+BrdU experiments with
Helicobacter pylori (HP) infection. HP infection causes the appearance of small, focal regions of
SPEM beginning around 6 weeks after initiation of infection (Saenz et al., 2018). We generated
TAM+BrdU mice and allowed them to rest for 1 month and initiated HP infection. We then
waited an additional 2 months to allow HP infection to cause metaplasia in the corpus. After 2
months of HP infection, TAM+BrdU mice had small numbers of corpus units with SPEM, while
the rest of the corpus was unaffected and closely mimicked TAM+BrdU mice without HP
infection chased for 3 months (Figure 3.6A). Within the metaplastic units, 67±4% of metaplastic
cells retained BrdU. Additionally, 22±5% of neck cells (GSII only) retained label in metaplastic
units after HP infection, same as the 22±2% seen in TAM+BrdU mice chased for 3 months
without HP infection (Figure 3.5B,D). Given that neck cell label-retention within metaplastic
units of HP infected mice was similar to TAM+BrdU mice chased for 3 months without HP
infection, this indicated that neck cells did not transdifferentiate into the metaplastic cells. If
SPEM cells had arisen from a small number of stem or progenitor cells, we would expect the
multiple rounds of proliferation to dilute the BrdU. Instead, the BrdU+ metaplastic cells appeared
to principally arise at the expense of the preexisting labeled chief cell population with minimal
proliferation. On average, metaplastic units had 6 BrdU+ ‘yellow’ SPEM cells following HP
infection, while the ‘red’ chief cell population lost 8 labeled cells, with no change in ‘green’ neck
cells. Similar results were seen in 15 mice over 8-12 weeks’ infection (Figure 3.6B).
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Figure 3.6 Additional Helicobacter pylori data
A) Non-metaplastic regions of mice given BrdU+TAM, rested one month, then infected with HP
for two months closely resemble units in mice given BrdU+TAM followed by a three month
chase. B) Metaplastic units following 12 weeks HP infection resemble those at 8 weeks.
To test whether acute drug-induced SPEM arises in the same manner as HP-induced SPEM, we
generated TAM+BrdU mice and chased them for three month and subsequently injected them
with an additional three days of TAM to induce metaplasia. Re-injury with TAM induced a
population of BrdU+ SPEM cells to arise while BrdU+ chief cells decreased and BrdU+ neck cells
remained their label (Figure 3.5C-D). To ascertain that the expanded label-retaining GIF+GSII+
cells were truly metaplastic, we co-stained for additional SPEM markers Clusterin and CD44v
(Wada et al., 2013; Weis et al., 2013) and found both markers to overlap with the label-retaining
cells (Figure 3.7A) . These findings are consistent with HP-induced injury and strongly support
the idea that SPEM arises from pre-existing chief cells following injury. We noticed a lesser
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amount of label retention following TAM than in HP infection, likely due to label dilution
because TAM-induced SPEM is much more proliferative than Hp-induced SPEM (Figure 3.7B).

Figure 3.7 Additional SPEM data
A) BrdU-retaining SPEM cells (BrdU+ and GSII to the base of the unit) following re-injury with
TAM express clusterin (left) and CD44v (right), indicating that they are fully metaplastic. B)
Label-retaining SPEM cells following HP infection (left) are largely quiescent (Ki67, red, marks
nuclei of cells in the cell cycle), whereas SPEM cells following TAM (right) are proliferative
An alternate model for how SPEM forms posits that progenitors in the isthmus or neck give rise
to metaplastic cells upon injury (Hayakawa et al., 2015; Kinoshita et al., 2018b). Previous data
from our group showed that SPEM can arise from pre-existing cells when all proliferation is
blocked with fluorouracil (Radyk et al., 2018). To confirm that metaplastic cells arise via
plasticity of pre-existing cells when proliferation is not constrained, we gave continuous BrdU
one day prior to injury and then through two days of TAM. We harvested stomachs following
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two days of TAM instead of the normal peak-SPEM timepoint of 3 days TAM to view the
gastric units as SPEM was actively forming. The presence of cells positive for both GIF and
GSII but not yet BrdU+ (Figure 3.5E) confirmed that SPEM cells arise from existing cells at the
base of the unit, as all SPEM cells would be BrdU+ if they arose from a progenitor population.
To further address potential contributions of isthmal progenitors to metaplasia, we injected mice
that had undergone the BrdU+TAM pulse and three-month chase with EdU for 4 days. After this
4 day label period, we observed EdU incorporated into isthmal cells, lower pit cells, and upper
neck cells, as expected. Negligible overlap was seen with BrdU+ cells at the base (Figure 3.8A).
We then injured mice that had undergone the BrdU+TAM pulse, a three-month chase, and a 4
day EdU label with TAM and sacrificed the mice the next day. EdU was diluted from the isthmal
and neck cells due to the high proliferation induced by TAM, and negligible EdU incorporation
was seen in BrdU+ SPEM cells at the base (Figure 3.8B). Thus, while a minority of SPEM cells
that no longer retain label may possibly arise from non-chief cells, our observations indicate that
the principle source of metaplastic cells following injury are pre-existing chief cells.
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Figure 3.8 EdU+ progenitors do not give rise to EdU+ SPEM cells
A) EdU (cyan) injected for four days labels isthmal, pit (red), and upper neck (green) cells with
no overlap with BrdU+ chief cells (white) B) Label-retaining SPEM cells following HP infection
(left). B) Mice as in panel (A) injected with TAM three days. No EdU staining is seen in SPEM
cells.

3.8 Metaplastic cells can redifferentiate into chief cells following recovery
from injury
To track SPEM cell fate upon recovery, we treated mice with the TAM+BrdU pulse, a threemonth chase, a second round of TAM, then allowed them to recover for two weeks. While many
units completely diluted their label (<4 BrdU+ GIF and/or GSII positive cells) due to the high
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proliferation, units that were not washed out retained BrdU in 47±7% of chief cells (Figure 3.9AB). Upon recovery, an average of 7.3±0.3 chief cells per unit retained label, equal to the sum of
the 2.8±0.1 chief cells and 4.6±0.3 SPEM cells retaining label following the TAM injury. This
indicates that SPEM cells re-differentiate into chief cells with minimal additional proliferation or
death.

Figure 3.9: Metaplastic cells can redifferentiate into chief cells following recovery from
injury
A) Stomach of mouse given BrdU+TAM pulse, 3 month chase, 3 days TAM, then allowed to
recover for 2 weeks (BrdU, white; GIF, red; GSII, green). B) BrdU retention for neck (green),
chief (red), and SPEM/transitional (yellow) cells quantified for panel A. *P<0.05, **P<0.01, and
***P<0.001 in one-tailed Student’s t tests.

3.9 Discussion
In this study, we combined nucleotide analog labeling techniques with acute and chronic gastric
injury models to test the dynamics of gastric cells at homeostasis and following injury. Our
pulse-chasing strategies, including pulsing BrdU throughout TAM injury then tracking labelretaining cells, expanded upon previous reports which mostly relied on long pulses or simple
pulse-chase set-ups. Our combined results indicate that chief cells largely maintain their own
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census at the unit base independently from other lineages at homeostasis, and they retain the
capability to replace themselves upon injury (Figure 3.10, Figure 3.11).

Figure 3.10: Chief cells appear to maintain an independent population at homeostasis
(Left) Our proposed model for how each major gastric cell population is maintained in
homeostasis. Stem cells (grey) give rise to pit cells (purple) neck cells (green) and parietal cells
(blue). Chief cells form a self-maintaining population at the base largely independent of input
from upper cell populations. Colors on arrows denote cell conversions. (Middle) Upon
metaplasia inducing injury such as infection with Helicobacter species or acute drugs, units lose
their parietal cells and see proliferative expansion of the isthmus and neck cells. Chief cells
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dedifferentiate to metaplastic cells (yellow) and re-enter the cell cycle as well. (Right) As the
injury resolves, SPEM cells can redifferentiate into chief cells, then the unit reverts to its normal
homeostatic maintenance.
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Figure 3.11: Models for BrdU pulse-chase experiments comparing the canonical isthmal
stem cell model with our independent base model.
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Multiple experiments suggest that chief cells form a largely self-maintaining population. Our
TAM+BrdU pulse chase strategy allows us to monitor label retention in chief cells, and we see
2/3 of chief cells maintaining label after nine months (Figure 3.2). This longer-than-expected
label retention has three possible explanations: 1) the population could be replenished from other
label-retaining cells, 2) individual chief cells may live longer than nine months, or 3) BrdU+
chief cells may infrequently self-replicate, spreading their label between progeny. Option 1 is
unlikely since neck and parietal cells reach their minimal retention levels by five months.
Individual chief cells were calculated to live around 160 days by two independent studies
(Karam and Leblond, 1993c; Quante et al., 2010), making option 2 unlikely as well. Option 3
seems correct, as chief cells are known to proliferate and die at low levels (Suzuki et al., 1983;
Karam and Leblond, 1993c), and we likewise show low levels of BrdU accumulate in chief cells
over time. The majority chief cells that incorporate BrdU in our continuous BrdU experiments
are nonadjacent to the transitional zone, with BrdU uptake scattered from the upper-most to the
lower-most chief cell (Figure 3.1). This is only possible if chief cells are either dynamically
migrating in the base or, consistent with our model, if they are self-propagating.
Our conclusion that chief cells predominately maintain their own census is also supported by our
two-week BrdU pulse-chase experiments (Figure 3.4). A two-week pulse is sufficient for 68% of
neck cells to incorporate label. Following an eight-week chase, all but 16% of necks cell lose
label, yet there is no increase in BrdU+ chief cells, indicating that neck cells predominately have
a fate other than transitioning into gastric chief cells. This is supported by a paper showing that
neck cells have a distinct function, with protective proteins expressed by neck cells seen coating
the canaliculi of neighboring parietal cells (Hanby et al., 1999). The authors point out that having
a cell with one secretory function converting to a cell with a distinct secretory function would be
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unique throughout the GI tract and unlikely to occur. However, as no apoptotic death is observed
in neck cells and lower neck cells are not proliferative (Figure 3.4), it is unclear from our
experiments what the final fate of these cells might be.
While our experiments suggest a new model for cellular dynamics in the homeostatic stomach,
our data does not conflict with the body of gastric literature. Published continual labeling
experiments show label incorporation into neck cells significantly earlier than in chief cells,
helping lead to the model wherein neck cells transition into chief cells (Karam and Leblond,
1993c; Ramsey et al., 2007). Our results agree with this, as neck cells label long before chief
cells, yet chief cells will eventually label with continuous pulsing based on their low intrinsic
proliferation. Even our data that label is retained by a small proportion of neck cells, transitional
cells, and parietal cells for several months is consistent with the expansive works published by
Dr. Karam in 1993, as he is never able to fully label any of these populations with 3H-thymadine
infusion (Karam, 1993; Karam and Leblond, 1993c). Our model also does not conflict with
papers showing non-expanding subpopulations within the chief cell zone at homeostasis, such as
Lgr5+ chief cells or the minority of chief cells labeled by Mist1CreERT2;RosaYFP (Leushacke et
al., 2017; Weis et al., 2017), or with those showing expanding chief cell subpopulations, such as
Troy+ chief cells, which are shown to slowly expand to fill the base even at homeostasis (Stange
et al., 2013b). Our BrdU+TAM strategy labels nearly all chief cells (>80%) regardless of
subpopulation. A more-proliferative subset of chief cells could slowly replace less-proliferative
subsets at homeostasis while still retaining label as full population.
The transitional zone between the neck and chief cells remains enigmatic. Our data shows that
neck cells do not predominately mature into chief cells, questioning whether the transitional zone
is used for neck-to-chief cell transitioning, as has long been believed (Suzuki et al., 1983; Karam
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and Leblond, 1993c). It is intriguing to speculate that the transitional zone may allow small
numbers of cells to move down from neck to base and up from base to neck, though our
experimental design cannot sufficiently test this. A two-way model would be consistent with
ours and published data. Multiple papers show that a small number of chief cells can eventually
obtain label that was only pulsed into neck cells, with <5 chief cells per unit eventually gaining
label following a TFF2-CreERT2 pulse (Quante et al., 2010) and 10% of chief cells taking up
3

H-Thymadine following a short pulse and longchase (Hattori and Fujita, 1976a). Yet another

report indicates that chief cell progeny can occasionally escape the base and populate full gastric
units at homeostasis (Stange et al., 2013b). Our data do not conflict with either of these
phenomena. We never stain 100% of the chief cells, and 20% of the labeled population is lost
within the nine month chase. This could result from chief cell proliferation diluting the label or
from a small contribution from the necks to the base. Surprisingly, we observed that nearly one
transitional cell and nearly one neck cell per unit retain label even following nine months
chasing. This can either indicate that a subset of both populations live an order of magnitude
longer than expected, or it could be marking a small number of chief cell-derived cells able to
cross up through the transitional zone into the neck of the unit. Further work is needed to clarify
these transitional zone dynamics.
We also show that chief cells can directly become SPEM cells following chronic Hp infection or
acute injury with TAM and that these SPEM cells can redifferentiate into chief cells upon
recovery. One major limitation of using label-retention to track cells throughout an injury
response is that it is impossible to determine the origin of a BrdU-negative cell. In mice given
BrdU-TAM, a three month chase, and then re-injury with TAM, a BrdU-negative SPEM cell
could result from many things: 1) a chief cell which was already BrdU-negative
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dedifferentiating, 2) a BrdU+ chief cell dedifferentiating but diluting its label through
proliferation, or 3) a cell from higher in the unit becoming a SPEM cell. Thus, all we can
conclude is that BrdU+ SPEM cells must derive from pre-existing BrdU+ cells. BrdU+ SPEM
cells likely arise via chief cell dedifferentiation since the two BrdU+ neck cells per unit found
following BrdU+TAM and a three month chase would need to divide several times to give rise to
the 6 BrdU+ SPEM per unit, yet the neck cells retain their label in both injury models. Similarly,
it is extremely unlikely that BrdU+ SPEM cells could result from isthmal progenitors, as less than
1 label-retaining cell is seen near the isthmus in each unit prior to injury, necessitating numerous
rounds of proliferation to form 6 SPEM cells. This was further confirmed by showing that SPEM
cells arise before proliferation occurs in early TAM treatment and by injecting three-month
chased mice with EdU for 4 days before causing TAM-induced SPEM. EdU was retained in
upper isthmal and pit cells, but negligible EdU is seen near the metaplastic bases. This indicates
either that if SPEM cells were to arise from the isthmus, they would proliferate enough to lose
label before becoming SPEM cells. Similar limitations remain for analyzing BrdU-negative chief
cells following recovery from the TAM insult. Thus, while we cannot say that all SPEM cells
arise from or redifferentiate to chief cells, we can say that the BrdU+ portion likely do, showing
that chief cells have the ability to maintain at least a portion of their population following injury.
Growing published evidence supports that chief cells are more independent than previously
assumed. While it was long believed that parietal cell loss triggers SPEM, our lab demonstrated
that parietal cell loss alone is not sufficient to induce chief cell dedifferentiation and highlighted
that neck cells can undergo regenerative proliferation with no change in the base (Burclaff et al.,
2017). Another study revealed that chief cells can dedifferentiate with parietal cells present
(Busada et al., 2019). These reports are consistent with chief cells functioning largely
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independently from all other gastric lineages, which has been obscured by the temporal
intertwining of parietal cell death, neck cell proliferation, and chief cell dedifferentiation
following physiological insults.
Our data is consistent with a new model wherein chief cells largely maintain their own
population at homeostasis and through injury recovery (Figure 3.10). As a population, we see
that chief cells can undergo two rounds of dedifferentiation and redifferentiation without dying.
In the initial BrdU+TAM pulse, chief cells dedifferentiate and proliferate minimally to acquire
label then redifferentiate into BrdU+ chief cells. The second TAM injury repeats this process,
though it dilutes some of the label. This holds implications for gastric health. Our lab has
proposed a Cyclical Hit Model of Tumorigenesis by which long-lived cells able to re-enter the
cell cycle following injury such as the gastric chief cells, pancreatic acinar cells, and intestinal
Paneth cells may initiate tumors independently of stem cell contribution (Mills and Sansom,
2015; Burclaff and Mills, 2018b; Burclaff and Mills, 2018a; Saenz and Mills, 2018a). Cycles of
dedifferentiation, proliferation, and redifferentiation in chief cells could cause mutations which
are then maintained within the long-lived chief cell population until a neoplastic mutation locks
the cells in a proliferative, cancerous state. Thus, it is important to search for conserved
mechanisms for dedifferentiation between organs - such as the conserved Paligenosis pathway
that was recently identified between SPEM and pancreatic acinar cells dedifferentiating in
acinar-to-ductal metaplasia (Willet et al., 2018b) - to find potential therapies for blocking or
reversing this plasticity to prevent or treat early cancers.
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Chapter 4: Chief cells can differentiate in the
absence of parietal cells
4.1 Introduction
Parietal cells (PCs) have long been regarded as important for proper zymogenic chief cell
maintenance and function. Mature chief cells are lost, many to dedifferentiation, following
parietal cell injury in autoimmune gastritis (Adams et al., 1964) or chronic Helicobacter pylori
infection (Lennerz et al., 2010). The relationship between PC loss and metaplasia has been
known for decades, with researchers commenting on the “intimate association among the parietal
cell loss in the fundic gland, a rise in pH value and the development of intestinal metaplasia”
(Watanabe et al., 1980) 40 years ago. Multiple acute drugs recapitulate this relationship in mouse
models, including DMP-777 (Nomura et al., 2005), L-635 (Weis et al., 2013), and tamoxifen
(TAM) (Huh et al., 2012b; Saenz et al., 2016), all of which cause PC loss and result in loss of
chief cells to dedifferentiation within 2-14 days. This dependence of s on PCs is further
published upon in gastric development, where several models have shown that PCs, or their
secreted components, are necessary for the development of mature chief cells. Models for the
constitutive killing of PCs have used the driver for Atp4b, a component of the H+/K+-ATPase
proton pump, to express diphtheria toxin (DT) (Li et al., 1996; Bredemeyer et al., 2009), Simian
Virus 40 (Li et al., 1995), or herpes herpes simplex virus (Canfield et al., 1996). All of these
models cause chronic loss of PCs from birth and result in a severe or complete depletion of chief
cells in adult mice. Similar loss of formation can be seen even without killing the PCs, such as
when acid secretion is blocked through constitutive knockout of ATP4b (Xiao et al., 2010) or
with loss of Sonic Hedgehog expression from PCs (Franic et al., 2001). Intriguingly, constitutive
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knockout of ATP4a, which is also necessary for acid secretion, did not result in depletion (Spicer
et al., 2000). From these experiments and pathological observations of the absence of mature
chief cells in areas of atrophic gastritis in human patients, gastroenterologists have long
considered the chief cell population to be dependent on PCs.

Recent work from our lab has questioned this conclusion. When mice with an Atp4b-driven
inducible DT receptor (HKiDTR) were injected with DT, nearly all PCs were killed, yet there
were surprisingly minimal effects on the chief cells, with most remaining mature (GSII-) and
non-proliferative. This was seen even when DT injections were administered for 16 days
(Burclaff et al., 2017). This clearly indicated that chief cells do not need PCs present to maintain
survival and maturity and that the loss of PCs in a gastric unit does not actively drive chief cell
loss or dedifferentiation. This acute model as used in its introductory publication could not show
whether chief cells could develop in the absence of PCs, though, as chief cells are calculated to
live nearly half of a year, so minimal turnover would be expected in 16 days (Karam and
Leblond, 1993c; Quante et al., 2010).

4.2 Results
To test whether chief cells can develop in the absence of PCs, two approaches were used. In the
first, we tested whether mature chief cells could redevelop following TAM-induced metaplasia
in the absence of PCs. We injected HKiDTR mice with TAM for three days to kill PCs and cause
chief cell dedifferentiation and metaplasia (Huh et al., 2012b). We then continued to inject daily
with DT to keep PCs away for 14 days but without direct effecting the chief cells or their
precursors. One mouse was sacrificed immediately following the 3 days of TAM, showing that
the drug killed PCs and caused chief cell dedifferentiation as expected. Other control mice were
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injected with TAM three days then allowed to recover for 14 days or with vehicle for three day
then 14 days of diphtheria toxin. Following the full 17-day time course, the TAM-then-rest mice
were seen to recover full chief cell and PC populations, with proliferation contained in the
isthmus as would be expected at homeostasis. As in the HKiDTR paper, mice only injected with
DT for 14 days had full PC loss and proliferation throughout the isthmus and neck, yet the chief
cells remained largely unchanged at the base (Figure 4.1A). Interestingly, mice treated with
TAM then DT appeared very similar to DT alone, with no sign of metaplasia at the base and a
full contingent of GIF+/GSII- mature chief cells, even though PCs were still absent (Figure 4.1A)
TAM-then-rest mice were seen to ‘overshoot’ in their chief cell population, with 18.1 chief cells
seen per unit following TAM recovery compared to 12.9 in a healthy unit. DT-alone or TAM +
DT were both seen with chief cell counts nearer their homeostatic levels, with 12.9 ad 14.0,
respectively (Figure 4.1B) Altogether, this shows that chief cells can recover following
metaplastic injury in the absence of PCs, though it is unclear whether these were newly-formed
chief cells or metaplastic cells which re-differentiated into chief cells.

63

Figure 4.1: Chief cells recover from tamoxifen even in the absence of PCs.
A) Stomachs from adult mice following three days of TAM then 14 days of recovery (left), three
days TAM then 14d DT (center), or just 14d DT injections (right) (top: green: GSII, red: antiBrdU, magenta: anti-GIF). Bottom: Hematoxylin and eosin staining of the same stomachs as on
top to visualize loss of PCs (large, round, bright pick cells). B) Quantification of GIF+/GSIIchief cells per gastric unit via immunofluorescence staining.

Since it is unknown whether chief cells recovering from injury follow the same developmental
pathways as those forming initially in newborn mice, we also tested if PCs were necessary for
these first chief cells to form in developing pups. We analyzed the stomach of a P5 mouse and
found that, consistent with the literature (Keeley and Samuelson, 2010), the epithelium of the
developing stomach largely consists of GIF+/GSII+ precursors instead of mature chief or neck
cells (Figure 4.2A) We thus picked P5 as the starting point and injected HKiDTR pups with DT
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daily from P5-P21, when populations of all mature gastric cell types are known to exist. H&E
staining on the P21 stomachs showed that PCs were efficiently killed at similar levels to adult
HKiDTR mice, yet a full population of GIF+/GSII- chief cells was still seen to develop at the
base of the units. Proliferation was also seen throughout the necks of the DT-injected pups, again
similar to adult mice, while proliferation is seen contained to the isthmus in control littermates by
P21 (Figure 4B). Since PCs were effectively killed before and during chief cell development, this
shows that mature PCs are not necessary for even primary chief cell development in a young
mouse stomach.

Figure 4.2: Chief cells develop in the young stomach even in absence of PCs.
A) Representative stomach from a P5 pup (green: GSII, magenta: anti-GIF). B) Stomachs of
HKiDTR (left) or WT (right) pups following DT injections from P5-P21 (green: GSII, red: antiBrdU, magenta: anti-GIF).
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4.3 Discussion
Many papers have shown that PCs or their secreted acid are necessary for chief cell formation in
mice. All of these were done with mechanisms for constitutively ablating PCs or knocking out
their acid secretion. The HKiDTR mouse model allows us to cleanly and inducibly ablate PCs,
which initially allowed us to demonstrate that PC loss does not necessarily initiate the full
metaplastic regenerative response as seen after all other forms of PC injury (Burclaff et al.,
2017). This mouse model allows us to take a further look at the question of chief cell
development. Here, we show that chief cells can recover following injury in adult mice and
develop for the first time in young mice all in the absence of mature PCs.

While our conclusion appears contradictory to the wealth of literature, there are several distinct
reasons for why our experiments might be showing different results. DT and TAM models are
very acute and fast acting damage models, allowing us to look at PC death and chief cell
dedifferentiation and recovery in a couple of weeks instead of the months-long experiments done
with constitutive mutations in most published work. We do not believe that the amount of time
that PCs are gone directly affects chief cell form and function, as the bases appear very similar
after two weeks DT as they do at three days DT. Instead, it is plausible that constitutive loss of
PCs or their acid from birth to adulthood might have allowed for colonization of the stomachs
with pathogenic bacteria which secondarily effected the metaplastic responses seen. Another
possibility arises from the experimental set up for how PCs are killed between experiments. Our
model expresses a toxin receptor on the PCs, only allowing a small amount of toxin into each
cell upon injection. Other models drive toxin or viral factors directly into the parietal cells. As
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neighboring cells are suspected to phagocytose dead cell debris of neighbors at the unit base
(Karam and Leblond, 1993c), it is possible that developing chief cells ingest toxin-filled PC
debris and are collaterally killed. Finally, it is also possible that other published PC-killing
experiments are more effective in their PC ablation, possibly killing PCs at an earlier stage or
even earlier in the development of the stomach in newborn mice. HKiDTR mice lose 95% of
PCs following DT injections, yet it is possible that chief cell maturation may eb supported by the
remaining 5% of PCs, the not-yet-killed pre-PCs, or a small population of PCs which arose
before P5. Our current model and data are insufficient to test which of these possibilities may be
the cause of our conflicting data.

Even though we cannot say specifically how our model results in different chief cell dynamics
than the body of published literature, our results still add important data and advance the field of
stomach development. We show for the first time that chief cells can develop and recover from
injury in the absence of PCs. This may be important for advancing our knowledge of human
health, as precancerous metaplasias are known to begin with atrophic gastritis, or loss of PCs
(Correa, 1988). Our results indicate that the progression to further damaged states might not
result from the loss of any specific PC factor or the physical loss of the cells themselves. Instead,
focus should be given to inflammation and colonizing pathogens to identify what specific factor
may be driving the metaplastic changes in the bases of the gastric units.

4.4 Methods and materials

Animals and Injections
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All experiments involving animals were performed following protocols approved by the
Washington University School of Medicine Animal Studies Committee. Mice were maintained
in a specified pathogen-free barrier facility under a 12-hour light cycle. Wild type C57BL/6 mice
were purchased from Jackson Laboratories (Bar Harbor, ME). Littermate controls were housed
together when possible. HKiDTR mice were derived from ROSA26iDTR/iDTR mice purchased
from Jackson Laboratories bred to Atp4b-Cre mice from our in-house stock.

To ablate PCs, diphtheria toxin (225ng/mouse in 0.9% sodium chloride saline; Sigma) was
injected intraperitoneally every day for up to 16 days. To induce SPEM, tamoxifen (5 mg/20 g
body weight; Toronto Research Chemicals, Inc, Toronto, Canada) was injected intraperitoneally
daily for 3 days. Tamoxifen was dissolved in 10% ethanol and 90% sunflower oil (Sigma),
following the procedure outlined in (Saenz et al., 2016).

Immunofluorescence

Mice were given an intraperitoneal injection of 5-bromo-2’-deoxyuridine (BrdU, 120 mg/kg) and
5-fluoro-2’-deoxyuridine (12 mg/kg) in sterile water 90 min before sacrifice. Following sacrifice,
stomachs were immediately excised and flushed with PBS, then inflated and fixed overnight in
cold formalin (3.4% formaldeyde in phosphate buffered saline; Sigma). Tissues were arranged in
3% agar in a tissue cassette, underwent routine paraffin processing, and 5μm sections were cut
and mounted on glass slides. Sections underwent a standard deparaffinization and rehydration
protocol, were blocked in 1% BSA, 0.3% Triton-X100 in PBS, left with primary antibodies
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overnight, washed then and incubated for one hour with secondary antibodies, washed, washed,
then mounted using ProLong Gold antifade reagent with DAPI (Invitrogen, CA).

Primary Antibodies used in this study: rabbit anti-gastric intrinsic factor (gift of Dr. David
Alpers, Washington University), goat anti-Brdu (gift of Dr. Jeff Gordon, Washington
University), and 1 g/ml fluorescently labeled GSII lectin (Alexafluor488, 594, Molecular
Probes). Secondary Antibodies included AlexaFluor (488, 594 or 647) conjugated donkey antigoat or anti-rabbit (Molecular Probes).

Immunofluorescence quantification

Chief cell census was quantified with at least three mice for each condition. Stomachs were
fluorescently stained with DAPI and anti-BrdU along with the neck cell marker GSII lectin and
chief cell marker anti-GIF. Images were captured as TIFF files from a Zeiss Axiovert 200
microscope with Axiocam MRM camera and with Apotome optical sectioning filter. Each
stomach had at least 5 images taken and only well-oriented gastric units were counted. Total
chief cell counts were averaged over total number of units counted for each mouse.
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Chapter 5: MNU can be used to initiate
gastric tumorigenesis
5.1 Introduction
The risk of developing cancer increases as a person ages, but we still don’t know why. The
intersection of cellular dedifferentiation and response to inflammation may hold the key. In
response to inflammation, one tissue can take on the characteristics of a different tissue in a
process called metaplasia. Metaplasia almost always occurs following inflammation, and this is
known to increase cancer risk, yet it remains unclear how. Mature cells can be recruited back
into the cell cycle in adult organs, termed dedifferentiation. The ability of differentiated cells to
be called back into a proliferative, more progenitor-like state may be a normal, evolutionarily
conserved feature of many adult tissues. Organisms may use this process to reserve differentiated
cells as potential stem cells during injury/inflammation (Mills and Sansom, 2015).
We believe that metaplasia arises when cells dedifferentiate and re-enter the cell cycle in
response to injury (Mills and Sansom, 2015). As normally post-mitotic cells re-enter the cell
cycle, they increase their risk of acquiring mutations. If the mutations do not cause death or cell
cycle arrest, the cells redifferentiate to their mature state once the tissue recovers. Through cycles
of dedifferentiation and redifferentiation, mutations accumulate in these long-lived cells until a
tumor-inducing mutation occurs, locking the cells into a proliferative state. For example,
pancreatic adenocarcinomas arise when mature acinar cells with constitutively active K-Ras
undergo metaplastic dedifferentiation, but activating K-Ras does nothing until another signal
causes the acinar cells to dedifferentiate and proliferate (von Figura et al., 2014). Likewise,
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melanocytes with constitutively active BRAF only induce melanomas upon dedifferentiation
(Kaufman et al., 2016). This could explain why tissue surrounding a tumor can harbor the same
mutations without malignancy. The cancer-driving power of the mutations are only fully realized
when the cell re-enters the cell cycle and can no longer redifferentiate.
Newly developed model systems from our lab should allow us to test this hypothesis in the
mouse stomach. We previously discovered that injecting a high dose of tamoxifen causes death
of the acid-secreting parietal cells, inflammation, and rapid and reversible gastric metaplasia,
with mature enzyme-secreting cells at the base dedifferentiating to re-enter the cell cycle. This
response occurs in a pattern recapitulating precancerous metaplasias caused by Helicobacter
pylori in human patients (Huh et al., 2012b; Saenz et al., 2016). We also bred mice expressing
the human diphtheria toxin receptor specifically on parietal cells. Treatment with diphtheria
toxin kills all parietal cells and results in inflammation and increased proliferation of the
constitutive stem cell, but not metaplasia (Burclaff et al., 2016). Both systems cause similar
parietal cell death and stem cell proliferation; the only difference is the lack of dedifferentiation
with metaplastic proliferation after diphtheria toxin. These systems will allow us to specifically
test for the first time whether metaplastic dedifferentiation of mature, long-lived cells is critical
for mutation accumulation and cancer initiation as opposed to increased stem cell proliferation
and inflammation alone.

5.2 Results
Previous reports show that FVB mice form more tumors with less death than C57Bl6 mice when
treated with the carcinogen N- methyl-N-nitrosourea (MNU) (Yamamoto et al., 2002). 25
FVB/NJ mice were ordered from Jackson Laboratories then treated with a published protocol for
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MNU (Yamachika et al., 1998), wherein 240ppm MNU is given in the drinking water for a full
week on alternating weeks for ten weeks. To test whether rounds of injury/metaplasia increase
chances for tumor formation, mice were split into three groups: 10 mice were treated with MNU
with rounds of tamoxifen administered on weeks 1, 3, and 5, 10 were treated with MNU and
rounds of vehicle, and 10 were only given rounds of tamoxifen with no MNU (Figure 5.1A).
Published literature shows that tumors should form by week 36.

Starting 10 weeks following the MNU cycles, mice were live-imaged to test for tumor formation
using a FMT imager to track tumorigenesis. ProSense 680 (Perkin Elmer, enzymatically
activated by Cathepsin B and other lysosomal enzymes) and MMPSense 750 FAST (Perkin
Elmer, enzymatically activated by MMP-2, MMP-9 and others) have both been shown to be able
to track gastric cancer in mice in vivo (Ding et al., 2012), even in a context of chronic
inflammation (Zhang et al., 2008). Immunofluorescent signal was observed in the abdomen of
HD-TAM treated mice, so we performed a bio-distribution assay to quantify the amount of
fluorescence coming from each individual harvested organ. This indicated that the signal was
originating in the spleen and liver, with minimal signal emanating from the gastric tissue (Figure
5.2B,C).
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Figure 5.1: MNU timecourse and in vivo fluorescence imaging.
A) The timecourse for the pilot trial of MNU + rounds TAM or vehicles. Following published
protocols, MNU was given via drinking water on alternating weeks for 10 weeks. TAM or VEH
were injected on two consecutive days on weeks 1, 3, and 5. Living mice were to be imaged
starting on week 20 for tumor formation. B) The stomach regions of mice were seen to fluoresce
in the channel for ProSense680 at D3 TAM. C) The Bio-distribution of the ProSense 680 probe
was checked in freshly harvested organs immediately following in vivo live imaging. Most
signal was seen in the spleen and liver, with negligible fluorescence originating from the
stomach (upper right).

Once we found that the in vivo immunofluorescence probes gave non-stomach-specific signal,
we tried an alternate form of in vivo live imaging on the same mice: PET/CT scanning using
Fludeoxyglucose (18-FDG) glucose analogue to highlight tissues with highly metabolic cells.
Signal was seen around the expected area for the stomach in many mice (Figure 5.2A). To
determine whether the signals originated from the stomachs themselves, the mice with the best
PET/CT signaling were sacrificed by the Small Animal Radiology Core personnel. Stomachs
showed signal, yet the upper duodenum and other nearby organs did as well, so it remains
unclear whether the signal seen on the PET scanning was truly stomach specific. Since we were
not allowed to be present during the sacrifice due to the radioactive injections, we were unable to
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fix the stomachs ourselves, resulting in poor orientation for scanning for polyps on the full
stomach or histological staining (Figure 5.2B).

Figure 5.2: PET/CT Scanning on MNU treated mice.
A) Signal seen in live mice using PET/CT Scanning with 18-FDG. Hearts, kidneys, and bladders
are expected to fluoresce due to their high metabolic activity. Stomach tissue was not always
seen (blue circle, left image), yet some mice had high signal in what appeared to be the outline of
the stomach epithelium (blue circle, right image). B) Stomach pinned out after fixing following
harvesting at the Small Animal Cancer Imaging Core.

Throughout the experiment, many mice died from infection, fighting, isofluorane and imaging,
or sacrifice for bio-distribution imaging, leaving only 7 TAM+MNU mice, 6 VEH+MNU mice,
and 3 TAM-only mice living longer than 30 weeks. Of these, 5/7 TAM+MNU, 2/6 VEH+MNU,
and 0/3 TAM-only mice showed evidence of gastric polyps/tumors, nearly all in the antral
portion of the stomach (Figure 5.3 A,B) While not quantified, many mice showed polyps in their
liver, kidneys, or other organs as well (Figure 5.3C).
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Figure 5.3: MNU induced tumors.
A) The most impressive tumors were seen in an MNU+TAM mouse which died at week 30.
Most tumor formation was confined to the antral region (blue arrowhead) with some sparse
polyps seen in the corpus region as well (yellow arrowhead). 2) Polyp formation on the badlyoriented stomachs following the bio-distribution assay for 18-FDG was monitored via
hematoxylin and eosin staining did not allow for proper staging of the polyp severity. C) A large
cancerous kidney found in a dead mouse at week 30, an example of MNU off-target effects.

A second trial was begun to increase N and to fix stomachs with better orientation. In this trial,
the same 10 week MNU protocol was followed, but TAM or VEH was injected every 4 weeks
throughout the entire experiment to test whether the rounds of metaplasia have more effect after
the cells had undergone the MNU treatments. 15 MNU+TAM, 15 MNU+VEH, 5 TAM-only,
and 5 VEH-only mice were tested. Mice died from all groups nearly weekly starting at week 17,
with cause of death generally undetermined. So many mice died that the remaining mice were all
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sacrificed at week 26 to have enough N to use the data, yet almost no polyps were seen at this
early time point.

5.3 Discussion
These pilot trials were mainly used to test the techniques for long-term carcinogenesis studies,
and they were successful in that manner. The 10-week published MNU protocol was seen to
cause polyp formation in the stomachs of FVB/N mice when they lived for longer than 30 weeks
from the beginning of the experiment. While there were rarely well-oriented fixed stomachs
available to directly analyze polyp/tumor pathology, preliminary numbers indicate that TAMtreated mice are twice as likely to form polyps/tumors as VEH-treated mice within the MNU
protocol. This is consistent with the Cyclical Hit Model of Tumorigenesis, wherein long-lived
cells may undergo rounds of dedifferentiation and redifferentiation resulting from physiological
injury over the lifetime of an animal. These rounds of entering and leaving the cell cycle may
allow the long-lived cells to accumulate and store mutations, eventually leading to tumorigenesis
in a stem cell-independent manner (Burclaff and Mills, 2018b; Burclaff and Mills, 2018a).

The pilot studies also showed us many ways to improve experimental design for future trials. It
was demonstrated that TAM-treated mice have more fluorescence in their spleen and liver than
in their stomachs when probed with ProSense 680 and MMPSense 750 FAST. Since these two
organs reside near the stomach, it is difficult to ascertain if any signal is specific to the stomach
when imaging live mice. PET/CT scanning with 18-FDG appears to mark the actual stomach,
with the curve of the antrum likely visible in some images. However, bio-distribution imaging
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indicated that the upper duodenum also had signal, so future work should verify that the signal is
stomach-specific.

The issue of mice dying was also highlighted by both trials. While some death may be
unavoidable in these experiments due to their length and number of injections, a large amount of
early death seemed to result from the mice fighting. All FVB/N mice used were males ordered in
bulk from Jackson Laboratories. Future studies should consider using female mice or males bred
in-house and only housed with direct siblings to reduce fighting. If the mice can be kept alive
throughout the experiment, it will be exciting to see further studies repeat these trials to properly
determine whether rounds of injury and/or metaplasia increase tumor incidence and rate.

5.4 Methods and Materials
Animals and tumorigenesis
All experiments involving animals were performed following protocols approved by the
Washington University School of Medicine Animal Studies Committee. Mice were maintained
in a specified in-and-out facility under a 12-hour light cycle. Wild type FVB/N mice were
purchased from Jackson Laboratories (Bar Harbor, ME). Mice were kept on a low-fluorescence
chow prior to in vivo fluorescence imaging to minimize autofluoresence throughout the GI tract.
To induce tumorigenesis, mice were given N- methyl-N-nitrosourea (MNU, 240ppm, Toronto
Research Chemicals) in their drinking water on alternating weeks for 10 total weeks.
Tamoxifen (5 mg/20 g body weight; Toronto Research Chemicals) or vehicle (10% ethanol, 90%
sunflower oil, Sigma) were injected intraperitoneally for two days.
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Live near-infrared fluorescence imaging
Mice were pre-imaged on a FMT Imager without probes injected to record the natural
autofluorescence of the stomach region. Immediately following the pre-imaging, mice received
ProSense 680 (2nmol/150µl, Perkin Elmer) via tail-vein injection. The following day, mice were
injected with MMPSense 750 FAST probes (2nmol/100µl, Perkin Elmer) 6 hours before
imaging.
To image, mice were knocked out using isofluorane then their full abdomen was shaved smooth
with an electric razor and Nair hair remover. Mice were imaged for the manufacturer-installed
channels for Prosense 680 and MMPSense 750 Fast on a fluorescence molecular tomography
(FMT4000, Perkin Elmer) system with a Region of Interest drawn around the stomach area of
their upper left abdominal quadrant.

PET/CT Scanning
All PET/CT scanning and relevant injections were done by the Small Animal Cancer Imaging
core at Washington University. Mice were fasted overnight prior to imaging, then injected with
18-FDG. Kinetic imaging was taken for 1 hour after probe injection. Images were viewed using
Inveon Research Workplace software

Histology
When possible, stomachs were harvested, flushed in PBS, opened along the greater curvature,
then pinned out in fresh 10% formalin overnight at 4 °C. Images of full stomachs were taken
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using a dissecting microscope (Olympus SZX7). Stomachs were then cut into thin strips and
embedded in agar for normal processing and mounting onto glass slides. Polyp pathology was
imaged after staining for hematoxylin and eosin following the standard protocol.
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Chapter 6: Nitric Oxide may act as a damage
signal between dying parietal cells and the
gastric epithelium
6.1 Introduction
The major physiological and morphological changes of SPEM are becoming better
understood, yet work remains to characterize its molecular regulation, especially the mechanism
by which it is initiated. SPEM consistently seems to occur in units with injured/dead parietal
cells (PCs), suggesting that there are intercellular signals passed between PCs and the stem cells,
neck cells, and chief cells which respond to their atrophy. Two possible mechanisms could
explain how this signaling occurs. Healthy PCs may secrete signals that promote normal adult
gastric differentiation and inhibit SPEM. In this idea, SPEM changes only begin after sufficient
PC atrophy occurs such that there may be differentiation-promoting/SPEM-inhibiting products
are lost from the PCs as they are killed. The other, not mutually exclusive, possibility is that
injured/dying PCs may express an as-yet-uncharacterized damage signal which is received by the
surrounding cells to actively induce SPEM (Mills and Shivdasani, 2011). To date, several
paracrine-acting factors have been identified to originate from healthy PCs, supporting the first
theory. Known PC-elaborated factors include amphiregulin, sonic hedgehog, VEGF-B, BMP4,
and EGF family members (Goldenring et al., 1996; Mills et al., 2001; Nitsche et al., 2007; Nam
et al., 2009; Huh et al., 2010; Xiao et al., 2010). To our knowledge, no one has published factors
that PCs secrete specifically during injury that might affect neighboring epithelial cells.
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Nitric oxide (NO) is a small, short-lived, soluble gaseous signaling molecule often used
in intercellular and intracellular signaling. NO is a well-studied signaling molecule implicated in
many systems throughout the body including neuronal, cardiovascular, renal, pulmonary,
endocrine, and immune system signaling (Nathan, 1992). The mammalian body has three nitric
oxide synthases (NOS): the constitutively expressed neuronal and endothelial synthases (nNOS
and eNOS), which are activated by intracellular calcium and calmodulin, and the inducible nitric
oxide synthase (iNOS), which is regulated at the transcriptional level by cytokines and other
signals (Nathan, 1992)
There is only one known protein receptor for NO in the cell: soluble guanylyl cyclase
(sGC), which converts GTP to cGMP when activated by NO binding (Pyriochou and
Papapetropoulos, 2005). NO remains bound to sGC with a half-life of around 2 minutes, which
decreases to 5 seconds with MgGMP present, indicating that sGC can have quick and dynamic
response times (Kharitonov et al., 1997). NO levels are also extremely dynamic. Physiological
levels of NO can range over six orders of magnitude, from picomolar to micromolar levels
(Hetrick and Schoenfisch, 2013). These levels can also change quickly due to NO’s low half-life
(<10 seconds), and data shows that iNOS can inactivate within minutes (Palmer et al., 1987;
Hetrick and Schoenfisch, 2013). Both of these characteristics make NO-sGC signaling extremely
responsive to quick stimuli.
While sGC is the only known protein receptor for NO and it is considered the ‘classical’
signaling mechanism, NO can also have sGC independent effects within the cell (Martinez-Ruiz
et al., 2011). NO has been shown to S-nitrosylate thiol-containing proteins, binding to cysteine
residues (Stamler, 1994). NO is also able to form disulfide bridges and induce post-translational
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modifications to various proteins (Burke et al., 2013). Several enzymes include cysteines at their
active sites, so NO can have wide ranging effects outside of NO-sGC signaling.
Preliminary data from our lab indicate that inducible nitric oxide synthase expression is
observed in PCs following injury. NO produced in these dying cells could explain why SPEM
only occurs locally in units with dying PCs. Thus, NO may be one of the key activating signals
inducing SPEM. Here, we study whether NO signaling propagates the gastric damage response
following PC injury and attempt to determine whether it acts through sGC in the process.

6.2 Results
Previous unpublished data from our lab indicated that inducible nitric oxide synthase
(iNOS) expression is observed in PCs 6-12 hours post HD-TAM and in tissue from human
gastric cancer patients following H pylori infection, though no expression is seen in homeostatic
PCs (Khurana, S.S. Dissertation, 2014). To continue this project, I began by confirming iNOS
expression in PCs following HD-TAM as well as in tissue from mice injected with DMP-777
(gift of Dr James Goldenring, Vanderbilt University). While iNOS is seen in some PCs following
damage, its expression is often light with only rare individual PCs expressing high iNOS (Figure
6.1). This may be a result of experimental technique or it could be indicative of an extremely
short and controlled expression time for iNOS within dying cells. Regardless, it makes
quantifying iNOS+ PCs impractical.
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Figure 6.1: iNOS expresses in individual PCs following injury.
A) Immunofluorescence staining of parietal cells after 12h TAM (Blue: hoescht, green: VEGFb
(PCs), red: iNOS). B) Immunohistochemical staining for iNOS following 6hr TAM. Grey
arrowheads show PCs lightly expressing for iNOS. C) Immunofluorescence staining of parietal
cells after 7 days of DMP-777, stained as in A.

To test whether NO introduced to the full mouse body is sufficient to increase gastric
proliferation, the NO donor S-nitroso-N-acetyl penicillamine (SNAP) was injected
intraperitoneally into uninjured mice (Singh et al., 1996). When injected at 3mg/kg mouse
weight for 3 days, SNAP caused significantly increased gastric proliferation, though it only
effected a subset of mice (Figure 6.2A,B). Also, the proliferation increase was still confined to
the isthmus of the gastric units, and no SPEM or other damage response signatures were seen.
The biphasic proliferative response and lack of metaplasia may result from the method of
introduction, as physiological NO is a short-lived and locally-acting signal. Therefore, a diffuse
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injection of an NO donor having any effect on gastric proliferation was considered as a positive
indication that local NO may have important effects.

Figure 6.2: The NO donor SNAP has a limited effect on gastric proliferation.
A) Quantification of proliferating cells per unit in mice injected with varying concentrations of
SNAP for three days. B) Compiled proliferation data from all experiments where mice were
injected with vehicle or 3mg/kg SNAP for 2 or 3 days. SNAP is seen to significantly increase
proliferation, though the effect is mainly seen in a subset of the mice.

We next wanted to see whether NO production via iNOS expression is necessary for the full
damage response to occur. Aminoguanidine hemisulfate (AG) inhibits iNOS activity without
affecting basal NO production from eNOS or nNOS (Corbett and McDaniel, 1996). If NO is
active as PCs are injured yet still alive, we would expect the effect to be seen early in the damage
response. Therefore, we injected AG before and alongside 24 hours HD-TAM and monitored
proliferation. We saw no difference in BrdU+ cells per unit at 24h TAM with or without AG coinjected (Figure 6.3)
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Figure 6.3: Inhibition of iNOS activity has no significant effect on proliferation.

Seeing that NO levels appear to effect gastric proliferation following SNAP injections, we
wanted to test whether NO acted through its sole known protein receptor, sGC. Staining for sGC
indicated expression in the cytoplasm of chief cells and, to a lesser extent, neck cells (Figure
6.4A), consistent with the cellular populations shown to respond to PC injury. To test the
necessity of sGC for the proper damage response, sGCflox/flox mice were purchased from Jackson
Laboratories and bred to Mist1-CreERT mice. Interestingly, Mist1-CreERT; sGCflox/flox mice did
not appear to lose sGC expression following low dose tamoxifen administration, and sGC-floxed
mice showed no difference in their response to HD-TAM (Figure 6.4B,C).
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Figure 6.4: sGC in chief and neck cells is unchanged following floxing.
A) Immunofluorescence staining for sGC in a wild type stomach (blue: hoescht, red: sGC,
yellow: GIF, green: GSII). sGC is seen to strongly overlap with GIF expression and is also
expressed, to a lesser extent, in GSII+ neck cells. B) Immunofluorescence staining for sGC in
control mice and in Mist1CreER;sGCflox/flox mice after a week of low-dose tamoxifen to induce
the Cre recombinase. C) Quantification of proliferating cells per gastric unit show no change
between control mice and mice with sGC floxed.

All of the experiments done so far modulated NO levels or reception on a systemic level, but NO
is known to be a highly localized signaling agent. To model more physiological NO expression
from PCs, TetO-iNOS-lacZ mice (Mungrue et al., 2002) were crossed with a constitutively
active PC-specific Cre driver line (ATP4b-Cre) and a ROSA26-LSL-rtTA.IRES.EGFP line,
which will only express the rtTA “Tet-On” system in the presence of a Cre driver. These crosses
should result in mice that express iNOS specifically in PCs, and only following induction via
doxycycline injection. They have the added benefit of driving LacZ reporter expression in any
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cell that expresses iNOS. Unfortunately, the LacZ reporter was only seen in rare clumps of nonPC cells following induction (Figure 6.5). Since NO was not being produced in PCs or
efficiently across the stomachs, it was impossible to draw conclusions from these mice.

Figure 6.5: Sporadic iNOS is driven from Tet-On iNOS overexpression mice.
LacZ coloration was developed in Tet-On iNOS mice, yet LacZ was only seen in rare units and
in those it is expressed in the pit cell region. No parietal cell-specific expression was observed
(not shown).

6.3 Discussion
NO expression is known to affect proliferation and other cellular processes in many
physiological systems. Its solubility and short half-life, along with the highly controlled
expression of iNOS allowing for dynamic NO concentration changes, make NO a prime
candidate signal for how injured PCs might alert the rest of the gastric unit to damage and the
need for increased proliferation. Experimental data support that NO may be active in such a role,
as iNOS is seen in some PCs following injury and full-body NO increases raised gastric
proliferation. Yet many complicating factors are seen for each experiment. While iNOS is seen
87

in some PCs following injury, it often stains extremely lightly, only staining as highly expressed
in rare individual cells. SNAP shows a relatively weak effects compared to the full range of
proliferation seen following injury, yet, it must be remembered that these blunt systemic drugs
lack the intricate intra-glandular gradients that would be expected from a local signaler such as
NO. Inhibiting iNOS activity via AG with D3 or 24h TAM had no noticeable effect on
proliferation. Also, sGC expression was seen in chief cells and neck cells, two populations of
cells known to proliferate following PC injury, however, sGC staining remained consistent even
in sGC-floxed mice, so no conclusions could be drawn from these experiments. Likewise, our
‘Tet-On’ system to drive iNOS expression specifically in PCs following doxycycline injection
could not be verified, as the LacZ reporter that should be driven alongside iNOS expression only
appeared in rare clusters of cells.

Thus, while NO still holds promise as an agent used by injured cells to initiate proliferation of
their surrounding cells, our available tools were insufficient to fully test whether this is the case
in the stomach following PC injury.

6.4 Methods and Materials
Animals and Injections
All experiments involving animals were performed following protocols approved by the
Washington University School of Medicine Animal Studies Committee. Mice were maintained
in a specified pathogen-free barrier facility under a 12-hour light cycle. Wild type C57BL/6 mice
were purchased from Jackson Laboratories (Bar Harbor, ME). Littermate controls were housed
together when possible. To induce SPEM, tamoxifen (5 mg/20 g body weight; Toronto Research
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Chemicals, Inc, Toronto, Canada) was injected intraperitoneally daily for 3 days. Tamoxifen was
dissolved in 10% ethanol and 90% sunflower oil (Sigma), following the procedure outlined in
(Saenz et al., 2016). S-nitroso-N-acetyl penicillamine (SNAP, Sigma) was dissolved in 0.9%
saline and normally injected three times daily with 3 mg /kg mouse mass. Aminoguanidine
(Sigma) was also dissolved 0.9% saline and injected at 400mg/kg.

Immunofluorescence
Mice were given an intraperitoneal injection containing 5-bromo-2’-deoxyuridine (BrdU, 120
mg/kg) and 5-fluoro-2’-deoxyuridine (12 mg/kg) in sterile water 90 min before sacrifice.
Following sacrifice, stomachs were immediately excised and flushed with PBS, then pinned out
and fixed in freshly prepared methacarn (60% methanol, 30% chloroform, 10% glacial acetic
acid) for 20 minutes or fixed overnight in cold formalin (3.4% formaldeyde in phosphate
buffered saline; Sigma Aldrich, MO). Tissues were arranged in 3% agar in a tissue cassette,
underwent routine paraffin processing, and 5μm sections were cut and mounted on glass slides.
Sections underwent a standard deparaffinization and rehydration protocol, were blocked in 1%
BSA, 0.3% Triton-X100 in PBS, left with primary antibodies overnight, washed then and
incubated for one hour with secondary antibodies, washed, washed, then mounted using ProLong
Gold antifade reagent with DAPI (Invitrogen, CA).

Primary Antibodies used in this study: rabbit anti-human gastric intrinsic factor (gift of Dr.
David Alpers, Washington University), goat anti-Brdu (gift of Dr. Jeff Gordon, Washington
University), goat anti-VEGFb (1:100, Santa Cruz), rabbit anti-iNOS (Abcam), rabbit anti-sGC
(Sigma) or 1 g/ml fluorescently labeled GSII lectin (Alexafluor488, 594, Molecular Probes).
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Secondary Antibodies included AlexaFluor (488, 594 or 647) conjugated donkey anti-goat, antirabbit, or anti-mouse (Molecular Probes).

Immunofluorescence quantification
All timepoints were quantified with at least three mice, with representatives from both genders.
Stomachs were fluorescently stained with bisbenzimide and either anti-BrdU or anti-VEGFb
markers along with the neck cell marker GSII lectin and zymogenic cell marker anti-GIF. Images
were captured as TIFF files from a Zeiss Axiovert 200 microscope with Axiocam MRM camera
and with Apotome optical sectioning filter. Each stomach had at least 5 images taken containing
10+ well-oriented gastric units each. Units were counted using the neck staining, and total
quantifications of proliferating cells (BrdU+) or PCs (VEGFb+) were averaged over total unit
numbers per mouse.

Tet-On system
TetO-iNOS-lacZ mice (Mungrue et al., 2002) were crossed with a constitutively active PCspecific Cre driver line (ATP4b-Cre) and a ROSA26-LSL-rtTA.IRES.EGFP line. To activate the
rtTA, mice were injected intraperitoneally with Doxycycline hyclate (10 mg/mL solution in 0.9%
saline injected at 10uL/g mouse mass, Sigma) daily for three days.

For LacZ staining, we followed a modified version of the protocol used in (Stange et al., 2013b).
Freshly harvested stomachs were fixed in 4% PFA for 1 hour at 4 °C then washed in a solutions
containing 100 mM sodium phosphate, 2 mM MgCl2, 0.1% sodium deoxycholate, and 0.02%
Triton x-100. Stomachs were then stained overnight in a solution containing 1 mg/mL X-gal, 5
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mM potassium ferricyanide, and 5mM potassium hexacyanoferrate. The following day, the
stomachs were washed then post-fixed overnight in 4% PFA before being processed into blocks
as usual.

91

Chapter 7: Neck cells undergo many of the
defined steps of Paligenosis when re-entering
the cell cycle following injury
7.1 Introduction
Recent work from our lab has highlighted that long-lived, mature cells between organs follow a
conserved pathway to revert to a regenerative state, which we have termed paligenosis (Willet et
al., 2018b). The pathway was defined in gastric chief cells and pancreatic acinar cells, and
corresponding data was shown in numerous other organs. As chief cells and acinar cells are both
terminally differentiated secretory cells, in is unproven whether paligenosis occurs in less
mature, non-secretory, or even intermediate cells.
Neck cells are triangular cells found interspersed between parietal cells in the neck of the gastric
unit. Classical papers using 3H-Thymidine pulse chase experiments indicate that neck cells are a
short-lived intermediate population between the stem cell and the chief cell population at the
base of the gastric unit with a turnover time of 9-16 days (Hattori and Fujita, 1976a; Karam and
Leblond, 1993c). The idea that neck cells transdifferentiate into chief cells is further supported
by the presence of transitional cells found between the neck and chief cell regions co-expressing
neck and chief cell markers (Suzuki et al., 1983; Ramsey et al., 2007). Some have argued that
neck cells should be regarded as an independent population since they appear to secrete
protective proteins, and it would be unique throughout the GI tract to have a functional
population mature into a separate functional population (Hanby et al., 1999), however, the
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prevailing agreement in the field is that neck cells largely act as the bridge between stem cells
and chief cells (Goldenring et al., 2011a).
While the contribution of neck cells in tamoxifen-mediated spasmolytic polypeptide-expressing
metaplasia (SPEM) has been largely overlooked due to the large changes undergone by the
parietal cell and chief cell populations, our recent work with HKiDTR mice highlight that neck
cells re-enter the cell cycle following parietal cell injury (Burclaff and Mills, 2018a). Neck cells
are normally non-proliferative, with around 0.33 neck cells per unit taking up BrdU in a 90 min
pulse (Burclaff et al., 2017), raising the question of how neck cells re-enter the cell cycle when
the parietal cells are injured. Do neck cells follow the same paligenosis pathway as more mature
secretory cells, or are they able to re-enter the cell cycle in a different manner due to their
smaller size and simpler structure? Our lab’s tamoxifen (TAM) and targeted diphtheria toxin
(DT models should allow us to test this.

7.2 Results
As recently published by our lab, mature cells need to undergo key regulatory changes to
properly re-enter the cell cycle following injury (Willet et al., 2018b). Chief and acinar cells both
have active Mtorc1 at homeostasis, as detected via phosphor-S6 immunostaining. This is quickly
shut off following injury yet needs to return before the cells proliferate. Autophagy and
lysosomal activity must also occur to reduce the levels of rough ER, secretory vesicles, and
mitochondria in the complex secretory cells. Finally, metaplastic genes are seen to express in
both cell types, including Sox9 and CD44v. All of these processes can be tested with specific
attention paid to the neck cells following injury from TAM or targeted DT.
We first tested whether metaplastic genes express in neck cells following injury. Unlike chief
and acinar cells, neck cells express high Sox9 at homeostasis, and this was not seen to change
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following injury (Figure 7.1). However, other metaplastic genes such as CD44v and clusterin
quickly express in neck cells following PC injury, as already shown in (Burclaff et al., 2017),
consistent with the paligenosis pathway.

Figure 7.1: Sox9 expression in healthy and injured stomachs.
Immunofluorescence staining for Sox9 in healthy stomachs and stomachs of mice treated with
DT or TAM for 3 days (red: GIF, green: GSII, white: SOX9). SOX9 expression in GSII+ appears
consistent regardless of damage status.

We next examined mTorc1 activity using immunofluorescence staining for its downstream target
pS6. Unlike chief and acinar cells, neck cells are not normally pS6+, so the initial deactivating
step could not occur. However, mTorc1 was seen to activate throughout the neck regions by 24h
TAM or DT, indicating that neck cells use mTorc1 activity in their proliferative response to
injury similar to chief cells (Figure 7.2A) Intriguingly, nearly all neck cells are pS6+ following
DT even in units where the PCs have not yet died, raising questions about how they recognize
that damage is occurring, but that is outside the scope of this project. To test whether this
mTorc1 activity is necessary for neck cell proliferation, we treated mice with rapamycin before
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and alongside TAM or DT. When cell type-specific proliferation was quantified at D3 TAM or
DT following rapamycin treatment, neck cell-specific proliferation was significantly decreased
for both (Figure 7.2B,C). This indicates that neck cells have an mTorc1-activation checkpoint
before they can properly proliferate, consistent with the paligenosis pathway.

Figure 7.2: Neck cells have dynamic mTorc1 activity following injury.
A) Immunofluorescence for pS6 (green) in a healthy mouse stomach or 24h after injection with
TAM or DT to HKiDTR mice. B,C) Quantification of proliferating cells by population following
three daily injections of TAM or DT (Red = chief cells, yellow = SPEM cells, green = neck cells,
blue = no differentiation markers expressed).
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We next looked at autophagy and lysosomal activity in neck cells following injury. Neck cells
would be expected to have less need for these processes, as they are already much smaller and
less complex than chief cells, yet the question remains whether they necessitate any level of
downscaling to successfully re-enter the cell cycle. Neck cells are closely latticed between
parietal cells which are constitutively high for autophagy and lysosomy proteins, making
analyzing neck cell autophagy by immunofluorescence difficult. We instead used transmission
electron microscopy (tEM) to count autophagic events happening in individual neck and chief
cells following TAM and DT. Autophagy is easy to identify in tEM images, determined as a
double membrane surrounding contents separated from the rest of the cytoplasm (Figure 7.3A).
A low level of autophagic events were seen in both cell types at homeostasis. These increased in
both cell types 24h following TAM or DT, with a greater change seen in chief cells, as expected
(Figure 7.3B). This indicates that increased autophagy does occur in neck cells following injury.
To test whether this autophagy was necessary for proper re-entry into the cell cycle, we analyzed
the proliferative response to TAM in lysosomal-defective Gnptab-/- mice. The main phenotype of
these mice is gland dropout following TAM, yet to probe neck cell-specific effects we had to
quantify proliferation in the remaining full units. With that selection bias, the total decrease in
proliferation was less than expected, yet neck cell-specific proliferation was still significantly
decreased (Figure 7.3C). To avoid the gland dropout, we tried inhibiting lysosomal function by
injecting Lys05, which is published to de-acidify lysosomes with 10x the efficiency of
hydroxychloroquine (McAfee et al., 2012). We injected Lys05 before and throughout TAM, and
extremely varied phenotypes were seen, ranging from full proliferative SPEM to SPEM lacking
proliferation to regions with no SPEM and very few proliferating cells (Figure 7.3D). Due to the
variance, we did not quantify neck cell-specific proliferation, but the stomachs lacking SPEM or
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proper proliferation reinforce the need for lysosomal activity for the proper regenerative response
to occur across gastric cell types. So while we were ultimately unable to directly prove that neck
cells need lysosomal activity to proliferate, data from several experiments indicate that they have
increased autophagy and that neck cells with inhibited lysosomes proliferate less following
injury, consistent with paligenosis in chief cells.

Figure 7.3: Neck cells activate autophagy following injury.
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A) Example transmission electron microcopy image of two chief cells 8h following TAM. Chief
cells are outlined in red. Autophagic events are circled in yellow. B) Quantification of
autophagic events per cell in neck cells and chief cells in healthy stomachs or stomachs 24h
following TAM or DT injections. C) Quantification of proliferating cells by population
following three daily injections of TAM either alone or with Lys05 injected one day prior and
alongside the TAM (Red = chief cells, yellow = SPEM cells, green = neck cells, blue = no
differentiation markers expressed). * denotes significance for the population indicated P < 0.05.
D) Immunofluorescence images of stomachs following injections with Lys05 and TAM (red:
GIF, green: GSII, white: BrdU). All mice were treated identically, yet phenotypes ranged from
proliferative SPEM (left) to non-proliferative SPEM (middle) to no proliferation or SPEM
(right).

Unpublished data from our lab implicate another gene, Ifrd1, in the paligenotic response in chief
and acinar cells, with Ifrd1-/-mice unable to properly proliferate following gastric or pancreatic
injury (Mark Lewis, unpublished). We bred Ifrd1-/- mice with HKiDTR mice to test whether the
knockout has any effect on neck cell proliferation. Across four knockout or control mice,
proliferation was unchanged following DT treatment (Figure 7.4).

IFRD1 KO has no effect on
DT-mediated proliferation

BrdU+ Cells
Per Gastric Unit

15

10

5

0
DT D3

Ifrd1ko + DT D3

Figure 7.4: IFRD1 status has no effect on neck cell proliferation following injury.
Quantification of proliferating cells per unit at D3 DT showed no difference in proliferative
capacity between HKiDTR or HKiDTR;Ifrd1flox/flox mice.

98

7.3 Discussion
Paligenosis presents a useful paradigm for studying how non-proliferative cells re-enter the cell
cycle following injury. This may advance our knowledge of acute injury responses, chronic
inflammatory or metaplastic conditions, and possibly even cancer initiation (Burclaff and Mills,
2018b; Burclaff and Mills, 2018a). Our understanding of paligenosis is still nascent, and more
phases and necessary proteins in the mechanism are currently being fleshed out by our group.
However, as the mechanistic knowledge increases, it will also be important to say which cell
types can and do undergo this important process. Will any non-proliferative cell that becomes
regenerative following injury undergo the conserved changes? Will it depend on maturation
state, cell age, or some cadre of genes being expressed by the cell at homeostasis? Here, we tried
to answer some of these questions by looking at the regenerative response of gastric neck cells,
which are smaller, shorter-lived, and less complex than chief cells.
Neck cells were found to undergo very similar changes as chief cells following injury, though
often to a lesser extent. While neck cells express novel genes such as CD44v and Clusterin
before proliferating, Sox9, one of the main metaplastic genes used to describe paligenosis, is
already expressed by neck cells, possibly indicating that they may naturally be in a more
metaplastic or closer to a regenerative state. Likewise, mTorc1 activation is necessary for proper
neck cell proliferation, yet there is no mTorc1 originally active in the cells, so neck cells undergo
less initial changes than chief cells. Finally, autophagy appears to occur and be necessary for
proper proliferation in neck cells, yet neck cells were seen to increase their autophagic events per
cells by a much smaller amount than chief cells.
While the three main changes defined in the introductory paligenosis paper may occur in neck
cells, they lack other characteristics of the cell types shown to undergo paligenosis. For example,
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they have no noticeable change in Sox9 and they do not need to lose mTorc1 activity in Phase 1.
Ifrd1 depletion also has no effect following DT, while it decreases basal proliferation following
TAM. As future work in our lab and others should continue to define further steps and proteins
involved in paligenosis, each newly defined aspect should be tested in neck cells or other
intermediate and non-secretory cells to help solidify which cell types can undergo the full
response.

7.4 Methods and Materials
Animals and Injections
All experiments involving animals were performed following protocols approved by the
Washington University School of Medicine Animal Studies Committee. Mice were maintained
in a specified pathogen-free barrier facility under a 12-hour light cycle. Wild type C57BL/6 mice
were purchased from Jackson Laboratories (Bar Harbor, ME). Littermate controls were housed
together when possible. HKiDTR mice were bred from ROSA26iDTR/iDTR mice purchased from
Jackson Laboratories bred to ATP4b-Cre mice from our in house stock. Data for GNPTAB-/mice were taken directly from counts done for previously published experiments (Willet et al.,
2018b).

To ablate PCs, diphtheria toxin (225ng/mouse in 0.9% sodium chloride saline; Sigma) was
injected intraperitoneally every day for up to 16 days. To induce SPEM, tamoxifen (5 mg/20 g
body weight; Toronto Research Chemicals, Inc, Toronto, Canada) was injected intraperitoneally
daily for 3 days. Tamoxifen was dissolved in 10% ethanol and 90% sunflower oil (Sigma),
following the procedure outlined in (Saenz et al., 2016). mTorc1 activity was inhibited with daily
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injections of rapamycin beginning one day before TAM or DT (Sigma). Rapamycin was
prepared by dissolving 30mg/mL in 100% ethanol then suspended the ethanol solution 1:50 in
0.25% Tween20, 0.25% PEG in 1xPBS, and 100µL/20g mouse mass was injected. Lysosomal
activity was inhibited by injecting 40 or 60mg/kg mouse mass Lys06 daily beginning one day
before TAM or DT (dissolved in PBS, Selleck Chemicals).

Immunofluorescence
Mice were given an intraperitoneal injection of 5-bromo-2’-deoxyuridine (BrdU, 120 mg/kg) and
5-fluoro-2’-deoxyuridine (12 mg/kg) in sterile water 90 min before sacrifice. Following sacrifice,
stomachs were immediately excised and flushed with PBS, then inflated and fixed overnight in
cold formalin (3.4% formaldeyde in phosphate buffered saline; Sigma). Tissues were arranged in
3% agar in a tissue cassette, underwent routine paraffin processing, and 5μm sections were cut
and mounted on glass slides. Sections underwent a standard deparaffinization and rehydration
protocol, were blocked in 1% BSA, 0.3% Triton-X100 in PBS, left with primary antibodies
overnight, washed then and incubated for one hour with secondary antibodies, washed, washed,
then mounted using ProLong Gold antifade reagent with DAPI (Invitrogen, CA).

Primary Antibodies used in this study: rabbit or goat anti-gastric intrinsic factor (gift of Dr.
David Alpers, Washington University), goat anti-Brdu (gift of Dr. Jeff Gordon, Washington
University), rabbit anti-Sox9 (Millipore), goat anti-clusterin (Santa Cruz), mouse anti-CD44v
(CosmoBio), rabbit anti-pS6 (Cell Signaling), goat anti-cathepsin D (Santa Cruz), and 1 g/ml
fluorescently labeled GSII lectin (Alexafluor488, 594, Molecular Probes). Secondary Antibodies
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included AlexaFluor (488, 594 or 647) conjugated donkey anti-goat, anti-mouse, or anti-rabbit
(Molecular Probes).

Tissue preparation and imaging for electron microscopy was done as previously described
(Ramsey et al., 2007).

Immunofluorescence quantification
Proliferation counts were quantified from at least three mice for each condition. Stomachs were
fluorescently stained with DAPI and anti-BrdU along with the neck cell marker GSII lectin and
ZC marker anti-GIF. Images were captured as TIFF files from a Zeiss Axiovert 200 microscope
with Axiocam MRM camera and with Apotome optical sectioning filter. Each stomach had at
least 5 images taken and only well-oriented gastric units were counted. BrdU+ cell types were
identified as ZC (red, GIF+/GSII-), transitional/SPEM cells (yellow, GIF+/GSII+), neck cells
(green, GIF-/GSII+), or non-secretory cells (blue, GIF-/GSII-). Total counts were averaged over
total unit numbers per mouse.
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Chapter 8: Conclusions and Future
Directions
8.1 Overall summary
Surprisingly little is known about the cellular populations of the stomach compared to other wellstudied organisms. Since the stomach field lacks genetic drivers to mark most cell types in the
adult stomach, much of our knowledge of the lifespans and interactions of gastric cells comes
from simple pulse-chase experiments using 3H-thymadine or by analyzing fixed tissues with
immunostaining or in electron microscopy. This evidence has led the field to believe that all cells
in the stomach arise from the isthmal stem cells, with neck cells transitioning to chief cells after
around two weeks of migrating to the unit base, yet no direct proof of this has been shown.
Gastric cancer is the third most deadly form of cancer worldwide (Ferlay et al., 2015), yet little is
known about the earliest steps of tumor progression. Pelayo Correa, a trailblazer in modeling
gastric carcinogenesis, described a pathway to gastric cancer beginning with irritants causing
superficial gastritis followed by atrophic gastritis, or chronic loss of parietal cells and mature
chief cells, which then leads to intestinal metaplasia and eventually dysplasia and carcinoma
(Correa, 1988). Thus, atrophic gastritis is an important step that should be well understood for
the prevention and early treatment of gastric tumorigenesis. In the decades following Pelayo’s
work, the pathological condition of atrophic gastritis has been histologically described as
Spasmolytic Polypeptide-Expressing Metaplasia (Schmidt et al., 1999), and it has become
understood that the loss of mature chief cells is likely a result of their dedifferentiation into the
metaplastic cells themselves (Nam et al., 2010). Furthermore, atrophic gastritis/SPEM has been
shown to increase risk of cancer in patients (Kakinoki et al., 2009). Yet with these advances in
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our understanding of the significance of SPEM, little is known about how it is initiated. Many
papers have postulated that the loss of parietal cells causes the metaplastic changes to occur, as
parietal cells are lost before all physiological forms of SPEM, but this has never been specifically
tested. In the present work, we undertook multiple strategies to investigate what causes chief
cells to dedifferentiate following injury, determine lifespan and fate dynamics for neck cells and
chief cells at homeostasis and following injury, and test mechanisms involved in the re-entry of
chief and neck cells to the cell cycle following injury.
In Chapter 2, we set out to identify signals from dying parietal cells which initiate the
metaplastic response by developing a new model for selectively ablating parietal cells through
apoptosis using an inducible diphtheria toxin receptor. As parietal cell death has long been linked
to the chief cell changes, we expected this model to cause the normal SPEM response, similar to
our high dose tamoxifen model, but in a more defined system allowing for easier analysis of
damage signals. Instead, we found that targeted apoptosis of parietal cells caused increased
proliferation through the neck of the gastric unit, but no proliferation or metaplasia in the chief
cells (Burclaff et al., 2017). We further show that metaplasia can still be initiated when parietal
cells are killed via DT and then the mice are co-injected with TAM or DMP-777. This work
presents interesting hints about the dynamics of the gastric epithelial populations, as chief cells
and parietal cells no longer appear as interconnected in their fates as previously believed. It also
suggests that neck cells and chief cells may be more independent than previously understood, as
necks can be called to proliferate following injury despite the absence of a chief cell response
During my time in lab, papers were published questioning the veracity and specificity of the
Mist1 promotor to track chief cell fate (Hayakawa et al., 2015; Kinoshita et al., 2018b). As Mist1
lineage tracing accounts for the bulk of the published data proving that chief cells give rise to
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SPEM cells (Nam et al., 2010), we developed a novel BrdU pulse-chase strategy to track the fate
of long-lived cells in the stomach, as discussed in Chapter 3. Normal continuous pulsing with
Brdu marks >10% of chief cells even after 8 weeks, so we pulsed BrdU throughout three days of
TAM injections, allowing us to mark nearly all epithelial cells once the stomachs recovered from
the TAM injury. BrdU is quickly diluted from proliferative populations, allowing us to track
long-lived label-retaining cells over months of chasing. The results were surprising, with two
thirds of chief cells retaining label even at 9 months chase, showing that they do not die and get
replaced from neck cells in their published life-span of half a year. This indicates that the chief
cell population is either extremely long-lived or that it maintains itself through rare duplication
events. We tested whether all necks give rise to chief cells, as Karam also indicated (Karam and
Leblond, 1993c), by pulsing BrdU into the necks for two weeks without injury, then chasing to
see whether the label-retaining neck cells transitioned into chief cells. By 4 and 8 weeks of
chase, neck cell labeling drastically decreased while chief cell staining stayed largely consistent,
indicating that the majority of neck cells must have some ultimate fate other than becoming a
chief cell and strengthening the idea that the chief cells are a self-maintaining population. We
next tracked label-retaining chief cells upon injury with TAM or Helicobacter pylori, and the
label-retention in chronic and acute metaplastic cells indicate that SPEM arises from chief cells
in both insults. Finally, we tracked label retaining SPEM through recovery and found that these
cells can redifferentiate into chief cells, supporting the Cyclical Hit Model, which posits that
tumors can arise from long-lived non-stem cells which can cycle between dedifferentiating and
redifferentiating in rounds of injury, accumulating and storing mutations along the way until one
traps it in a proliferative, neoplastic state.
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We further tested the independence of gastric chief cells by testing whether they can develop in
the absence of mature parietal cells. Many papers have shown that chief cells do not develop
correctly when parietal cells are ablated via Atp4b-Cre-driven viruses or toxins, yet these
systems add high amounts of the expressed toxic substance to the gastric unit, and most wait
until adulthood to test whether the chief cells are present. Our HKiDTR mice allowed us to test
whether chief cells depend on parietal cells in much quicker and less toxic experiments. We
injected with TAM for three days then DT for two weeks and showed that the metaplastic bases
could redifferentiate into chief cells even with parietal cells continuously ablated. To test
whether chief cells could develop in pups with no parietal cells present, we injected HKiDTR
mice with DT from P5-P21, yet we again found that chief cells could develop normally with no
parietal cells present. Further work will need to be done to ascertain why our model behaves
differently than previous models. Possible explanations include that a lower level of toxin is
introduced, that pre-parietal cells present already at P5 may be sufficient to provide necessary
signals, or that ablating parietal cells for more than a couple weeks allows for outside pathogens
to infect the stomach, causing a secondary metaplastic effect. Regardless, our experiments
indicate for the first time that chief cells do not rely on parietal cells to develop or to maintain
their maturation state.
Overall, the work in this dissertation has questioned multiple long-held notions in gastric
epithelial cell dynamics. The new HKiDTR mice allow us to show that parietal cell loss is not
sufficient to cause chief cell dedifferentiation, and that parietal cells are not even necessary for
chief cells to recover from injury or develop in young pups. Our novel strategy for pulse-chasing
BrdU throughout TAM injury also indicates that the relationship between neck cells and chief
cells needs to be examined further, neck cells do not appear to become chief cells. The BrdU
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evidence supports a model wherein chief cells in the adult stomach are a wholly self-maintaining
population, both at homeostasis and following acute or chronic injury. These experiments may
lay the groundwork for an entirely new understanding of the stomach, with the cell fates less
interconnected than previously believed, and the possibility that not every cell type is actually
replenished from a multipotent isthmal stem cell.

8.2 Future directions
1. Do cellular dedifferentiation, inflammation, and metaplasia increase cancer risk?
As discussed in Chapter 5, the carcinogen N- methyl-N-nitrosourea (MNU) can be used to drive
tumorigenesis within the mouse stomach (Yamamoto et al., 2002). Tumor formation appears to
be increased with rounds of metaplasia and inflammation caused by HD-TAM in pilot
experiments, yet more work needs to be done to show this with statistical significance. The
model has already been expanded to help with other projects in the lab. We have a paper under
review investigating Ddit4, a gene we found to be necessary for cells to properly respond to
tamoxifen-induced damage. A key figure in this paper is subjecting Ddit4 knockout mice to the
MNU system, and we found that the knockout mice formed more and larger tumors than wild
type mice (Miao, et al. Under review). We have multiple other projects being run looking at
further genes involved in the stomach’s response to injury, and MNU-tumorigenesis experiments
will help advance the significance of these as well.
We believe that the dedifferentiation of long-lived chief cells elicited by HD-TAM allows for
increased accumulation and retention of tumor-causing mutations, as illustrated in the Cyclical
Hit Model in Chapter 1 (Burclaff and Mills, 2018b; Burclaff and Mills, 2018a). We now have the
tools to test this theory in our lab. HD-TAM causes increased proliferation from the gastric
stem/progenitor cells, neck cells, and chief cells, while injections of diphtheria toxin (DT) to
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HKiDTR mice increases proliferation in the isthmus and through the neck, but no metaplastic or
proliferative effects are seen in the long-lived chief cells (Burclaff et al., 2017). Using these
models side-by-side within an MNU timecourse will allow us to track whether cycles of chief
cell dedifferentiation and redifferentiation increases tumorigenesis over rounds of injury and
increased stem//progenitor cell proliferation alone.
We prepared for testing this theory by engineering a mouse line with the human diphtheria toxin
receptor (DTR) gene driven directly by the ATP4b (HK) promotor (HKDTR) instead of relying
on a promotor-cre allele and an inducible LSL-DTR allele (HKiDTR). We made this transgenic
mouse in the FVB/N mouse background, since previous literature indicates that mouse strain has
a large effect on sensitivity to MNU, and FVB mice were shown to have high tumor formation
with a low mortality rate over the MNU timecourse (Yamamoto et al., 2002).
We prepared DNA for transgenic induction by synthesizing each gene portion separately
(Genescript) then ligating them together within a pGIT3G plasmid (gift of Dr Blair Madison,
Washington University). The construct included two copies of the cHSIV promotor in tandem
followed by the nucleotides -1035 to +25 of the mouse Atp4b gene, the portion often used to
drive parietal cell-specific gene expression (Zhao et al., 2010). A Kozak sequence
(gcc)GCCACCATGG immediately followed the promotor, then the DTR gene itself followed
(genbank #M93012 bp 56-682 (626 bp) from mRNA). To finish the construct, we added a gGIVS2 intron and the SV40 late PolA sequence. The full construct is modeled in Figure 8.1
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Figure 8.1: Transgenic construct for HKDTR mouse engineering.
A pGIT3G-ATP4b-intron-DTR plasmid was constructed by combining individual gene segments
for insulators, the Atp4b promotor, the human diphtheria toxin receptor, an intron, and an SV40
polyA site.

We digested the full construct with SfiI, removing the 2.2kb backbone from the 7.3kb vector,
separated the DNA bands with a long electrophoresis run, then extracted using a GeneJET Gel
Extraction Kit (Thermo Fisher). Purified DNA was sent to the Washington University Mouse
Genetics Core to be injected into the pronuclei of fertilized FVB/N oocytes. We received 16
founders from the core, as genotyped using DTR primers (DTR For:
CTGGACCTTTTGAGAGTCACTTTATCCTCC, DTR Rev:
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CTCTCCTATGGTACCTAAACATGAGAAGCC). Founders were paired with wild type
FVB/N mice (Jackson Laboratories) to breed.
We next tested whether P1 progeny from each founder line developed a healthy stomach and
properly caused PC ablation upon DT injection. Lines found to cause irregular development of
the stomach were discontinued (Figure 8.2A), leaving only founder lines which developed and
responded to DT properly (Figure 8.2B-D)

Figure 8.2: Checking for proper HKDTR mouse development.
A) Some HKDTR founder lines failed to develop correctly, forming few and small parietal cells
and some corpus units appearing more antral-like. B) HKDTR lines with proper corpus gastric
unit development were selected for. C) HKDTR lines show good parietal cell loss upon DT
injection. D) HKDTR mice with D3 DT show proliferation through the neck but not in the base,
consisted with previously reported HKiDTR phenotypes.
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Future work will breed large numbers of mice expressing the HKDTR allele and run MNU
carcinogenesis trials similar to those detailed in Chapter 5. All trials will use the 10 week
protocol for administering 240ppm MNU in drinking water every other week. Trials will test the
effect of rounds of DT, TAM, or VEH (2 days injected every three weeks) either during or
following the 10 weeks of MNU. PET/CT scanning and stomach histology will be used to test
time to tumorigenesis emphasizing tumor number, size, and position. We hypothesize that
MNU+TAM mice should develop more gastric corpus tumors quicker than MNU+DT, with both
developing significantly more than MNU+VEH treated mice.

2. Do dying parietal cell secrete metaplasia-inducing signals?
While HKiDTR mice efficiently kill parietal cells upon DT injection without initiating SPEM,
they do not prove that dying parietal cells cannot secrete signals sufficient to drive chief cell
dedifferentiation. DT is known to kill its targeted cells purely through apoptosis, while agents
such as TAM and DMP-777 are believed to kill some cells through necrosis or other more
immunogenic methods. These differences in death mechanism may account for differences seen
in the chief cell response to DT vs TAM. To test this, Atp4b-Cre;iDTR;mTmG mice can be used
to FACS sort parietal cells away from other gastric populations, as in (Willet et al., 2018b).
Parietal cell can be cultured ex vivo for multiple days, as described in (Gliddon et al., 2008).
This protocol was successfully completed in previous work in our lab, but a yeast infection
prevented useful data from being obtained (data not shown). When parietal cells are cultured at
high concentrations, TAM, DT, DMP-777, or VEH will be added to kill the parietal cell in each
drug-dependent way. Media from each well will then be collected and gavaged into the stomachs
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of untreated mice. Mice gavaged with media from DT or vehicle treated parietal cells would be
expected not to have any gastric effects, while those from TAM or DMP-777 may experience
chief cell dedifferentiation if dying parietal cells secrete metaplasia-inducing signals.
If metaplasia is found to occur following gavage with media from DMP-777 or TAM-treated
parietal cells, each media can be probed using ELISA for levels of candidate proteins such as
known cytokines and interleukins. Mass spectrometry can also be used to discover new candidate
proteins in an unbiased manner. Newly implicated proteins can be studied further in vivo, with
simple experiments tracking their expression at homeostasis or in injury, testing their necessity
for SPEM through knock-out experiments from the Atp4b-Cre promotor, and testing whether
they are sufficient to induce SPEM through knock-in experiments, possibly using the Mist1CreERT2 promotor to inducibly express them directly to the base of the gastric unit.

Closing Remarks
The experiments proposed above will complement the other work completed in this dissertation
to significantly advance our knowledge of plasticity and gastric cell dynamics. As shown in
Chapter 3, it is becoming increasingly clear that mature cells can undergo multiple rounds of
dedifferentiation and redifferentiation, a trait that will likely be conserved in other tissues such as
the pancreas as well. This experimental data shows that the rounds of plasticity needed for the
Cyclical Hit Model of Tumorigenesis (Mills and Sansom, 2015; Burclaff and Mills, 2018b;
Burclaff and Mills, 2018a; Saenz and Mills, 2018a) to be feasible can occur in vivo. I test that
the rounds of plasticity can occur in vivo in Chapter 3, so undertaking the MNU + TAM or DT
timelines proposed ere will finally directly test whether the chief cell plasticity increases tumor
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formation over increased proliferation alone. This will be important information for the stomach
as well as every other organ with long-lived cells shown to have the ability to re-enter the cell
cycle.
The second experiment proposed above will show whether chief cells are completely
independent of parietal cells. Chapters 2 and 4 show that the presence of parietal cells is not
necessary for chief cells to maintain their mature state, re-differentiate following injury, or
develop in young pups. A recent publication even shows that SPEM can occur before parietal
cells are lost (Busada et al., 2019). The future work outlined above will allow us to demonstrate
whether signals from parietal cells dying through necrosis or other non-apoptotic forms of death
are sufficient for triggering chief cell dedifferentiation and the full regenerative SPEM response.
This will inform the field whether our long-held belief that the fates of chief cells and parietal
cells are closely intertwined is valid or if both populations maintain themselves independently of
the other and just happen to respond to similar injury stimuli on similar timescales.
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Appendix 1: Modeling murine gastric
metaplasia through tamoxifen-induced acute
parietal cell loss

The following chapter was published in Gastrointestinal Physiology and Diseases

Saenz, Jose B., Joseph Burclaff, and Jason C. Mills. "Modeling murine gastric metaplasia
through tamoxifen-induced acute parietal cell loss." In Gastrointestinal Physiology and
Diseases, pp. 329-339. Humana Press, New York, NY, 2016.
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A1.1 Summary
Parietal cell loss represents the initial step in the sequential progression toward gastric
adenocarcinoma. In the setting of chronic inflammation, the expansion of the mucosal response
to parietal cell loss characterizes a crucial transition en route to gastric dysplasia. Here, we detail
methods for using the selective estrogen receptor modulator tamoxifen as a novel tool to rapidly
and reversibly induce parietal cell loss in mice in order to study the mechanisms that underlie
these pre-neoplastic events.

A1.2 Introduction
Gastric adenocarcinoma remains one of the leading causes of cancer-related deaths
worldwide (1). The sequence of events leading to the development of gastric dysplasia and
neoplasia begins with the loss of acid-secreting parietal cells, a process known as oxyntic
atrophy, followed by the expansion of pre-neoplastic changes in the setting of chronic
inflammation (2). The early mucosal response to oxyntic atrophy includes reorganization of the
gastric unit, characterized initially by an increased proliferation of gastric progenitor cells and
the reprogramming of post-mitotic chief cells at the base of the gastric gland into a proliferating
population of metaplastic cells (3). Overall, the pattern of gastric unit reorganization that
characterizes the response to oxyntic atrophy is known as spasmolytic polypeptide-expressing
metaplasia (SPEM), as the metaplastic chief cells express spasmolytic polypeptide (also known
as trefoil factor family 2; TFF2). SPEM can either be a transient alteration in the gastric
landscape, followed by repair and restoration of normal architecture, or it can represent a crucial
pre-neoplastic event en route to gastric dysplasia in the setting of chronic inflammation. The
study of the mechanisms underlying the development and evolution of SPEM has been
accelerated by recently developed tools (4-6) that rapidly induce SPEM in animal models of
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gastric dysplasia. Here, we describe the discovery and use of the selective estrogen receptor
modulator, tamoxifen, as a model for studying SPEM.
In addition to its widespread therapeutic use as hormonal therapy, tamoxifen has recently
found a role in conditional gene targeting in the mouse (7). Notably, the development of a
ligand-dependent Cre-ER recombinase, in which the Cre enzyme is fused to a mutated hormonebinding domain of the estrogen receptor, has allowed for the use of tamoxifen to modulate gene
expression in a spatiotemporal fashion (8). As a result, tamoxifen now serves as a tool for
regulating tissue-specific Cre activity.
However, the use of tamoxifen for induction of the Cre-ER recombinase led to a
serendipitous discovery in the mouse stomach that has broadened its role beyond the Cre-ER
system and implicated tamoxifen as a unique agent for studying the early events following
oxyntic atrophy (9, 10). Serial intra-peritoneal injections of various strains of wild-type mice
with tamoxifen induced apoptosis in the vast majority of parietal cells, metaplastic changes in the
chief cells at the bases of the gastric glands, and an increased proliferation of gastric progenitor
cells, changes characteristic of and consistent with SPEM. This effect is reproducible (11),
estrogen-independent, and reversible, with a normalization of gastric histology within weeks of
tamoxifen discontinuation (10). The tamoxifen administration protocol described below therefore
offers a unique method for reproducing oxyntic atrophy and dissecting early pre-neoplastic
events leading to gastric dysplasia.

A1.3 Materials
Preparation of tamoxifen stock
1.

Tamoxifen (see Note 1).
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2.

Sterile sunflower seed oil (see Note 2).

3.

Ethanol (200 proof).

4.

Sonic dismembrator with microtip (2 mm).

5.

Eppendorf tubes (1.5 mL).

6.

Benchtop vortex machine.

7.

Pipettor.

8.

Protective headphones.

Mouse injection
1.

Insulin syringe with needle (0.5 mL, 27 gauge x 0.5 inch).

2.

Balance.

3.

Alcohol wipes.

A1.4 Methods
Carry out all procedures at room temperature unless otherwise specified.
The following protocol corresponds to a tamoxifen solution dissolved in 10% ethanol and 90%
sunflower seed oil (see Note 3).
Preparation of tamoxifen stock
1.

Weigh mice (see Note 4).
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2.

Weigh out 25 mg of dry tamoxifen and place it in a 1.5 mL Eppendorf tube (see Note 5).

3.

Slowly add 100 µL of 100% ethanol, trying to keep the tamoxifen at the bottom of the

tube. Do not shake, mix, or pipet.
4.

Measure 900 µL of sterile sunflower seed oil in a separate 1.5 mL Eppendorf tube.

5.

Sonicate the tamoxifen/ethanol mixture in the Eppendorf tube at 40% amplitude in 20-

second pulses until the tamoxifen is completely dissolved (see Note 6).
6.

Immediately combine the tamoxifen/ethanol mixture with the sunflower seed oil. Cap and

vortex the solution to ensure adequate mixing (see Note 7).
7.

The tamoxifen mixture can be stored at 4ºC for up to three days or at -20ºC indefinitely

(see Note 8). Allow the mixture to warm to room temperature prior to injection.

Tamoxifen treatment
1.

Using the insulin syringe needle, measure out the appropriate amount of the tamoxifen

mixture so as to inject 5 mg tamoxifen for every 20 g mouse body weight (see Note 9).
2.

Sanitize the injection site by wiping the mouse abdomen with an alcohol wipe. Intra-

peritoneally inject the vehicle (10% ethanol/90% sunflower seed oil) or tamoxifen mixture (see
Note 10).
3.

Repeat the injection for three consecutive days using the same tamoxifen stock, stored at

4ºC.
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4.

Mouse stomachs can be harvested at any time following the first injection or thereafter,

and tissue can be processed accordingly (see Note 11, Figures A1.1 and A1.2).

Figure A1.1: Tamoxifen treatment results in acute parietal cell loss.
Representative hematoxylin and eosin stain of gastric corpus from wild-type C57BL/6 mice
after intra-peritoneal injection with 3 days of either vehicle (a; Control) or 5 mg/20 g body
weight tamoxifen (b; HD-TAM). Note the relative decrease in parietal cells (black arrowhead)
compared to the vehicle-treated mouse. An apoptotic body (yellow arrowhead) adjacent to a
dying parietal cell is highlighted (inset)
119

Figure A1.2 Tamoxifen treatment causes acute parietal cell loss and alters the GSII
expression pattern in gastric units.
(a) Representative immunostain of the gastric corpus of a mouse intra-peritoneally injected
with vehicle alone (Control) for 3 days demonstrates normal-appearing gastric units,
highlighted by abundant parietal cells (stained with H +/K+ ATPase; green) and neck cells
120

(stained with GSII; red). Nuclei are stained with Hoescht (blue), and representative gastric
units are highlighted by dashed lines. (b) A representative immunostain of the gastric corpus
from a mouse intra-peritoneally injected with 5 mg/20 g body weight tamoxifen for 3 days
(HD-TAM) shows an acute loss of parietal cells, as demonstrated by the relative paucity of
VEGFb-staining cells (green). Fragments of parietal cells are highlighted by the white
arrowheads. In addition, note the shift in GSII expression (red) toward the bases of glands in
tamoxifen-treated mice compared to the vehicle-treated controls. Nuclei are stained with
Hoescht (blue), and representative gastric units are highlighted by dashed lines

A1.5 Notes
1.

The source of tamoxifen has no appreciable effect on the ability to induce parietal cell

loss. Tamoxifen stocks from three separate commercial suppliers, Sigma (St. Louis, MO),
Cayman Chemical Company (Ann Arbor, MI), and Toronto Research Company (Toronto,
Canada), have demonstrated similar efficacy (10). In addition, parietal cell toxicity is specific to
tamoxifen and not a general toxic effect of selective estrogen receptor modulators, as treatment
with raloxifene, a member of the estrogen receptor modulator family with pro- and antiestrogenic effects, had no appreciable toxicity at a comparable dose (10).
2.

To sterilize the sunflower seed oil, heat an appropriate amount in an Erlenmeyer flask on

a hot plate to 85-90°C for 15-20 minutes. Do not boil. Allow the flask to cool and store 40-mL
aliquots at room temperature. Alternatively, the sunflower seed oil can be autoclaved prior to
use.
3.

The free base form of tamoxifen and one of its commonly used active metabolites, 4-

hydroxytamoxifen (see Note 12), are largely insoluble in water. The original formulation for
intra-peritoneal injection was found to be soluble in 60% ethanol (12), and its solubility has since
been optimized in a sunflower seed oil/ethanol mixture (see Note 13). Tamoxifen citrate, an oral
formulation that has been developed for administering tamoxifen to mice via chow (13; see Note

121

10), is soluble in water at 0.3 mg/L at 20°C. Tamoxifen free base powder should be stored at 20°C in the dark.
4.

Our experience has shown that three different wild-type mouse strains (C57BL/6,

BALB/c, and FVB/N; all purchased from the Jackson Laboratory) have similar gastric mucosal
responses to tamoxifen treatment (10). In our limited experience with the strain, BALB/c mice
are particularly sensitive to tamoxifen treatment, with mice commonly dying of unknown causes
during treatment. Mice are typically used at 6-8 weeks of age, but SPEM is effectively induced
in mice as old as 6 months of age. The effects on older mice are less obvious, potentially due to
increased body fat causing changes in tamoxifen metabolism and distribution.
5.

An injection dose of 5 mg/20 g mouse weight over 3 days results in a dramatic

phenotype, with >90% loss of parietal cells, a significant increase in gastric progenitor cells, and
morphologic changes in the chief cells at the bases of glands in the gastric corpus, histologic
changes consistent with the induction of SPEM (10, Figures A1.1B and A1.2B). However, we
have previously shown that tamoxifen injections at lower doses (≤1 mg/20 g body weight) can be
used for efficient, inducible Cre-mediated recombination in the context of the Cre-ERT/loxP
system, without the development of SPEM (9). It is thus possible to obtain specific
recombination of floxed alleles in tamoxifen-inducible Cre lines in a dose-dependent manner
while avoiding the stomach-altering effects seen at higher tamoxifen doses. Interestingly, though
this has not been formally tested, SPEM induction by tamoxifen seems to have an all-or-none
response, where no detectable damage can be seen at ≤ 1 mg/20 g mouse body weight, but ≥ 3
mg/20 g mouse body weight causes near complete SPEM, without an intermediate phenotype.
6.

Make sure to wear protective headphones when using the sonicator.
122

7.

Vortex the solution for at least 20 seconds. Allow the solution to sit at room temperature

for several minutes. Proper mixing is crucial, and the mixture should be homogeneous. If it looks
cloudy or layered, discard the mixture and start over.
8.

No appreciable decline in the ability of tamoxifen to induce SPEM has been seen for

tamoxifen mixtures stored at 4°C over the duration of injections. Similarly, the tamoxifen stock
can be stored at -20° until further use. Our lab, however, makes a fresh tamoxifen stock prior to
each treatment regimen and uses this stock for the duration of the treatment.
9.

Given the viscosity of the tamoxifen mixture, aspiration into the syringe can take 10-15

seconds.
10.

Various tamoxifen formulations and numerous modes of tamoxifen administration have

been reported. We focus here on intra-peritoneal administration, which we use most commonly,
though we also observe SPEM induction with oral gavage. It is worth noting that other methods,
in addition to oral gavage (14), for inducing Cre recombinase activity via tamoxifen have been
used, including via drinking water (15), chow (13, 16), and subcutaneous implantation (17). In
that respect, we can only attest that oral gavage and intra-peritoneal administration of tamoxifen
cause SPEM and have not tested the effects of other modes of tamoxifen administration.
11.

The effects of tamoxifen on the mouse stomach can be seen within 12-24 hours of the

first intra-peritoneal injection (10). Our laboratory nomenclature designates the first day of
tamoxifen injection as day 0 (D0), with the last day of injection corresponding to day 2 (D2). A
recent report found that a single intra-peritoneal injection at 4 mg/25 g mouse body weight
induced a 57% loss of parietal cells in the gastric corpus (11). In our experience, the peak effect
(i.e., maximal parietal cell loss, see Figures A1.1B and A1.2B) is seen at one day following the
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third tamoxifen injection (D3). We have also achieved ≥90% loss of parietal cells at D3 even
after a single injection of tamoxifen at 5 mg/20 g mouse body weight. The single-injection
protocol, however, shows more variability between mice than the 3-day injection protocol. A
recovery of the gastric epithelium and a return to normal histology are seen within 14-21 days
(10). Like previously described pharmacologic induction of SPEM (see Note 14), the effects of
tamoxifen on the mouse stomach are transient. Many studies using tamoxifen-inducible Cre lines
wait at least 2 weeks prior to assessing recombination, by which point parietal cells have largely
recovered. This may explain how tamoxifen-induced parietal cell loss is often missed by
investigators using tamoxifen to induce gene recombination in the stomach.
12.

Tamoxifen is a prodrug that is hepatically metabolized to produce two predominant

active metabolites, 4-hydroxytamoxifen and N-desmethyl-4-hydroxytamoxifen (18). Multiple
studies have used 4-hydroxytamoxifen for induction of the Cre-ERT2 system. It is worth noting
that 4-hydroxytamoxifen has shown higher affinity for the estrogen receptor than tamoxifen in
vitro (19) and a greater inhibitory effect on proliferation of normal human breast cells as well as
breast cancer cell lines in culture (20-22). Differential effects between tamoxifen and 4hydroxytamoxifen have also been reported in apoptosis of human mammary epithelial cells (23)
and uterine gene expression in rats (24). In our limited experience, intra-peritoneally
administered 4-hydroxytamoxifen, at commonly used doses for Cre recombinase induction,
induces less SPEM in mice compared to similar doses of tamoxifen.
13.

It has been speculated that the observed effects of intra-peritoneal tamoxifen

administration could be unrelated to the tamoxifen itself and rather an effect of the ethanol
solvent on parietal cells. Though the effect of ethanol on parietal cell membranes and H+/K+
ATPase function has been reported (25), our experience has shown that intra-peritoneal injection
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of mice with ethanol does not induce substantial parietal cell loss. On the other hand, excluding
ethanol as a solvent results in poor solubility of tamoxifen. Oral gavage or intra-peritoneal
injection of the resulting suspension, rather than solution, might cause suboptimal absorption and
less substantial and/or consistent SPEM induction. Differences in solubilization methods may
also explain why some investigators using tamoxifen for Cre recombinase induction may not
have observed SPEM in their control mice.
14.

Previous methods for inducing oxyntic atrophy and SPEM have been described, varying

in their mechanism of action, onset of effect, and degree of inflammation (see Table 1). Chronic
infection of mice with Helicobacter felis (26) or of Mongolian gerbils with Helicobacter pylori
(27) results in the emergence of SPEM within months of infection. In contrast to these chronic
infectious models, pharmacologic induction of SPEM has provided a more rapid and reversible
means for achieving the same result. The neutrophil elastase inhibitor DMP-777 has been shown
to cause a rapid loss of parietal cells in rats and mice within 3-4 days of daily dosing (4, 5).
Treatment with this parietal cell-specific apical membrane protonophore leads to the emergence
of SPEM within 7-10 days, in the absence of inflammation. Like tamoxifen (10), the effects on
parietal cell loss can be mitigated by pretreatment with omeprazole. More recently, a related
variant of DMP-777, known as L-635, was found to produce a more rapid onset of SPEM in
mice within 3 days of treatment (6). The mechanism of action of L-635 is similar to that of
DMP-777, though, unlike DMP-777, the onset of SPEM is accompanied by an exuberant
inflammatory response.
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Appendix 2: Unintended targeting of Dmp1Cre reveals a critical role for Bmpr1a
signaling in the gastrointestinal mesenchyme
of adult mice

The following chapter was published in Bone Research
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targeting of Dmp1-Cre reveals a critical role for Bmpr1a signaling in the gastrointestinal
mesenchyme of adult mice." Bone research 5 (2017): 16049.
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A2.1 Abstract
Cre/loxP technology has been widely used to study cell type-specific functions of genes.
Proper interpretation of such data critically depends on a clear understanding of the tissue
specificity of Cre expression. The Dmp1-Cre mouse, expressing Cre from a 14-kb DNA
fragment of the mouse Dmp1 gene, has become a common tool for studying gene function in
osteocytes, but the presumed cell specificity is yet to be fully established. By using
the Ai9 reporter line that expresses a red fluorescent protein upon Cre recombination, we find
that in 2-month-old mice, Dmp1-Cre targets not only osteocytes within the bone matrix but
also osteoblasts on the bone surface and preosteoblasts at the metaphyseal chondro-osseous
junction. In the bone marrow, Cre activity is evident in certain stromal cells adjacent to the
blood vessels, but not in adipocytes. Outside the skeleton, Dmp1-Cre marks not only the
skeletal muscle fibers, certain cells in the cerebellum and the hindbrain but also gastric and
intestinal mesenchymal cells that express Pdgfra. Confirming the utility of Dmp1-Cre in the
gastrointestinal mesenchyme, deletion of Bmpr1a with Dmp1-Cre causes numerous large
polyps along the gastrointestinal tract, consistent with prior work involving inhibition of BMP
signaling. Thus, caution needs to be exercised when using Dmp1-Cre because it targets not
only the osteoblast lineage at an earlier stage than previously appreciated, but also a number
of non-skeletal cell types.

A2.2 Introduction
Dentin matrix protein 1 (DMP1) is an extracellular phosphorylated glycoprotein belonging to the
SIBLING (small integrin-binding ligand N-linked glycoprotein) family of proteins.1 Originally
discovered in the dentin matrix, DMP1 is also highly expressed in other mineralized tissues
including bone and cartilage.2,3,4 Functional studies have demonstrated important functions of
DMP1 in regulating not only biomineralization but also phosphate homeostasis in both mice and
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humans.5,6,7,8 Expression of DMP1 has also been detected in a variety of non-mineralizing tissues
in the mouse, these including brain, liver, muscle, kidney, and pancreas, but its function there is
not known.9
Cre/loxP technology enables gene deletion in specific cell types and thus allows for interrogation
of gene function in a cell type-specific manner. Conditional deletion in specific lineages depends
on the unique expression pattern of the Cre recombinase. The Dmp1-Cre transgenic mouse line
was generated to express Cre from a 14-kb promoter fragment (−9 624 to +4 439) of the mouse
Dmp1 gene.10 The promoter encompassed a 9 624-bp promoter, the 95-bp exon 1, the 4 326-bp
intron I plus the 17-bp initial noncoding sequence of exon II. The initial characterization of the
mouse line with the Rosa26R mouse (expressing β-galactosidase upon Cre recombination)
identified strong Cre activity in osteocytes and odontoblasts but not osteoblasts.10 However,
detection of β-galactosidase expression relied on an enzymatic reaction in vitro known to be
susceptible to tissue preparation and reaction conditions. In fact, a more recent analysis of
Dmp1-Cre with a reporter mouse expressing a fluorescent protein revealed Cre activity in
additional cell types besides osteocytes, most notably skeletal muscle and osteoblasts.11 The
study also implicated cells within the bone marrow and those in the brain, but did not provide a
detailed description. Thus, a systematic survey of tissues targeted by Dmp1-Cre in the mouse is
warranted.
Much work has been done to decipher the contribution of BMP signaling to gastrointestinal
development and maintenance, but the specific role of BMP reception by mesenchymal tissue
remains unclear. In the stomach, Mx1-Cre-mediated Bmpr1a deletion resulted in polyp
formation at the esophageal and antral transition zones.12 Similarly, Bmpr1a removal by the
ubiquitous inducible CAGGCreER driver cause dantral polyps and antral-pyloric hyperplasia.13
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Conversely, overexpression of the secreted BMP antagonist Noggin in parietal cells and
intestinal villi caused gastric cysts and intestinal polyps, respectively.14,15 However, when BMP
signaling was selectively disrupted in the intestinal epithelium through deletion of Bmpr1a, no
polyps formed despite increased proliferation and altered morphology within the epithelium.16
On the other hand, stromal deletion of Bmpr2 with nestin-Cre led to colorectal epithelial
overgrowth and polyp formation, but the interpretation there was complicated by the fact that
nestin-Cre targets multiple lineages including the epithelium.17 Overall, BMP signaling within
the mesenchymal compartment likely contributes to normal gastrointestinal development and
maintenance, but this notion warrants further investigation.
Here we assess the cell types targeted by Dmp1-Cre in 2-month-old mice by monitoring the
expression of a red fluorescent protein (dtTomato) from the Ai9 reporter allele. Consistent with
previous findings, Dmp1-Cre targets not only osteocytes but also osteoblasts and preosteoblasts,
along with a subset of bone marrow stromal cells, as well as the skeletal muscle and certain brain
cells. Unexpectedly, Dmp1-Cre selectively targets gastrointestinal mesenchymal cells with high
efficiency. Deletion of Bmpr1a with Dmp1-Cre results in polyposis throughout the stomach and
intestines, demonstrating a critical role of mesenchymal BMP signaling in maintaining a normal
gastrointestinal tract.

A2.3 Materials and Methods
Mouse strains
Dmp1-Cre, Ai9, and Bmpr1af/f mouselines are as previously described.10,18,19 Ai9 mice were
purchased from the Jackson Laboratory (Bar Harbor, ME, USA); Dmp1-Cre and Bmpr1af/f mice
were generously provided by Dr Jian Q Feng (Baylor College of Dentistry) and Dr Yuji Mishina
(University of Michigan), respectively. Littermate mice with the genotype of Dmp1-Cre;
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Bmpr1af/f (CKO) or Bmpr1af/f (control) were generated by breeding the two genotypes as
previously produced.20 The mice were in a mixed genetic background between C57BL6 and 129
strains. Both males and females were analyzed with similar results. All mouse procedures used in
this study were approved by the Animal Studies Committee at Washington University.

Cryostat sections
Two-month-old mice were perfused with 4% paraformaldehyde (PFA) as described previously.21
After perfusion, tibias were dissected and fixed in 4% PFA at 4 °C overnight. The fixed tibias
were decalcified in 14% EDTA (pH 7.4) for 3 days, incubated in 30% sucrose at 4 °C overnight
and then snap-frozen in optimal cutting temperature (OCT) embedding medium. Frozen sections
were cut at 8 μm thickness with a cryostat equipped with CryoJane (Leica, Buffalo Grove, IL,
USA). The sections were kept at −20 °C until analyses.

Immunofluorescence staining
For detection of Pdgfra, perilipin, or endomucin, immunostaining was performed on cryostat
sections using mouse polyclonal Pdgfra antibody (1:100; R&D Systems), or rabbit monoclonal
perilipin antibody (1:100; Cell Signaling Technology, Danvers, MA, USA), or rat monoclonal
endomucin antibody (1:100, Santa Cruz, Biotechnology, Dallas, TZ, USA). The secondary
antibodies are as follows: Alexa Fluor 488 goat anti-mouse IgG (for Pdgfa); Alexa Fluor 488
goat anti-rabbit IgG (for perilipin), and Alexa Fluor 488 goat anti-rat IgG (for endomucin) (all at
1:500, Life Technologies, Grand Island, NY, USA). Sections were mounted with
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VECTASHIELD Mounting Medium containing DAPI (Vector Laboratories, Burlingame, CA,
USA). Images were acquired with a Nikon confocal microscope (Melville, NY, USA).

Analyses of the gastrointestinal tract
For proliferation assays, mice were injected intraperitoneally with 5-bromo-2’-deoxyuridine
(BrdU, 120 mg·kg−1) and 5-fluoro-2’-deoxyuridine (12 mg·kg−1) in sterile water 90 min before
killing. Following killing, stomachs were immediately excised and flushed with phosphatebuffered saline then inflated with freshly prepared formalin (10% formaldehyde, Sigma, St.
Louis, MO, USA) in phosphate-buffered saline and the pylorus clamped with a hemostat.
Inflated stomachs and segments of the small and large intestines were allowed to fix overnight in
10% formalin then transferred to 70% ethanol. Tissues were arranged in 3% agar in a tissue
cassette, underwent routine paraffin processing, and 5 μm sections were cut and mounted on
glass slides. For immunohistochemistry, sections underwent a standard deparaffinization and
rehydration protocol then were blocked with 5% horse serum for 1 h before staining for BrdU
using Goat anti-BrdU (1:20 000, gift of Dr Jeff Gordon, Washington University) and biotinylated
horse anti-goat (1:200, Vector Laboratories) antibodies. Images were acquired using a
Nanozoomer Slide Scanner (Hamamatsu, Japan, model 2.0-HT).

A2.4 Results
Dmp1-Cre targets osteoblast-lineage cells, skeletal muscle, and bone marrow perivascular cells
To characterize the targeting specificity of Dmp1-Cre, we generated Dmp1-Cre; Ai9 mice (one
copy each of Dmp1-Cre and Ai9) and analyzed tdTomato expression on sections of the limbs at
2 months of age. As expected, limb sections from the control Ai9 mice did not exhibit any red
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fluorescence (Figure A2.1a-f), but those from Dmp1-Cre; Ai9 mice showed strong signals both
in the long bone and in the adjacent skeletal muscle (Figure A2.1a’–f’). Targeting of the skeletal
muscle was not previously reported, but was detected here in all muscle fibers (Figure A2.1f’).
Within the long bone, Dmp1-Cre marked not only osteocytes but also osteoblasts in both cortical
and cancellous bone (Figure A2.1b’ and c’). In addition, the chondro-osseous junction
immediately below the growth plate, an area enriched in preosteoblasts, expressed a strong signal
even though the growth plate was negative (Figure A2.1d’). Red fluorescence was also detected
in certain cells within the bone marrow, although generally at a lower intensity than those other
cell types described above (Figure A2.1e’). Co-immunostaining experiments revealed that the
red fluorescence-positive marrow cells were perivascular as they showed close proximity to the
endothelium-expressing endomucin (Figure A2.2). On the other hand, perilipin staining showed
that the bone marrow adipocytes were not targeted by Dmp1-Cre and generally did not show a
close association with the targeted cells (Figure A2.3). Thus, in addition to osteocytes, Dmp1Cre targets early-stage osteoblast-lineage cells, bone marrow perivascular cells as well as the
skeletal muscle.
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Figure A2.1: Dmp1-Cre targets osteoblast lineage cells, skeletal muscle, and bone marrow
cells in 2-month-old mice.
(a,a’) Confocal microscopy images of direct fluorescence from tdTomato on longitudinal
sections of the proximal tibia. (b–f’) Images at a higher magnification for different areas of bone
as indicated. B, bone; M, skeletal muscle; GP, growth plate. Green arrow, osteoblast; white
arrow, osteocyte. Line in (d’) denotes chondro-osseous junction.
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Figure A2.2: Dmp1-Cre targets bone marrow cells near blood vessels.
Immunostaining against endomucin and direct fluorescence of tdTomato on sections of the tibial
bone marrow from 2-month-old Dmp1-Cre; Ai9 mice. (a) tdTomato; (b) endomucin; (c) merged
image.

Figure A2.3: Dmp1-Cre does not target bone marrow adipocytes.
Immunostaining against perilipin and direct fluorescence of tdTomato on sections of the tibial
bone marrow from 2-month-old Dmp1-Cre; Ai9 mice. (a) tdTomato; (b) perilipin; (c) merged
image.

Dmp1-Cre targets brain cells as well as gastrointestinal mesenchymal cells
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We next examined other tissues of the Dmp1-Cre; Ai9 mouse for potential targeting by Dmp1Cre. No red fluorescence was detected in the liver, the spleen, or the gonadal fat depot. Coronal
sections of the head through the parietal bone revealed a small number of red cells throughout
the cerebellum and the hindbrain (Figure A2.4). The positive cells were present in both the
molecular and granular layers of the cerebellum but did not present a specific distribution
pattern; their identity was not pursued in the present study. In the stomach and the small
intestine, Dmp1-Cre targeted many cells within the lamina propria of the mucosa (Figure A2.5).
Co-immunostaining experiments identified the targeted intestinal cells as mesenchymal cells
expressing Pdgfra (Figure A2.6). Interestingly, although Pdgfra-positive cells were also present
in the muscle wall, Dmp1-Cre targeted nearly exclusively those within the laminar propria of the
mucosa. Thus, Dmp1-Cre may be a useful tool for studying gene function in the mesenchyme of
the gut mucosa.
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Figure A2.4: Dmp1-Cre targets cells in the cerebellum and the hindbrain.
Direct fluorescence of tdTomato on coronal sections of the cerebellum (a-b’) and the hindbrain
(c,c’). G, representative granular layer; M, representative molecular layer. Brain anatomy based
on Allen Mouse Brain Atlas.
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Figure A2.5: Dmp1-Cre targets lamina propria of the stomach and the small intestine.
Direct fluorescence of tdTomato on cross-sections of the stomach (a,a’) and the small intestine
(b,b’). M, mucosa; Mu, muscle wall. Inset in (a’) shows higher magnification of a mucosa area,
denoting epithelium (white arrowhead) versus mesenchyme (yellow arrowhead).
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Figure A2.6: Dmp1-Cre targets Pdgfra-positive mesenchymal cells in the small intestine.
Immunostaining against Pdgfra and direct fluorescence of tdTomato on cross-sections of the
small intestine. M, mucosa; Mu, muscle wall; (a) tdTomato; (b) Pdgfra; (c) merge of tdTomato
and Pdgfra; (d) merge of tdTomato, Pdgfra and DNA staining by DAPI.

Deletion of Bmpr1a in gastrointestinal mesenchyme results in polyposis
BMP signaling has been shown to have critical roles in development and maintenance of the
gastrointestinal tract, but the significance of BMP signaling within the mesenchyme has not been
demonstrated. The highly efficient targeting of the gastrointestinal mesenchyme by Dmp1-Cre
prompted us to analyze the gut of mice with the genotype of Dmp1-Cre; Bmpr1af/f (CKO). The
CKO mice presented a notably higher incidence of rectal prolapse than the control littermates
after 3 months of age, indicating abnormalities of the gastrointestinal tract. Histological analyses
of the stomach at 5 months of age revealed that the CKO mice developed large polyps in the
gastric antrum (Figure A2.7b and b’), whereas the Bmpr1af/f littermate exhibited no abnormality
as expected (Figure A2.7a and a’). These polyps contain both epithelial and mesenchymal cells,
with largely unremarkable morphology but occasional foci with mild nuclear crowding and
hyperplasia (Figure A2.7b’). In the corpus, the CKO mice exhibited a mild pit/foveolar cell
hyperplasia with expansion of surface cells relative to glandular invaginations (Figure A2.7d’).
Examination of the intestine revealed large polyps in the CKO mice, typically with 20+ polyps in
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the small intestine and 50+ in the large intestine, some as large as 2 mm in diameter. The polyps
appeared largely hamartomatous, composed of a mixture of unremarkable epithelial,
mesenchymal, and immune cells (Figure A2.8). Some polyps in the small intestine also
contained foci harboring highly proliferative epithelium (Figure A2.8b’, bracket). Surveying of
the CKO mice at different ages revealed that the gastrointestinal phenotype was fully penetrant
by 33 days of age (n=4) but not at 14 days. Thus, Bmpr1a signaling in the mesenchyme is critical
for maintaining the integrity of the gastrointestinal tract in postnatal mice.

Figure A2.7: Dmp1-Cre Bmpr1af/f mice develop gastric hyperplasia and polyps.
(a,b) H&E staining of sections through the entire stomach of control (Bmpr1rf/f) (a) versus CKO
(Dmp1-Cre; Bmpr1af/f) (b) littermate mice at 5 weeks of age. (a’,b’) Boxed areas in a and b,
respectively, shown at higher magnification. (c,d) Gastric units in the gastric corpus of control
(c) versus CKO (d) littermate mice. (c’,d’) Boxed areas in (c,d) shown at higher magnification.
(d’), long stretches of surface pit cells with no opening into gastric units. Yellow arrowheads
denote increased prominence of capillaries. H&E, hematoxylin and eosin.
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Figure A2.8: Dmp1-Cre Bmpr1af/f mice develop intestinal polyps.
(a–d) H&E staining of cross-sections through small (a,b) or large intestines (c,d) of control
(Bmpr1af/f) (a,c) or CKO (Dmp1-Cre; Bmpr1af/f) (b,d) littermate mice. Yellow arrowheads in b
denote fusing and blunting of villi. (a’–d’) Higher-magnification images of boxed areas in (a–d),
respectively, showing a polyp in small (b’) or large (d’) intestine. Yellow bracket in (b’) denotes
a pocket of proliferating epithelial cells stained brown for BrdU labeling. H&E, hematoxylin and
eosin.

A2.5 Discussion
The current study has three principal findings. First, Dmp1-Cre targets the osteoblast lineage
starting at the preosteoblast stage, considerably earlier than previously believed. This result
confirms our previous observation by using the mT/mG reporter mouse.20 Second, Dmp1-Cre
also targets several non-skeletal tissues, including the skeletal muscle as previously noted, and
the mesenchyme of the gastrointestinal mucosa as demonstrated here for the first time.21 Finally,
by exploiting the unintended targeting in the gut, the study clarifies that deletion of the Bmpr1a
receptor only in the mesenchyme of the gastrointestinal tract without affecting the epithelium is
sufficient to cause hamartomatous polyps. Overall, Dmp1-Cre joins Osx-Cre as another example
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for a bone-targeting Cre line to possess additional activities.22 The study further underscores the
importance of assessing unintended recombination activities of many Cre strains.23
Although both Osx-Cre and Dmp1-Cre target preosteoblasts, osteoblasts, and osteocytes, they
show important differences in other aspects. Although Osx-Cre marks a majority of the bone
marrow stroma, Dmp1-Cre targets a relatively small number of cells in the bone marrow.22,24 The
Dmp1-targeted cells are near the blood vessels and appear to be stromal cells in nature. Others
have recently shown that most of the Dmp1-targeted cells in the marrow represent a subset of the
Cxcl12-abundant reticular cells.25 The two Cre lines also show differences in the gastrointestinal
tissues. Although Osx-Cre marks the epithelium of the mucosa in a mosaic fashion, Dmp1-Cre
labels all of the Pdgfra-positive mesenchymal cells within the lamina propria. Distinct from OsxCre, Dmp1-Cre also targets all skeletal muscle fibers, as well as certain cells in the cerebellum
and the hindbrain, likely reflecting the endogenous DMP1 expression in those tissues as
previously reported.9 Similarly, Dmp1-Cre activity in the stomach and the intestines is consistent
with endogenous Dmp1 expression, as documented by the Human Protein Atlas
(http://www.proteinatlas.org/). Thus, identification of a regulatory sequence truly specific to
osteocytes would require further dissection of the Dmp1 promoter. Among the other organs
expressing DMP1, we did not detect Cre activity in the liver but did not examine the kidney or
the pancreas.9 It should be noted that the efficiency of Cre recombination might vary between
Ai9 and the floxed gene of interest. The actual deletion efficiency of the targeted gene ought to
be determined in a gene-specific manner. Nonetheless, we have presented a clear example that
Dmp1-Cre can be used effectively to delete Bmpr1a in the gastrointestinal mesenchyme. Thus,
the relevance of the other targeted cell types besides osteocytes should be considered when
Dmp1-Cre is used in genetic studies.
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BMP signaling has critical roles in normal development and maintenance of the gastrointestinal
system. Loss of function mutations in Bmpr1a is a major cause for juvenile polyposis in
patients.26 Here we show that deletion of Bmpr1a with Dmp1-Cre in the mouse results in the
formation of numerous polyps throughout the intestine; the phenotype is reminiscent of those
caused by overexpression of noggin from the villin promoter.14 This similarity, together with the
lack of polyposis when Bmpr1a was deleted in the epithelium, argues that the effect seen from
the villin-driven Noggin may largely stem from the inhibition of BMP signaling in the
mesenchyme instead of the epithelium as originally believed.16 Overall, the study provides
evidence that BMP signaling within the mesenchyme by itself is critical for proper
gastrointestinal maintenance.
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Appendix 3: Metaplastic cells in the stomach
arise, independently of stem cells, via
dedifferentiation or transdifferentiation of
chief cells

The following chapter was published in Gastroenterology

Radyk, Megan D., Joseph Burclaff, Spencer G. Willet, and Jason C. Mills. "Metaplastic cells in
the stomach arise, independently of stem cells, via dedifferentiation or transdifferentiation of
chief cells." Gastroenterology 154, no. 4 (2018): 839-843.
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A3.1 Abstract
Spasmolytic polypeptide-expressing metaplasia (SPEM) develops in patients with chronic
atrophic gastritis due to infection with Helicobacter pylori; it might be a precursor to intestinal
metaplasia and gastric adenocarcinoma. Lineage tracing experiments of the gastric corpus in
mice have not established whether SPEM derives from proliferating stem cells or differentiated,
post-mitotic zymogenic chief cells in the gland base. We investigated whether differentiated cells
can give rise to SPEM using a non-genetic approach in mice. Mice were given intraperitoneal
injections of 5-fluorouracil, which blocked gastric cell proliferation, plus tamoxifen to induce
SPEM. Based on analyses of molecular and histological markers, we found SPEM developed
even in the absence of cell proliferation. SPEM therefore did not arise from stem cells. In
histologic analyses of gastric resection specimens from 10 patients with adenocarcinoma, we
found normal zymogenic chief cells that were transitioning into SPEM cells only in gland bases,
rather than the proliferative stem cell zone. Our findings indicate that SPEM can arise by direct
reprogramming of existing cells—mainly of chief cells.

A3.2 Stem Cell Independent Gastric Metaplasia
Spasmolytic Polypeptide-Expressing Metaplasia (SPEM) arises in the setting of chronic atrophic
gastritis (CAG) in humans infected with Helicobacter pylori and may be a precursor to intestinal
metaplasia and gastric adenocarcinoma(Schmidt et al., 1999; Petersen et al., 2017b). CAG is
characterized by chronic inflammation, parietal cell death, and metaplastic expansion of cells
coexpressing spasmolytic polypeptide (TFF2) and zymogenic chief cell (ZC) markers. Genetic
lineage tracing studies have not definitively identified the cell-of-origin for SPEM cells. Tracing
from Mist1CreERT2-expressing cells indicated ZCs at the gland base gave rise to SPEM (Nam et
al., 2010; Stange et al., 2013b; Leushacke et al., 2017; Matsuo et al., 2017; Choi et al., 2018).
Another report disputed this because occasional cells in the upper, isthmal stem cell region of the
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gland also expressed Mist1CreERT2, indicating SPEM might be derived isthmally (Hayakawa et al.,
2015). We use a new approach to determine if differentiated cells can give rise to SPEM.
For an isthmal stem cell to generate a gland full of SPEM cells, its progeny must
proliferate to reach the gland base. We inhibited proliferation with the anti-mitotic drug 5Fluorouracil (5FU) and found one 150mg/kg (Stange et al., 2013b) intraperitoneal injection of
5FU was sufficient to block proliferation for 24h with return to near-normal levels by 48h
(Figure A3.1A,B).
Long-term 5FU is toxic beyond 4-5 days, thus we used a SPEM induction method shown
by multiple labs to cause maximal, synchronous SPEM within three days: high dose tamoxifen
(HDT) (Huh et al., 2012b; Saenz et al., 2016). Our selected 5FU+HDT regimen caused no mouse
mortality, but blocked nearly all proliferation at the peak SPEM stage: <0.5 in 5FU+HDT vs. >8
cells/unit in HDT alone (Figure A3.1C).
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Figure A3.1: SPEM can occur without proliferation.
A) IHC staining for BrdU after one dose of 5FU (150mg/kg; intraperitoneal injection). Eosin Y
counterstain. B) Experimental timeline and proliferation quantification. C) 5FU+HDT
experimental timeline and proliferation quantification. D) Immunofluorescence of stomachs after
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72h vehicle, 5FU, HDT, or 5FU+HDT treatment (red, GIF; green, GSII; blue, DAPI). Dotted
line: gastric unit. E) Cell populations quantified, # indicates significance compared to vehicle, *
indicates significance between treatment groups. R is significance between red columns, Y
between yellow columns. F) Immunofluorescence of stomachs (red, GIF; green, Clusterin; blue,
DAPI). *p≤0.05, **p≤0.01 ***p≤0.001, variance analyzed with ANOVA/Tukey (N ≥ 3
mice/group)

We monitored SPEM by immunofluorescence for the ZC marker, gastric intrinsic factor
(GIF; red), and a lectin (GSII; green), which co-labels with TFF2. In control mice, GIF was
located in ZCs at the gland base, separated from the GSII+ mucous neck cells in the middle of the
gland. Consistent with previous reports (Huh et al., 2012b; Saenz et al., 2016), HDT caused
SPEM, defined by pathognomonic GSII+GIF+ co-staining at the gland base (Figure A3.1D), yet
few SPEM cells appeared at 24h (Figure A3.2). 5FU alone, or with HDT, did not significantly
alter outcomes at any timepoint. At 72h, similar numbers of SPEM cells formed in HDT and
HDT+5FU: 6.0±1.5 SPEM cells in HDT, 5.6±1.0 in HDT+5FU (Figure A3.1D,E). Additionally,
5FU vs. HDT+5FU mice displayed a similar magnitude of GIF+ cell loss and GIF+GSII+ SPEM
cell increase (Δ -3.7±1.3 GIF+ cells/unit, Δ +5.2±0.8 GIF+GSII+ cells/unit), while GSII+ neck
cells decreased only slightly (ΔG: -0.76 ±0.75), implicating ZCs as the principal source for
SPEM cells when proliferation is blocked.
Equivalent SPEM was confirmed in HDT±5FU mice by qRT-PCR for SPEM-associated
transcripts Mist1, Gif, He4, and Clusterin (Engevik et al., 2016) (Figure A3.3) and
immunofluorescence for Clusterin (Figure A3.1F).
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Figure A3.2: No SPEM occurs 24h after HDT treatment.
A) Immunofluorescence of stomachs after 24h of vehicle, 5FU, HDT, or 5FU+HDT treatment
(red, GIF; green, GSII; blue, DAPI). B) Quantification of cell populations, # indicates
significance of treatment compared to vehicle, * indicates significance between specified
treatment groups. G is significance between green columns. *p≤0.05, variance analyzed with
ANOVA/Tukey (N ≥ 3 mice/group)
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Figure A3.3: qRT-PCR for SPEM-associated genes.
A) Transcripts of zymogenic cell markers analyzed from RNA isolated from the whole gastric
corpus of mice treated with vehicle, 5FU, HDT, or 5FU+HDT for 24 hours. B) Same RNA
described from A analyzed for markers known to increase in SPEM. C) Transcripts of
zymogenic cell markers analyzed from RNA isolated from the whole gastric corpus of mice
treated with vehicle, 5FU, HDT, or 5FU+HDT for 72 hours. D) Same RNA described from C
analyzed for markers known to increase in SPEM. *p≤0.05 **p≤0.01 ***p≤0.001, variance
analyzed with ANOVA/Tukey (N ≥ 3 mice/group)
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We examined the differentiation pattern and location of occasional cells escaping the
5FU blockade at 72h. Proliferating cells in control mice lacked neck/ZC markers, indicating
proliferation primarily in isthmal stem cells (Figure A3.4A,B). HDT mice harbored proliferating
isthmal, neck, SPEM, and occasional BrdU+ ZCs (Figure A3.4A,B). The 5FU+HDT regimen
was designed such that cells escaping 5FU blockade at 72h would be in their first cell cycle, as
gastric epithelial cells average one division per day (Potten, 1998). As expected, <1 cell/unit was
BrdU+ at 72h 5FU+HDT, and units with >1 BrdU+ cell were exceedingly rare (Figure A3.4A).
Proliferating cells could not be found prior to 72h (Figure 3.5). Proliferating cells at 72h
expressed neck, SPEM, or ZC markers (Figure A3.4B). Interestingly, the largest cohort did not
label with GSII or GIF. We suspect these cells are parietal cell progenitors based on cells, at 96h
following HDT, expressing BrdU and beginning to show the characteristic, thick apical staining
of parietal cell marker, ezrin (Lo et al., 2017) (Figure A3.6). Figure A3.4C plots zones in which
proliferating cells emerged from isthmus to base, excluding upper pit/foveolar cells (Figure
A3.7). In control mice, almost all proliferation was in the isthmus. In HDT and 5FU+HDT,
proliferating cells appeared throughout the gland. Thus, multiple lines of evidence presented here
indicate, in addition to isthmal stem cells, multiple cell types throughout the gland exhibit
plasticity and can proliferate in response to damage.
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Figure A3.4: Metaplastic cells arise below the isthmus
A) Immunofluorescence of stomachs after 72h vehicle, 5FU, HDT, or 5FU+HDT (green, GSII;
red, GIF; white, BrdU; blue, DAPI; arrowheads, rare BrdU+ cells in 5FU+HDT). B) Proliferating
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cell populations quantified. C) Location of BrdU+ cells below the bottom-most AAA+ pit cell. D)
Hematoxylin & eosin of early human SPEM (yellow circle) E) Immunofluorescence on serial
section from 2D (red, PGC; green, GSII; blue, DAPI; arrowhead: SPEM cell). Yellow circle is
SPEM area. F) Human SPEM within gland base showing transitional ZCSPEM forms. Dotted
box indicates area shown at higher magnification. Cells outlined in colors according to cell type
(red, normal ZCs; blue, hybrid SPEM; yellow, full SPEM). *p≤0.05 **p≤0.01 ***p≤0.001,
variance analyzed with ANOVA/Tukey (N ≥ 3 mice/group)

Figure A3.5: Proliferation is sufficiently blocked over the course of injury in 5FU+HDT
mice.
A) Immunofluorescence of stomachs after 24h of vehicle, 5FU, HDT, or 5FU+HDT (green,
GSII; red, GIF; white, BrdU; blue, DAPI). B) Quantification of proliferating cell populations. # #
p≤0.01, variance analyzed with ANOVA/Tukey (N ≥ 3 mice/group)
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Figure A3.6: Proliferating pre-parietal cells begin to appear 96h after HDT treatment.
Timeline of treatment scheme. Immunofluorescence of stomachs after 96h of vehicle, 5FU,
HDT, or 5FU+HDT (green, GSII; red, ezrin; white, BrdU; blue, DAPI). Yellow boxes indicate
BrdU+ ezrin+ cells with basolateral surfaces of each cell outlined in dashed white line.

We stained for proliferative SPEM with CD44v (CD44v9 in humans) (Engevik et al.,
2016). HDT and 5FU+HDT mice exhibited CD44v staining at the gland base (Supplementary
Figure 5B) and increased expression of proliferation-associated markers Check2 and Ccnb2 by
qRT-PCR, indicating basally-located cells are poised to divide in 5FU+HDT stomachs (Figure
A3.7).

157

Figure A3.7: Proliferation after SPEM induction.
A) Immunofluorescence of stomachs after 72h of vehicle, HDT, or 5FU+HDT treatment (red,
GIF; purple, AAA (Anguilla anguilla lectin); white, BrdU; blue, DAPI). Yellow arrowheads
indicate cells that were not counted in quantification because they are in the pit zone and, thus,
above the bottom-most AAA+ cell. B) Immunofluorescence of stomachs treated with vehicle,
5FU, HDT, or 5FU+HDT for 72h (red, CD44v; green, GSII; blue, DAPI). Dotted line: outlined
unit bases. C) Transcripts of proliferative markers analyzed from RNA isolated from the whole
gastric corpus of mice treated with vehicle, 5FU, HDT, or 5FU+HDT for 72 hours.
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Our data suggest stem cells are responsible for pit- and neck cell-localized proliferation
following HDT; however, SPEM itself is largely derived from ZCs, supporting previous work
suggesting two foci of proliferation in the stomach (Burclaff et al., 2017). Our mouse
experiments reflect ZC to SPEM transitions observed in humans previously extensively
characterized from a large dataset of adenocarcinoma and gastritis biopsy and resection
specimens (Lennerz et al., 2010). Figures A3.4D-F and A3.8 depict representative stomach
glands from 10 additional patients with gastric adenocarcinoma. We again observe hybrid cells
(cells with features of mature ZCs and SPEM cells) occurred predominantly in the base.
Specifically, we see apparent transition among a variety of cell phenotypes from mature ZCs
(expressing PGC in large apical granules) to cells expressing abundant PGC with scant GSII
(likely indicating early SPEM change) to phenotypically complete SPEM conversion (scant PGC
with abundant GSII) (Figure A3.4F). A stem cell-origin of SPEM in humans would mean cell
fate changes to SPEM cells should occur at the isthmus, and SPEM cells would have to expand
downward and replace mature ZCs to populate the base. Thus, the interpretation that SPEM
originates exclusively from the isthmus would be inconsistent with the presence of cells
transitioning to SPEM consistently found in the base.
Differentiated cells are long-lived and may accumulate mutations that become unmasked
upon cell cycle re-entry after injury. For example, Kras mutations in ZCs or pancreatic acinar
cells can fuel tumorigenic transformation (Leushacke et al., 2017). Therefore, our current work,
highlighting how differentiated cells are called back into the cell cycle in an acute injury model,
should interest those studying tumorigenesis and/or regeneration.
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Figure A3.8: Human SPEM in gastric cancer patients
A) H&E of human corpus glands with early atrophic gastritis exhibiting focal gland bases
transitioning to SPEM. Arrows refer to parietal cells in healthy glands. SPEM gland outlined in
yellow has a wide lumen and lacks parietal cells. B) Same as panel A but a different patient with
more active gastritis. Early SPEM gland outlined in yellow shows opening of lumen at gland
base (yellow arrow) and contains degenerating parietal cells (black arrows). C)
Immunofluorescence of human SPEM (red, PGC; green, GSII; blue, DAPI). Note many hybrid
forms in gland bases ranging from cells with only red PGC (mature, normal ZCs) to those
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showing mature SPEM (prominent green GSII, scant red PGC). D) Immunofluorescence of the
base of yet another patient’s corpus. A mature SPEM gland is located next to a normal gland
with mature ZCs. A third gland shows hybrid forms wherein ZCs express focal, apical GSII
(yellow arrowheads). E) Table detailing the demographic aspects and pathological diagnoses of
the 10 patients analyzed in this manuscript.

A3.3 Methods and Materials
Animals and Injections
All experiments involving animals were performed according to protocols approved by the
Washington University School of Medicine Animal Studies Committee. Mice were maintained
in a specified pathogen-free barrier facility under a 12-hour light cycle. Wild-type C57BL/6 mice
were purchased from Jackson Laboratories (Bar Harbor, ME). All mice used in experiments
were females 6−8 weeks old. To induce SPEM, tamoxifen (250 mg/kg body weight; Toronto
Research Chemicals, Inc, Toronto, Canada) was administered daily for 3 days by intraperitoneal
injection. Tamoxifen was dissolved in a vehicle of 10% ethanol and 90% sunflower oil (Sigma,
St Louis, MO) as described previously (Petersen et al., 2017b). To block proliferation, 5-FU (150
mg/kg body weight; Sigma F6627) was given by intraperitoneal injection twice daily for 2 days.
5-FU was dissolved in a solution containing 10% dimethyl sulfoxide and 0.9% sodium chloride.
All mice were given an intraperitoneal injection containing BrdU (120 mg/kg) and 5-fluoro2′deoxyuridine (12 mg/kg) 90 minutes before sacrifice.

Patient Samples
Human gastric tissue was obtained with approval from the Institutional Review Board of
Washington University School of Medicine. The database of metaplastic samples showing
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hybrid SPEM forms has been described previously (Schmidt et al., 1999; Nam et al., 2010;
Stange et al., 2013b).

Immunofluorescence and Immunohistochemistry
Stomachs were excised immediately, flushed with phosphate-buffered saline (PBS) via the
duodenal stub and then inflated with freshly prepared 4% paraformaldehyde. The stub was
clamped by hemostat, and the stomach suspended in fixative in a 50-mL conical for 8−12 hours,
followed by 3 rinses in 70% EtOH, arrangement in 2% agar in a tissue cassette, and routine
paraffin processing. Sections (5 μm) were cut, deparaffinized, and rehydrated with graded
xylenes, alcohols, and water, then antigen-retrieved in sodium citrate buffer (2.94 g sodium
citrate, 500 uL Tween 20, pH 6.0) using a pressure cooker. Slides were blocked in 5% normal
goat serum, 0.2% Triton-X 100, in PBS. Slides were incubated overnight at 4°C in primary
antibodies, then rinsed in PBS, incubated 1 hour at room temperature in secondary antibodies
and/or fluorescently labeled lectin (Alexa Fluor 647 made by directly conjugating E-Y
Laboratories [San Mateo, CA] lectin to Molecular Probes [Eugene, OR] Alexa Fluor 647), rinsed
in PBS, mounted in ProLong Gold Antifade Mountant with 4′6-diamidino-2-phenylindole
(Molecular Probes). For immunohistochemistry, steps were identical except the following. An
extra quenching step was performed for 15 minutes in a methanol solution containing 1.5%
H2O2 after antigen retrieval. Substrate reaction and detection was performed using ImmPACT
VIP Peroxifase (horseradish peroxidase) Substrate Kit (Vector Laboratories, Burlingame, CA) as
detailed per the manufacturer’s protocol and slides were mounted in Permount Mounting
Medium.
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Imaging
Fluorescence microscopy was performed using a Zeiss Axiovert 200 microscope with an
Axiocam MRM camera and Apotome II instrument for grid-based optical sectioning. Postimaging adjustments, including contrast, fluorescent channel overlay, and pseudo-coloring, were
performed with Axiovision and Adobe Photoshop CS6. Histology of stomach and
immunohistochemistry were imaged using an Olympus BX51 light microscope and Olympus
SZX12 dissecting microscope w/12 MPixel Olympus DP70 camera. Images were analyzed and
post-imaging adjustments were performed with Adobe Photoshop CS6.

Antibodies
Primary antibodies used in this study were as follows: fluorescently conjugated Anguilla anguilla
lectin (Alexa Fluor 647; 1:1000; EY Laboratories), goat anti-BrdU (1:20,000; a gift from Dr Jeff
Gordon, Washington University, St Louis, MO), rat anti-CD44 v10-e16, ortholog of human v9
(1:200; Cosmo Bio, Tokyo, Japan), goat anti-Clusterin (1:100; Santa Cruz Biotechnology, Santa
Cruz, CA), mouse anti-ezrin (1:250; Santa Cruz Biotechnology), fluorescently conjugated GSII
lectin (Alexa Fluor 647; 1:1,000; Invitrogen, Carlsbad, CA), rabbit anti-human gastric intrinsic
factor (1:10,000; a gift from Dr David Alpers, Washington University, St Louis, MO), and sheep
anti-PGC (1:10,000; Abcam, Cambridge, MA). Secondary antibodies included Alexa Fluor 488,
594, or 647−conjugated donkey anti-goat, anti-rabbit, or anti-mouse (1:500; Molecular Probes).
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Immunofluorescence and Immunohistochemistry Quantification
For counts from units expressing neck, chief, and proliferative markers all time points were
quantified with at least 3 mice as previously described by Burclaff et al, 2017 (Burclaff et al.,
2017). Stomach corpus slides were stained for BrdU, the neck cell marker GSII, and zymogenic
cell marker GIF. Images were captured as TIFF files from a Zeiss Axiovert 200 microscope with
an Axiocam MRM camera with an Apotome optical sectioning filter (Carl Zeiss, Jena,
Germany). Each stomach had at least 5 randomly distributed 20× images taken, which contained
10 or more well-oriented gastric units. Units were counted using the neck staining, and total
quantifications of proliferating cells (BrdU) were averaged over the total unit numbers per
mouse. For total proliferation counts from immunohistochemistry at least 3 mice per treatment
group were quantified. Stomach corpus slides were stained with an antibody for BrdU. Whole
slides were scanned using a NanoZoomer 2.0 HT microscope and analyzed with NanoZoomer
Digital Pathology software (Hamamatsu; Hamamatsu City, Japan). At least 40 corpus units were
analyzed and counted per stomach. Proliferation rate for each mouse was an average of all units
counted.

Quantitative Real-Time Reverse Transcription Polymerase Chain Reaction
RNA was isolated using RNeasy (Qiagen, Valencia, CA) per the manufacturer's protocol. The
quality of the mRNA was verified with a BioTek (Winooski, VT) Take3 spectrophotometer and
electrophoresis on a 2% agarose gel. RNA was treated with DNase I (Invitrogen), and 1 μg RNA
was reverse-transcribed with SuperScript III (Invitrogen) following the manufacturer’s protocol.
Measurements of complementary DNA abundance were performed by real-time quantitative
164

reverse transcription polymerase chain reaction using either a Stratagene (La Jolla, CA)
MX3000P detection system or a Bio-Rad (Hercules, CA) CFX Connect system. Power SYBR
Green master mix (Thermo Scientific, Waltham, MA) fluorescence was used to quantify the
relative amplicon amounts of each gene (normalizing gene was TATA box binding protein).
Primer design and sequence are in Figure A3.9.
Gene

Sequence

Clusterin Forward

CCAGCCTTTCTTTGAGATGA

Clusterin Reverse

CTCCTGGCACTTTTCACACT

Gif Forward

GAAAAGTGGATCTGTGCTACTTGCT

Gif Reverse

AGACAATAAGGCCCCAGGATG

He4 Forward

TGCCTGCCTGTCGCCTCTG

He4 Reverse

TGTCCGCACAGTCCTTGTCCA

Mist1 Forward

GAGCGAGAGAGGCAGCGGATG

Mist1 Reverse

AGTAAGTATGGTGGCGGTCAG

Tbp Forward

CAAACCCAGAATTGTTCTCCTT

Tbp Reverse

ATGTGGTCTTCCTGAATCCCT

Figure A3.9: Primers used for quantitative RT-PCR

Graphing and Statistics
All graphs and statistics were completed in GraphPad Prism (GraphPad, La Jolla, CA) using 1way analysis of variance with the Tukey post-hoc multiple comparison test to determine
significance. Sample sizes were determined based on statistical significance and practicality. P ≤
0.05 was considered significant.
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Appendix 4: Regenerative proliferation of
differentiated cells by mTORC1‐dependent
paligenosis

The following chapter was published in The EMBO Journal

Willet, Spencer G., Mark A. Lewis, Zhi‐Feng Miao, Dengqun Liu, Megan D. Radyk, Rebecca L.
Cunningham, Joseph Burclaff et al. "Regenerative proliferation of differentiated cells by
mTORC1‐dependent paligenosis." The EMBO journal (2018): e98311.
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A4.1 Abstract
In 1900, Adami speculated that a sequence of context‐independent energetic and structural
changes governed the reversion of differentiated cells to a proliferative, regenerative state.
Accordingly, we show here that differentiated cells in diverse organs become proliferative via a
shared program. Metaplasia‐inducing injury caused both gastric chief and pancreatic acinar cells
to decrease mTORC1 activity and massively upregulate lysosomes/autophagosomes; then
increase damage associated metaplastic genes such as Sox9; and finally reactivate mTORC1 and
re‐enter the cell cycle. Blocking mTORC1 permitted autophagy and metaplastic gene induction
but blocked cell cycle re‐entry at S‐phase. In kidney and liver regeneration and in human gastric
metaplasia, mTORC1 also correlated with proliferation. In lysosome‐defective Gnptab−/− mice,
both metaplasia‐associated gene expression changes and mTORC1‐mediated proliferation were
deficient in pancreas and stomach. Our findings indicate differentiated cells become proliferative
using a sequential program with intervening checkpoints: (i) differentiated cell structure
degradation; (ii) metaplasia‐ or progenitor‐associated gene induction; (iii) cell cycle re‐entry. We
propose this program, which we term “paligenosis”, is a fundamental process, like apoptosis,
available to differentiated cells to fuel regeneration following injury.

A4.2 Introduction
In 1900, George Adami wrote about the relationship between mitotic and differentiated cells,
stating that he expected mitotic cells would generally devote energy toward replication and
differentiated cells toward performing physiological functions (Adami, 1900). He also observed
that upon injury, differentiated cells had the capacity to revert to a more primitive state,
becoming mitotic again to promote tissue repair. Adami's observations on such cellular plasticity
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have largely been forgotten, as the focus in the 20th century was nearly exclusively on the
unidirectional differentiation of stem cells into functional, “post‐mitotic” cells.

However, over the past decade or two, numerous examples have emerged to support plasticity in
differentiated cells. First, it became clear that normal, somatic cells could be reprogrammed to
pluripotency (Takahashi & Yamanaka, 2006). Furthermore, in tissues, injury can induce a repair
process that recruits largely post‐mitotic, differentiated cells back into the cell cycle in most, if
not all, organs and species, for example, glia (Boerboom et al, 2017; Mindos et al, 2017); lung
(Logan & Desai, 2015); heart in mammals (Wang et al, 2017) and fish (Karra et al, 2015); in
multiple gastrointestinal tract organs (Mills & Sansom, 2015). Each such example to date has
been studied essentially in isolation within the context of a particular type of injury and a single
organ; however, because the process is so widespread, we have postulated that it may be
governed by a shared, evolutionarily conserved molecular and cellular program that is
independent of tissue and species (Mills & Sansom, 2015).

It has long been known that the response of both the corpus of the stomach and the
digestive‐enzyme‐secreting (exocrine) pancreas to certain types of injury involves phenotypical
changes in cell differentiation and tissue architecture, known as metaplasia. In the acute setting,
the metaplastic response appears to be a tissue repair mechanism and can be temporary, with full
restoration of normal tissue architecture (Nomura et al, 2005; Huh et al, 2012). Chronically,
however, ongoing damage and long‐term metaplasia are associated with and may fuel the
majority of gastric and pancreatic adenocarcinomas (Mills & Sansom, 2015; Giroux & Rustgi,
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2017; Storz, 2017). In both organs, the cells of origin for the metaplastic, proliferating epithelial
cells are thought to be differentiated secretory cells (zymogenic chief cells in the stomach and
acinar cells in the pancreas) that reprogram to re‐enter the cell cycle (Mills & Sansom, 2015;
Murtaugh & Keefe, 2015; Mills & Goldenring, 2017; Radyk & Mills, 2017).

Here, we report that differentiated cells in both pancreas and stomach exhibit high levels of
mTORC1 activity during homeostasis. Proliferation‐inducing injury caused rapid mTORC1 loss
and a dramatic induction of autodegradative machinery (lysosomes and autophagy). As the
functional and structural components were recycled, cells changed gene expression patterns (e.g.,
inducing the metaplastic marker Sox9); thereafter, they reactivated mTORC1 and re‐entered the
cell cycle. Such changes in mTORC1 activity were corroborated in tissues from human patients.
Also, established models of injury to differentiated cells in mouse liver (Espeillac et al, 2011)
and kidney (Chang‐Panesso & Humphreys, 2017) correlate mTORC1 activity with the recruited
proliferating cells. Blocking mTORC1 with rapamycin in murine pancreas and stomach impaired
only cell cycle re‐entry but not earlier cellular changes. Differentiated cells in
autophagy‐defective Gnptab−/− mice were blocked from both SOX9 expression and cell cycle
re‐entry phases, consistent with the upstream autodegradative phase being necessary for
downstream mTORC1‐mediated S‐phase entry.

Our results in the context of numerous previous reports on cellular reprogramming lead us now
to propose that recruiting differentiated cells into a regenerative phenotype occurs via stepwise
metabolic and molecular phases that constitute a conserved, fundamental, cellular program, akin
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to mitosis or apoptosis. This cellular program occurs during cell fate changes of various types
(e.g., reversion, dedifferentiation, transdifferentiation, reprogramming). The lack of a standard
term for the actual cellular process itself impedes finding shared features that transcend cell
types, tissues, and model systems. We propose a new, unifying term: “paligenosis” from the
Greek: pali/n/m (meaning backward or recurrence) + genea (born of, producing) + osis (an action
or process).

A4.3 Diverse organs show similar changes in metabolic activity during acute
injury
To induce injury in the stomach, we employed a high‐dose tamoxifen (“HD‐Tam”) injury model
that has been used by us and others (Huh et al, 2012; Burkitt et al, 2017; Lee et al, 2017;
Leushacke et al, 2017). HD‐Tam causes loss of nearly all acid‐secreting parietal cells in the body
of the stomach (Figures A4.1) and induces mature, differentiated digestive‐enzyme‐secreting
chief cells at the base of the unit to give rise to a proliferating cell population (Radyk et al,
2017). These former chief cells maintain low‐level expression of some mature chief cell markers
and induce expression of wound repair‐associated genes like mucins and TFF2 (aka spasmolytic
polypeptide). The pattern of parietal cell loss and abundant, proliferative cells co‐expressing
TFF2 and chief cell markers has been called spasmolytic polypeptide‐expressing metaplasia
(SPEM) or pseudopyloric metaplasia (Schmidt et al, 1999). Maximal parietal cell loss and
proliferation stemming from chief cells occurs at 3 days after the first dose of tamoxifen
(Schematized in Figure A4.2). By 7 days, parietal cells have returned, and the entire stomach
regenerates to pre‐treatment cell censuses within 14–21 days (Huh et al, 2012). HD‐Tam is a
rapid, synchronous method to model, in a manner that lends itself to molecular analyses, the
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mechanisms of stomach repair that also occurs in human stomachs infected with the bacterium
Helicobacter pylori.
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Figure A4.1: pS6 is an accurate proxy for rapamycin‐sensitive mTORC1 activity and
shows that loss of mTORC1 does not affect parietal cell death or induction of metaplastic
gene expression in reprogramming chief cells.
A) Injection schemes for injury experiments with rapamycin in stomach (left) and pancreas
(right). B) Representative epifluorescence images of the distribution of pS6 in the normal and
injured stomach ±rapamycin treatment. pS6 is restricted to the chief cell zone (base) and pit zone
of the normal corpus unit. At peak (HD‐Tam day 3) SPEM stages, it is located at high level
throughout the unit. Upon rapamycin treatment, all pS6 staining is lost throughout the normal
and injured corpus unit. The characteristic induction of GSII staining in reprogramming chief
cells at the base of gastric units (indicating SPEM) occurs at least as markedly in the presence of
rapamycin, indicating mTORC1 is not required for metaplastic gene induction. Green, pS6;
white, GSII; blue, DAPI. Scale bars: 50 μm. C) At peak metaplasia stages, pS6 235/6 is
upregulated in the stomach epithelium and rapamycin treatment at this stage abolishes all
staining. Scale bars: 50 μm. D) Representative epifluorescence images of the loss parietal cells
(marked by ezrin) upon injury and rapamycin treatment. Treatment with HD‐Tam caused the loss
of the vast majority of parietal cells throughout the corpus. Rapamycin does not rescue that
injury. Green, GSII; white, ezrin; blue, DAPI. Scale bars: 50 μm.
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Figure A4.2: mTORC1 activity undergoes dramatic changes during stomach and pancreas
metaplastic injury response.
A,B) Digestive‐enzyme‐secreting (zymogenic) mature cell populations in the stomach (A) and
pancreas (B) are recruited back into the cell cycle to fuel metaplasia in response to large‐scale
injury. Digestive enzyme expression (red) decreases, and markers of mucous neck cells (green,
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stomach) or duct cells (green, pancreas) increase in metaplastic, proliferating cells (red + green =
yellow). Stomach is further characterized by loss of acid‐secreting parietal cells (blue). (B)
Representative epifluorescence images of mouse gastric corpus glands during homeostasis, early
after injury (HD‐Tam 12 h) and at maximal metaplastic response (HD‐Tam Day 3), stained for
mTORC1 activity using a downstream target, pS6 as a proxy. Green, pS6; red, GIF (gastric
intrinsic factor, a chief cell marker); white, GSII (a mucous neck cell marker); blue, DAPI.
Right—higher magnification images of boxed areas on left focus exclusively on the base of the
unit where the digestive‐enzyme‐secreting cells are reprogramming. Yellow dashed area outlines
the base of a single gastric unit. Scale bar, 20 μm; boxed area pull out, 10 μm. C) Western blot of
pS6 (red) and β‐tubulin control (green) from whole corpus protein extracts at various injury time
points; pS6 (240/244 or 235/6) vs. tubulin fluorescent intensity from replicate blots quantified
below (error bars = standard deviation). *P < 0.05, ***P < 0.001. Statistical analysis with both
antibodies was done using ANOVA with a post hoc Dunnett's test. D) Representative
epifluorescence images of pS6 staining of pancreas during homeostasis, acute injury (cerulein 12
h), and maximal injury (cerulein day 5). Green, pS6; red, amylase; blue, DAPI. Boxed areas on
left depicted at higher magnification on right. Scale bar, 20 μm; boxed area pull out, 10 μm.

To induce injury in pancreas, we used a well‐described rapid method involving daily injection of
the secretagogue cerulein. Cerulein injections cause large‐scale damage to the
digestive‐enzyme‐secreting acinar cells of the exocrine pancreas (Adler et al, 1985; Niederau et
al, 1985; Saluja et al, 1985). To repair the damage, acinar cells re‐enter the cell cycle, forming
duct‐like structures called ADM (acinar‐to‐ductal metaplasia; schematic in Figure A4.2). In our
protocol, ADM peaks 5 days after commencement of cerulein. Thereafter, there is continued
damage if cerulein administration is maintained, but the pancreas gradually adapts to the injury
over 2 weeks. Similar to HD‐Tam injury in the stomach, cerulein injury models a metaplastic
process that can also be a precursor for pancreatic ductal adenocarcinoma.

To determine whether the reversion from the differentiated to the replicative state involves
conserved shifts in cellular energy use, we examined metabolic activity in both tissues using
phosphorylated ribosomal S6 protein (pS6). The principal mediator of S6 phosphorylation is the
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S6 kinase enzyme via the cellular metabolism hub mTOR complex 1 (mTORC1). To confirm
that S6 phosphorylation depends on mTORC1 activity, we treated mice with rapamycin, a
specific inhibitor of the mTORC1‐mediated S6 kinase activity. We used an antibody against
residues 240/244 of S6, because those sites are phosphorylated principally by pS6 kinase 1,
whereas the 235/236 phosphorylation sites can have input from other signaling pathways. For
example, 235/236 can be phosphorylated by p90 ribosomal S6 kinases that can be activated via
ERK signaling (Roux et al, 2007). Figure A4.1 shows that rapamycin, which is a specific
inhibitor of mTORC1‐mediated S6 Kinase activity, abolished pS6 240/44 staining, which was
normally abundant in gastric pit cells nearer the stomach lumen and in gastric chief cells.
Rapamycin also blocked S6 phosphorylation efficiently during the HD‐Tam protocol (Figure
A4.1). Antibodies against 235/236 also showed strong phosphorylation at peak metaplasia as
well as a similar abrogation of staining in the presence of rapamycin (Figure A4.1). As
anti‐240/244 antibodies have stronger signal in our experiments and are more specific for
mTORC1‐mediated phosphorylation, we will use anti‐240/244 pS6 as a surrogate for mTORC1
activity for the remainder of the manuscript unless otherwise mentioned.

HD‐Tam or cerulein caused dramatic changes in pS6 expression. In stomach, pS6 was largely
lost by 12 h. By 3 days, when SPEM is maximal in this system, the entire gastric unit expressed
abundant pS6 (Figure A4.2B). Molecular and cellular changes in the stomach following HD‐Tam
are sufficiently synchronous across the whole stomach that quantitative, molecular approaches
can be used (Huh et al, 2012). Quantitatively, phosphorylation status of both pS6 240/244 and
235/236 in the corpus of the stomach was decreased by nearly half within the first 4 h and
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returned to at or above baseline by 48 h (Figure A4.2C). In pancreas, despite a slower and less
synchronous time course, the same pattern of mTORC1 activity could be observed by
immunofluorescence. pS6 was abundant in acinar cells at baseline, was nearly undetectable by
24 h, and recovered in many cells by day 5, when ADM is maximal (Figure A4.2D).

Thus, both tissues, when recruiting proliferative cells for repair, undergo a well‐defined pattern
of changes in mTORC1 activity. During homeostasis, the organs are replete with differentiated
secretory cells that are not dividing but are energetically active in synthesizing protein using their
elaborate secretory apparatus (Mills & Taghert, 2012; Lo et al, 2017). When replicating cells
must be recruited from those differentiated cells, the cells shut off mTORC1 temporarily, then
re‐induce it at the time of maximal regenerative proliferation.

To further assess whether the upregulation of pS6 is a common feature during the recruitment of
differentiated cells to regenerate damaged tissue, we examined liver (two‐thirds partial
hepatectomy) and kidney (tunicamycin‐induced acute injury) for changes in S6 phosphorylation.
Both injury models have previously been shown to involve recruitment of differentiated cells
back into the cell cycle (Newberry et al, 2008). In kidney, as expected, tubules in the cortex and
outer medulla are damaged as evinced by vacuolation (Figure A4.3). Non‐damaged tubules show
increased BrdU as cells re‐enter the cell cycle (Figure A4.3). The proliferative tubules show
marked increase in pS6. Similarly, the well‐known recruitment of hepatocytes into the cell cycle
48 h following partial hepatectomy is also accompanied by increased S6 phosphorylation (Figure
A4.3).
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Figure A4.3: Acute kidney injury and partial hepatectomy both cause upregulation of
mTORC1 activity during proliferative phases.
A) Upon injury with tunicamycin, tubule cells in the kidney are damaged (white arrowhead) and
surviving tubule cells (yellow arrowhead) upregulate pS6. Scale bars: 100 μm. B) Upregulation
of the pS6 is associated with increased proliferation in this injury model as seen by BrdU+
nuclei. Scale bars: 100 μm. C) Two‐thirds partial hepatectomy causes a pronounced upregulation
of pS6 in the remaining hepatocyte mass. Scale bars: 20 μm. D) The pS6+ hepatocytes are highly
proliferative at this stage. Scale bars: 20 μm.
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A4.4 mTORC1 is required for injury‐induced proliferation
During SPEM and ADM, expression of genes encoding secretory cargo (like digestive enzymes)
is scaled down, whereas wound repair and progenitor‐associated genes are scaled up (Capoccia
et al, 2013). Many such scaled up genes (e.g., Cd44 and Sox9) are increased in both pancreas and
stomach during the recruitment of differentiated cells back into the cell cycle. To determine
whether blocking mTORC1 affected response to injury, we subjected mice to HD‐Tam or
cerulein and examined the effects of blocking mTORC1 with rapamycin (Figure A4.4). Figures
A4.1 and A4.4 show that parietal cell death occurred in HD‐Tam even without mTORC1
activity. The gastric units also remodeled as expected with chief cells assuming the ductular
morphology, characteristic of SPEM (Figure A4.4).
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Figure A4.4: Histological changes in the injured stomach and pancreas with and with
rapamycin treatment.
A) Representative hematoxylin and eosin counterstained images of HD‐TAM stomach tissue
±rapamycin. Treatment with tamoxifen causes acute loss of parietal cells (large eosinophilic
cells) by 12–24 h post‐injury. By 3 days, chief cells have reprogrammed into SPEM cells. The
general pattern of loss of parietal cells and conversion of chief cells to metaplastic cells is not
affected by rapamycin (right panels). Scale bars, 50 μm. B) Representative hematoxylin and
eosin counterstained images of pancreas tissue injured with cerulein at various stages
180

±rapamycin. Cerulein injury causes mosaic, asynchronous conversion of acinar cells into
proliferative, acinar‐ductal metaplastic cells with maximal features of the process at day 5 in our
protocol. By 2 weeks, the pancreas has compensated for the continuous injury and recovers a
relatively normal morphology. Dual treatment with rapamycin and cerulein does not rescue the
metaplastic response by day 5 and impedes normal tissue compensation by 2 weeks injury, with
most of the tissue continuing to show abundant metaplastic forms. Scale bars, 50 μm.

We next examined the effects of rapamycin on induced proliferation. We noted that in control
experiments, without HD‐Tam, proliferation of the cells in the isthmus (the narrow zone between
pit and upper neck, Figure A4.2), where there is active mitosis in homeostasis, was not affected
markedly by rapamycin (Figures A4.5A and C). However, rapamycin decreased the
injury‐induced proliferation by nearly half (P < 0.001; Figure A4.5C). The lack of proliferation
did not affect SPEM induction, as defined by cells co‐stained with GSII and the chief cell
marker, GIF (Figure A4.5A and B). Indeed, the SPEM marker SOX9 was induced in
reprogramming chief cells to levels at least as high as those observed in HD‐Tam without
rapamycin (Figure A4.6). That cells expressing molecular features of metaplasia can arise in the
absence of proliferation is consistent with multiple previous reports showing that chief cells can
give rise directly to SPEM cells without contribution from the isthmal stem cell (Nam et al,
2010; Radyk et al, 2017).
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Figure A4.5: Recruitment of proliferating cells during stomach and pancreas metaplastic
injury depends on mTORC1.
A) Representative immunofluorescence images of stomach tissue ± metaplastic injury ±
rapamycin treatment. Green, neck cells (GSII); red, chief cells (GIF); white, proliferating cells
(BrdU); blue, nuclei (DAPI). Scale bars 20 μm; 10 μm for bottom images. Bottom—boxed areas
from top pictures are shown at higher magnification with individual bases of gastric units (where
reprogramming occurs) outlined by dashed lines and proliferating cells by arrowheads. B) Cells
of each differentiation type, following scheme in Figure A4.2, are quantified by scoring
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immunofluorescence images from multiple experiments. Metaplastic injury induces a massive
accumulation of yellow (SPEM) cells and loss of red (Chief) cells (compare vehicle–vehicle with
vehicle‐Tam, D3) that is not significantly affected by rapamycin treatment (compare
vehicle‐Tam D3 with Rap‐Tam D3). C) Proliferative cells are quantified as for panel (B). Injury
induces massive proliferation (compare vehicle–vehicle with vehicle‐Tam D3) significantly
inhibited by rapamycin (compare vehicle‐Tam D3 with Rap‐Tam D3). D) Top panel arrowheads
indicate rare proliferative acinar cells during homeostasis with or without rapamycin treatment.
Cerulein induces proliferation of acinar cells recruited into the cell cycle that is inhibited by
rapamycin. Boxed areas are magnified in insets. Note multiple BrdU+ cells (green) staining with
amylase (red) a digestive enzyme, indicating acinar cell origin. BrdU+ cells following rapamycin
+ cerulein treatment are often not co‐stained with amylase. Blue, DAPI (nuclei). Scale bars 20
μm; 10 μm for insets. E) Quantification of multiple experiments with mice treated as in panel
(D).
Data information: ***P < 0.001; N.S. = not statistically significant; data displayed as mean ±
SEM from 3 independent experiments with quantification from up to 13 low‐power fields, from
each of 4–5 total mice; significance determined by ANOVA with Tukey's post hoc test.
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Figure A4.6: mTORC1 is not required for increased SOX9 during metaplasia.
A) Representative eosin counterstained IHC images of normal or metaplastic gastric tissue
stained for SOX9. SOX9, in control tissue, stains the isthmal and mucous neck cells, which are
proliferative progenitors (yellow arrowheads), of the corpus units and is generally excluded from
the base of units. Upon injury with HD‐TAM, SOX9 expression is induced in the base of units
(yellow arrowheads). Treatment with rapamycin does not alter either the normal or metaplasia
distribution of SOX9 (yellow arrowheads). Scale bars, 50 μm. B) Representative hematoxylin
counterstained IHC images of normal or metaplastic pancreatic tissue stained for SOX9. SOX9
expression in normal pancreatic tissue is restricted to the duct (see inset in top left panel which is
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a high magnification view of the boxed area). At peak metaplasia stages, SOX9 becomes
expressed in dedifferentiating acinar cells (see bottom left inset). Treatment with rapamycin in
normal (see top right inset) or injured (see bottom right inset) does not alter SOX9 expression.
Scale bars 50 μm; inset 25 μm.

Rapamycin had equivalent effects on the pancreas. Metaplastic induction of SOX9 was not
affected (Figure A4.6); however, cell proliferation was even more substantially blocked than in
the stomach (Figure A4.5D and E). This may be because the pancreas is entirely dependent on
reprogramming acinar cells as a source for proliferation, whereas the stomach also has a
constitutive stem cell that continues to proliferate even in the presence of rapamycin (Figure
A4.2). Continued HD‐Tam injections kill mice, so we cannot study adaptation of stomachs;
however, we have maintained cerulein injections for up to 2 weeks by which point wild‐type
pancreas usually adapts to the injury. Thus, we used the pancreas to determine whether
mTORC1‐dependent proliferation was required for pancreatic repair. Figure A4.4 shows that
2‐week cerulein with mTORC1 blocked led to tissue loss relative to cerulein treatment alone.

A4.5 Changes in mTORC1 also characterize human metaplasia
To determine whether mTORC1 activity is modulated in human disease states, we first examined
a database of stomach tissues from human patients exhibiting metaplastic response to H. pylori
infection, previously compiled at Washington University (Lennerz et al, 2010; Radyk et al,
2017). A representative region from this dataset is shown in Figure 3A. As in mice,
morphologically normal chief cells showed high pS6. In regions of SPEM, pS6 abundance
varied. In lesions that had histological features of cells undergoing acute conversion to SPEM
(what we have previously termed “hybrid SPEM” (Lennerz et al, 2010; Radyk et al, 2017) based
on examination of a large dataset of SPEM lesions), pS6 levels were high (Figure 3A). In regions
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where basal cells showed more uniform metaplasia (“established SPEM”), pS6 levels were
lower. In humans, SPEM is thought to be either transient and rapidly resolve (as in the mouse
HD‐Tam model) or chronic and persist for decades, involving large patches of the stomach
(Peterson, 2002). In the chronic case, SPEM is equivalent to the lesion pathologists call chronic
atrophic gastritis (Rugge et al, 2008). In addition, SPEM is thought to progress to (or predate)
another, proliferative, pre‐cancerous lesion, intestinal metaplasia (Yoshizawa et al, 2007; Correa
& Piazuelo, 2012; Spechler et al, 2017) and to increase risk for progression to a cytologically
atypical lesion, dysplasia, as well as to cancer itself.
To further clarify the link between mTORC1 activity and metaplastic changes in humans, we
analyzed pS6 levels in gastric tissue microarrays (Figure A4.7) comprising tissue cores
representing the following histological phenotypes: normal mucosa, SPEM, IM, dysplasia, and
gastric adenocarcinoma. pS6 showed consistent, mid‐level expression in nearly all normal
mucosal samples, in agreement with our smaller sample showing expression of pS6 in normal
chief cells and with our mouse data (Figure A4.8B). Both cancer and dysplastic lesions showed
higher average pS6 expression, though there was also more variability in that over a third of such
lesions showed much stronger expression than normal tissue, while about a third showed lower
expression (Figure A4.8B). On average, intestinal metaplasia pS6 levels were close to those of
normal mucosa (Figures A4.8B and A4.9). SPEM lesions showed a clear biphasic pattern with
the majority like the “established SPEM” with low‐to‐no detectable pS6 (cf. Figures A4.8A and
A4.9) but with some SPEM lesions having much stronger pS6 (Figures A4.8 and A4.9).
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Figure A4.7: Patient Demographics.
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Figure A4.8: mTORC1 activity correlates with stages of metaplasia during human gastric
tumorigenesis.
A) Immunofluorescent images of human gastric tissue from a patient with intestinal‐type gastric
adenocarcinoma elsewhere. In this non‐carcinoma containing region of the gastric corpus,
various states of metaplasia can be observed that reflect mouse injury models. Extensive
previous work (Lennerz et al, 2010) of a dataset of such resection specimens and of biopsies
showing SPEM in a non‐cancer setting has indicated likely stages of progression of SPEM from
essentially normal wherein large, pyramidal‐columnar cells at the base express only chief cell
markers like pepsinogen C (PGC, green) to “hybrid SPEM” (yellow arrowhead, inset) where
smaller, cuboidal columnar cells label with varying degrees of PGC and the neck/SPEM cell
marker GSII (purple) to “established SPEM” characterized by cells that label extensively with
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GSII and have scant PGC; established SPEM cells are mucus‐stuffed, with peripheral, basal,
flattened nuclei (blue, DAPI). Higher magnification of each cellular phenotype is shown by
color‐coded box on right. As parietal cells are lost in SPEM, the remnant one in the yellow
boxed area (labeled “PC”) is consistent with the normal chief cell phenotype (representative
individual cells outlined by white dashed lines). Note that there is consistently high expression of
pS6 (red) throughout the cytoplasm of such normal chief cells but that this pS6 varies in the
hybrid SPEM lesion and is largely scaled down in the established SPEM region (note pS6 only
around the nuclei of these cells). Scale bar, 20 μm; pullouts 10 μm. B) Analysis of a human
gastric tissue microarray with normal, metaplastic, and cancer tissue all represented from patients
with resections for gastric cancer. Serial tissues sections of the array were stained by
immunohistochemistry with pS6 or Ki67, counterstained with hematoxylin, and visually graded
by blinded observers, supervised by a human pathologist, for staining intensity (from score 0
meaning undetectable to 3 most intense). Top—average histological score is plotted for each
phenotype. Bottom—the relative fraction of tissue cores with each score is plotted (total scores
of each type provided at the top of each column. C) Given the biphasic nature of the SPEM
histological score and given that established SPEM, as observed in panel (A), shows decreased
pS6, we separated all the SPEM lesions into Ki‐67+ (“proliferative”) and Ki‐67− (“quiescent”)
and replotted as for panel (B).
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Figure A4.9: Representative IHC images from human tissue microarray.
A) Intestinal metaplasia (“IM” indicating the glands to upper left of red dashed line) is generally
proliferative as evinced by frequent Ki‐67+ cells (left) and is strongly pS6 positive. Most SPEM
has a quiescent phenotype (glands labeled on “qSPEM” side of panels) characterized by cells
with abundant mucus, flattened basal nuclei, and a lack of both Ki‐67 and pS6 staining Scale bar,
200 μm. B) Rare SPEM lesions show cells with cuboidal columnar morphology. These lesions
show Ki‐67 positivity usually associated with pS6 positivity. Boxed regions are shown at higher
magnification below. Scale bar, 200 μm; pullout, 50 μm.

SPEM lesions with lower pS6 activity tended to express abundant mucin as well as epitope for
the SPEM‐identifying lectin GSII (Figure A4.9A); nuclei tended to be flat and eccentric (Figure
A4.9). pS6‐expressing SPEM cells were more cuboidal columnar, resembling the SPEM cells in
the acute, proliferative mouse SPEM that resolves in a few days after HD‐Tam. We hypothesized
that SPEM with increased pS6 represented metaplastic cells that are actively proliferating (like
D3 HD‐Tam in mice) to repair an injury, whereas the decreased pS6 lesions of established SPEM
may be mitotically quiescent. Hence, we divided the SPEM lesions into mitotically active
(“proliferative SPEM”) and inactive (“quiescent SPEM”) based on Ki‐67 staining of the same
tissue core on another microtome section (Figure A4.9) and then correlated those phenotypes to
the previously scored pS6 expression for that lesion. Proliferative SPEM was far more likely to
be associated with pS6 expression, whereas quiescent SPEM was largely negative for pS6
(Figure A4.8C, P < 0.001 by χ2). Thus, pS6 is low‐moderate in normal, physiologically active
mucosa and high in most lesions that have increased proliferation (proliferative SPEM, IM,
dysplasia, cancer). We conclude that metabolic activity correlates with differentiation state and
recruitment into the cell cycle in humans as well as mice.
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A4.6 Loss of mTORC1 inhibits cell cycle progression at S‐phase
Because gastric chief cells respond to injury more synchronously than pancreatic acinar cells, we
are able to perform molecular analyses based on changes of gene expression. We used this
approach to determine specifically where the block in cell cycle re‐entry occurs when mTORC1
activity is inhibited. We analyzed Affymetrix GeneChips of whole gastric corpora ±HD‐Tam
(3D) ±rapamycin by Gene Set Enrichment Analysis (GSEA) with a combination of both a
publicly available and custom gene sets. In a control experiment to validate our approach, we
dissociated gastric epithelial cells from Atp4b‐Cre; ROSA26mTmG mouse stomachs and used
flow cytometry to isolate parietal cells (GFP+) from other epithelial cells (Tomato+). Expression
of isolated, amplified RNA applied to GeneChips was analyzed by Partek Genomics Suite, and
the 94 genes whose expression was enriched ≥ eightfold in parietal cells vs. other epithelial cells
was computed. As expected, GSEA showed that these PC‐enriched genes were highly
preferentially expressed in control stomachs vs. HD‐Tam stomachs; the addition of rapamycin
did not affect this pattern (Figure A4.10). Thus, global gene expression profiling with GSEA can
detect the loss of parietal cells that epitomizes HD‐Tam‐induced metaplasia and also shows that
parietal cell loss is independent of mTORC1, consistent with the histological data. In another
control experiment, we performed GSEA of a published gene set of mature chief cell enriched
genes (Capoccia et al, 2013) and contrasted HD‐Tam vs. HD‐Tam + rapamycin. There was no
substantial effect of rapamycin, suggesting that the change in chief cell gene expression induced
by injury is also not substantially affected by loss of mTORC1 (Figure A4.10).
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Figure A4.10: Gene Set Enrichment Analyses for Rapamycin + Tamoxifen experiments.

On the other hand, although many transcripts from a previously published gene set of
SPEM‐associated genes (Nozaki et al, 2008) did not show particular changes when rapamycin
was administered in HD‐Tam, there was a cluster of genes enriched only when mTORC1 levels
were normal (Figure A4.10). Injury that causes metaplasia induces both
wound‐healing‐associated genes (e.g., Clu, Sox9, CD44v) and proliferation‐associated genes.
Given that rapamycin blocks proliferation specifically in our histological analysis, we next
examined the effects of rapamycin on the cell cycle using GSEA. Figure A4.11A shows that,
indeed, rapamycin induces a marked de‐enrichment of cell cycle gene expression in HD‐Tam.
The block appears specifically at the S‐phase and beyond, as gene sets for G1‐S, S, G2, and
192

G2‐M showed that G1‐S genes were relatively similarly distributed regardless of mTORC1
activity, whereas genes expressed during the later stages in the cell cycle were skewed toward
the HD‐Tam alone condition (Figure A4.11B–E). We used a slightly different approach to
further investigate the interaction of mTORC1 with cell cycle stage by first determining the top
20 genes skewed most toward the HD‐Tam (vs. vehicle‐treated controls) in each cell cycle stage
gene set. We then determined the average increased expression of those genes in both HD‐Tam
and HD‐Tam + rapamycin vs. vehicle controls. Figure 4.11F shows that rapamycin decreased
expression of the 20 top G1/S‐phase HD‐Tam‐enriched genes by only 16 ± 3%, whereas gene
expression at other cell cycle stages was inhibited substantially more. Expression of G2/M‐phase
genes was decreased by 49 ± 3% with rapamycin treatment (P < 0.001, HD‐Tam vs. HD‐Tam +
rapamycin in G2‐M genes; P < 0.05 for G2‐M vs. G1‐S).
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Figure A4.11: mTORC1 activity is required predominately for progression through S‐,
G2‐, and M‐phases during metaplastic induction of proliferation.
A–E) Microarrays of stomach corpora at D3 ± HD‐Tam ± rapamycin were analyzed using GSEA
“Difference of Classes” function comparing rapamycin + HD‐Tam (“Tam+Rap”) vs. rapamycin
vehicle + HD‐Tam (“Tam”). Whitfield Gene Sets specific for either overall cell cycle genes or
specific phases of cell cycle are depicted. Note that rapamycin correlates with decreased cell
cycle gene expression that is largely due to decreased S‐G2 phase gene expression. F) The dot
194

plots are of the actual average expression levels (in rapamycin + HD‐Tam and HD‐Tam alone
Genechips) of the top 20 genes enriched in various Whitfield Gene Sets GSEA comparisons of
HD‐Tam vs. vehicle controls (both without rapamycin). Expression levels of HD‐Tam and
HD‐Tam + rapamycin for all genes were normalized to expression level in vehicle control
Genechip to facilitate plotting and expressed as Log2 such that 1 = 2‐fold enriched vs. control.
Note that average expression of G1‐phase genes is only somewhat reduced by rapamycin (by
t‐test of Tam vs. Rap‐Tam, *P < 0.05, **P < 0.01; ***P < 0.001), whereas later phases of the
cell cycle are substantially reduced (decrease in G2/M‐phase relative to G1‐phase by ANOVA
with Dunnett's post hoc test is ***P < 0.001). G, H) qRT–PCR of select transcripts. Control
genes known to be increased or decreased in SPEM (G) and genes associated with specifically
with G2‐M cell cycle phase (H). Expression was normalized to housekeeping gene Tbp, then
vehicle control samples for each gene were set at 1, and HD‐Tam and HD‐Tam + rapamycin
expression was normalized to the control sample (statistics for the entire set of cell cycle genes
among the different treatments are shown in legend, ***P < 0.001 by ANOVA with Tukey's post
hoc test; data represented as mean ± SEM of the means from 3 replicates from a total of 3
independent experiments).

To independently validate the GeneChip findings, we performed qRT–PCR that showed that the
expected decreases in a parietal cell (Atp4b) transcript and increase in a non‐cell‐cycle SPEM
transcript (Clu) were not affected by rapamycin (Figure A4.11G). Also matching the GeneChip
results, the G1 transcript, Ccnd1, was increased similarly regardless of mTORC1 status. As
expected, a G2/M‐phase transcript cohort was uniformly increased in HD‐Tam but not in
HD‐Tam + rapamycin (Figure A4.11H). Thus, molecular analysis indicates that inhibition of
mTORC1 activity does not substantially affect chief cell G1‐phase entry from the quiescent, G0
state but slows S, G2, and M‐phase progression. BrdU uptake and incorporation into DNA
occurs during S‐phase; thus, the block in BrdU seen histologically corroborates the molecular
data suggesting that mTORC1 is required for G1 to S transition.
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A4.7 Autodegradative machinery is massively upregulated early following
injury
We so far have observed that mTORC1 activity is rapidly extinguished within hours of inducing
injury. Later, as cells re‐enter the cell cycle, mTORC1 is rekindled. Blocking re‐emergence of
mTORC1 activity inhibits induced proliferation in both stomach and pancreas. In pancreas,
where repair is entirely dependent on reprogramming, loss of mTORC1 activity blocks tissue
regeneration. We hypothesized that the scaling down of mature cell architecture to “retool” a cell
for more efficient proliferation would likely involve activation of lysosomes and autophagic
machinery. The autodegradation of cellular structure could then liberate key macromolecules
(nucleotides, amino acids, lipids) that would both stimulate mTORC1 reactivation and provide
building blocks for replication. Figure A4.12 shows that there is a massive increase of lysosomes
(by luminal marker Cathepsin D, Figure A4.12A) and autophagosomal puncta (by LC3‐GFP,
Figure A4.12C) early following injury in gastric chief cells. Figure 5B quantifies a large spike in
lysosomes, as a percentage of their PGC+ (pepsinogen C; chief cell marker) cell area, by 12–24 h
of HD‐Tam that begins to resolve by later stages, when many cells have re‐entered the cell cycle.
Increased lysosomes, autophagosomes, and autolysosomes can also be seen at the ultrastructure
level (Figures A4.12D and E) on transmission electron microscopy (tEM). tEM analysis shows
that rER, mitochondria, and secretory granules are all targeted for recycling during these early
stages. The pancreas also shows an equivalent time course of changes in autodegradative
machinery, with a spike in lysosome and autophagic puncta 8–24 h following cerulein, followed
by decreasing, but still elevated levels, at D3 and near baseline levels at the time of maximal
proliferation and pS6 activity (D5: Figures A4.12F, A4.13).
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Figure A4.12: Lysosomal and autophagic pathways are upregulated acutely following
stomach and pancreas injury.
A) Injured zymogenic cells upregulate Cathepsin D+ puncta (green) 24 h follow HD tamoxifen.
Red, chief cells (GIF); blue, nuclei (DAPI). Boxed areas are shown at higher magnification at
right of each panel. Scale bars 20 μm; 10 μm for pullouts. B) Quantification of Cathepsin D+
area in chief cells at various stages following injury. **P < 0.01; ***P < 0.001 by ANOVA with
Dunnett's post hoc test. Each datapoint is an individual counted cell. C) LC3 puncta (detected by
GFP fluorescence in Lc3‐gfp mice) shows increased autophagosomal puncta paralleling
Cathepsin D+ results. Green, LC3‐GFP; red, GIF; blue, DAPI. Boxed areas are shown at higher
magnification and differing fluorescence channels in insets. Scale bars 20 μm. D) Transmission
electron micrographs of a normal zymogenic cell. Yellow arrowhead indicates a rare lysosome
seen during homeostatic conditions. E) Transmission electron micrographs of corpus units 24 h
follow tamoxifen injury. Various selected pullouts highlight double membrane‐bound structures
attacking cytosolic components in reprogramming chief cells. F) Acinar cells in pancreas have
increased LC3‐GFP+ puncta following acute injury with cerulein. Green, LC3‐GFP; red, GIF;
blue, DAPI. Scale bar 20 μm.
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Figure A4.13: Lysosomal activity is raised in the pancreas in early injury.

A4.8 Autodegradative machinery is required for normal progression to later
stages
We next sought to address whether autodegradative machinery activation is both upstream of and
required for metaplasia formation and proliferation. To do this, we used mice defective in
lysosomal hydrolase trafficking that have been shown previously to have defects in
autodegradative function specifically in exocrine secretory cells like chief and acinar cells
(Boonen et al, 2011). Gnptab−/− mice are deficient in an enzyme required for the addition of
mannose‐6‐phosphate to lysosomal enzymes to ensure their proper trafficking. We treated
Gnptab−/− and littermate controls (Gnptab−/+ and Gnptab+/+) with HD‐Tam or cerulein. HD‐Tam
treatment in Gnptab−/− mice caused the expected loss of parietal cells; however, chief cell
reprogramming was dramatically compromised (Figure A4.14). Most units did not show loss of
large chief cells with eccentric nuclei at all (red arrowhead, Figure A4.14), suggesting
reprogramming did not occur, whereas some gastric units showed complete loss of the base zone
where chief cells normally reside (green arrowhead, Figure A4.14), indicating chief cells were
aberrantly lost instead of reprogrammed. Rarer gastric units seemed to complete the
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reprogramming (yellow arrowhead, Fiure A4.14). In pancreas, we detected almost no ADM in
Gnptab−/− mice (Figure A4.14) by D5. Rather, cells remained in an aberrant acinar morphology
with considerable loss of eosinophilic cytoplasm but no decrease in size. By 2 weeks, whereas
wild‐type controls had largely adapted to the cerulein injury, in Gnptab−/− mice, the exocrine
pancreas comprised only scattered ducts and SOX9− acinar cells, still organized in typical
lobules. Cytologically, these remnant cells were characterized by generous pale cytoplasms
ranging from foamy to hyaline and lacking nearly all distinguishing features.
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Figure A4.14: Histological appearance of Gnptab−/− stomach and pancreas tissue at injury
time point.
A) Representative hematoxylin and eosin counterstained images of Gnptab+/− and Gnptab−/−
stomach tissue. Gnptab−/− chief cell cytoplasms have a hypertrophic, frothy appearance compared
to control zymogenic cells. Loss of parietal cells (fried‐egg appearing eosinophilic cells)
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following HD‐Tam is not affected by loss of GNPTAB; however, the base zones in Gnptab−/−
mice at day 3 HD‐Tam are usually resistant to dedifferentiation (red arrowheads) with large,
frothy chief cells remaining largely non‐reprogrammed. Another, less common phenotype is that
all chief cells are lost such that most of the base of the unit disappears (green arrowheads). Rare
units partially undergo morphological metaplastic changes, though usually those are also
associated with loss of basal cells (yellow arrowheads). Higher magnification views are to right
of each panel, with white bracket delineating particular region of interest in Gnptab−/− stomach
Scale bar 50 μm; pullout, 25 μm. B) Representative hematoxylin and eosin counterstained
images of Gnptab−/+ and Gnptab−/− pancreas. Similar to the stomach zymogenic cells, pancreatic
acinar cells also have a hypertrophic, frothy appearance. Whereas control samples treated with
cerulein show diffuse, asynchronous acinar‐to‐ductal metaplasia, Gnptab−/− mice have acinar
cells that simply become less eosinophilic and foamy over time without undergoing ADM. By 2
weeks, wild‐type pancreas has largely adapted to cerulein, whereas Gnptab−/− pancreas
parenchyma comprises only lobules of excessively pale (hyaline), frothy acinar cells and
scattered reactive ducts. Scale bar 50 μm; pullout, 25 μm.

We next examined the molecular phenotype of the block in Gnptab−/− mice. In control stomachs
in response to injury, reprogramming cells in the base showed the expected abundant increase in
metaplastic genes like Sox9 (Figure A4.15A) and the epitope for GSII (Figure A4.15C).
Proliferation in the base of the unit, where chief cells were reprogramming, was nearly
equivalent to the rate of proliferation in the normal stem cell zone in the neck (Figure A4.15B
and D). The bases of gastric units in Gnptab−/− mice were markedly compromised in both
metaplastic changes and proliferation (Figure A4.15A–D). In Gnptab−/− mice, chief cells in the
base remained both BrdU‐ and SOX9‐negative (Figure A4.15E and F). They also failed to
reactivate mTORC1, as pS6 in these mice was largely not detectable in the base (Figure A4.16).
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Figure A4.15: Lysosomal function is required for metaplasia‐associated gene expression
and increased proliferation.
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A) Immunohistochemical analysis of SOX9 expression at peak SPEM stages following gastric
injury. In control and Gnptab−/+ mice, SOX9 becomes expressed in reprogramming chief cells in
the bases of the corpus at SPEM stages, but not in Gnptab−/− mice. Color‐coded boxes shown at
higher magnification shown at right for panels (A and B). Scale bar, 50 μm; 25 μm pullout. B)
S‐phase, cell cycle marker BrdU is incorporated throughout the gastric corpus unit at peak SPEM
stages in control WT or Gnptab−/+ mice. In Gnptab−/− mice, the gastric unit bases, where
proliferation is recruited from chief cells, show a marked relative deficit in BrdU+ cells. Scale
bar, 50 μm; 25 μm pullout. C) Immunofluorescence analysis of injured gastric tissue from
Gnptab−/− and control mice. GIF/GSII co‐expression is the hallmark of SPEM. In control mice,
the vast majority of corpus unit bases are converted to GIF/GSII co‐expression state. In
Gnptab−/− mice, bases are resistant to conversion and remain as GIF single positive cells. Red,
GIF; green, GSII. Scale bar, 20 μm. D) Quantification of randomly sampled 20× fields stained
with BrdU. Distribution of BrdU in neck region vs. base region (note total = 100%) is plotted.
Note control mice have equivalent amounts of BrdU‐labeled cells in the neck and base (˜50% in
each), whereas Gnptab−/− mice BrdU‐labeled cells substantially shifted away from the
paligenotic base of units and into the isthmal‐neck region, where the constitutive stem cell is
active. E) Quantification of randomly sampled 20× fields stained with BrdU in control and
Gnptab−/− mice. Gnptab−/− mice have significantly more BrdU‐negative base cells compared to
control animals. F) Quantification of control and Gnptab−/− corpus units stained for SOX9 scored
for the amount of SOX9‐negative chief cells per unit at peak SPEM stages. Gnptab−/− mice have
significantly more SOX9‐negative bases compared to control animals. G) Representative
immunofluorescence images of injured control and Gnptab−/− pancreatic tissue at cerulein 5 days.
Red, amylase; green, BrdU; blue, DAPI. White arrows show proliferating, amylase+
acinar‐derived cells (note these are not seen in Gnptab−/− mice). Yellow arrowheads show
proliferating stromal cells that are not affected by loss of GNPTAB. Scale bar, 20 μm. H)
Representative immunohistochemistry of SOX9 stained control and Gnptab−/− pancreatic tissue
at cerulein 5 days. Gnptab−/− tissue has reduced metaplastic phenotype and reduced expression of
SOX9. Scale bar, 50 μm. I) Quantification of amylase+BrdU+ cells of control and Gnptab−/−
tissue in randomly sampled 20× fields at 5 days of cerulein injury.
Data information: **P < 0.01; ***P < 0.001 by t‐test with unequal variance; data represented as
mean ± SEM of the means from 10 low‐power fields each from 3 independent experiments.
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Figure A4.16: Lysosomal activity is required to re‐activate mTORC1 following HD
tamoxifen injury.
A) At peak metaplasia stages in Gnptab−/+ tissue, pS6 is re‐expressed throughout the stomach
epithelium, including intense staining within the pit and metaplastic base. Scale bars: 50 μm;
pullout, 25 μm. B) In Gnptab−/− tissue, pS6 is not reactivated in the base, indicating lysosomal
activity is required for mTORC1 re‐activation at later stages following injury. Boxed regions are
shown at higher magnification at right with a representative base (in which pS6 remains inactive
without lysosomal activity) outlined by dotted line. Lysosomal activity appears dispensable for
pit cells (at top of gastric unit) mTORC1 activity. Scale bars: 50 μm; pullout, 25 μm.
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In the pancreas, there was a similar defect in both BrdU (Figure A4.15G and I) and Sox9 (Figure
A4.15H). The remnant acinar cells that remained in Gnptab−/− mice following 2 weeks of
cerulein treatment expressed E‐cadherin and low levels of amylase but were not positive for
other mature acinar nuclear markers like GATA4 or metaplasia markers like CK8/18 (Figure
4.17).

Figure A4.17: Gnptab−/− acinar cells maintain mature markers following injury.

Finally, to determine whether the dropout of gastric bases was due to increased cell death in the
absence of lysosomal hydrolase activity, we examined tissue for cleaved caspase 3. In wild‐type
mice (either with or without rapamycin), we did not detect substantial apoptotic death of the
chief cells, consistent with our previous observations that death in HD‐Tam is essentially
confined to parietal cells (Huh et al, 2012; Radyk et al, 2017; Figure A4.1). In Gnptab−/− mice,
however, we frequently observed multiple cells in some bases of gastric units that were
undergoing apoptosis (Figure 4.18). Thus, in stomach, aberrant autodegradative function leads
either to stalling of the chief cell reprogramming process or cell death. In pancreas, we observed
205

a pattern of scattered apoptosis of acinar cells in wild‐type mice ±rapamycin following cerulein
treatment. Loss of GNPTAB did not seem to affect this basal rate of death, which is consistent
with the survival of many acinar cell remnants out to 2 weeks, as discussed above.

Figure A4.18: Loss of GNPTAB increases apoptosis of chief cells following injury.

A4.9 Discussion
There has been a recent burgeoning of examples of cellular plasticity in tissue in response to
injury, not to mention a growing, already large literature on in vitro systems for reprogramming
cells back to progenitors. The instances of such plasticity span numerous species and nearly all
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tissues. Despite the breadth of examples of cellular reprogramming, studies focusing on the
specific molecular mechanisms responsible for the process are still relatively scant. This is
particularly true in studies of cells in tissue, likely because investigators have focused more on
the outcome of cellular reprogramming—regeneration or tumorigenesis—than on the stepwise
mechanisms differentiated cells use to contribute to those outcomes. Here, we have speculated
that there could be a shared cellular program that governs the many diverse examples of
differentiated cells changing their fate to facilitate repair. There have been many terms that either
focus on the outcome of the program or are overly broad: “dedifferentiation”,
“transdifferentiation”, “reversion”, “reprogramming”. We now propose “paligenosis” as a
specific term describing the cellular process differentiated cells use to re‐acquire regenerative
capacity. We highlight that paligenosis may be a conserved cellular process with shared
molecular and cellular regulation akin to other basic cellular processes like mitosis and
apoptosis.
To support our assertion that there may be a shared program for recruiting differentiated cells,
we have analyzed the cellular and molecular changes that occur during injury‐induced
reprogramming in two distinct organs. Upon injury, both the stomach and pancreas have the
capacity to repair tissue damage through the recruitment of fully differentiated cells into a less
differentiated, proliferative state to replenish cell numbers. This pattern of change in cell
phenotype is known to pathologists as metaplasia. We find that the cellular and molecular
changes that characterize cells undergoing such metaplastic injury response in either stomach or
pancreas are remarkably similar. Specifically, we found that acutely following injury,
autodegradative pathways increase alongside a decrease in mTORC1 activity (Figure A4.19). As
the injury progresses, we observed the induction of genes that are known to occur during
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metaplasia followed by the rise of mTORC1 activity and increased proliferation (Figure A4.19).
A similar pattern of changes in mTORC1 activity relative to metaplasia and the differentiated vs.
proliferative phenotype was observed in human patients. We found that mTORC1 activity was
specifically required for progression through S‐phase. Previous literature has also shown that
mTORC1 activity is critical for S‐phase progression of cancer cells following DNA damage, as
mTORC1 is needed to generate pyrimidines in a nutrient‐poor environment (Robitaille et al,
2013; Silvera et al, 2017; Zhou et al, 2017). mTORC1 activation is also needed for yeast to pass
through G1 into S‐phase as they emerge from quiescence (Dhawan & Laxman, 2015;
Moreno‐Torres et al, 2015). Using an animal model of lysosomal dysfunction, we uncovered that
normal lysosomal function after injury is required for cell phenotype and gene expression
changes associated with metaplasia. In pancreas, where constitutive stem cells are not available
for regeneration, loss of either autodegradative function or mTORC1 activity compromised
eventual organ repair.

Figure A4.19: Schematic model of shared program: paligenosis.
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Data presented in the paper suggest that differentiated cells revert to a regenerative/proliferative
state via a program involving stepwise progression through three stages. Progression can be
blocked at intervening checkpoints. The potential context‐independent nature of this sequence of
structural‐energetic changes suggests that it is available to differentiated cells in multiple organs
and species. We have termed this general program of differentiated cells acquiring regenerative
potential “paligenosis”.

Recent advances in the understanding of how mTORC1 is controlled have described a role for
the lysosome as an activator of the pathway through the release of nutrients like key amino acids
(Zoncu et al, 2011). Thus, our current working model is that due to injury‐induced stress,
autodegradative pathways are upregulated, and flux increases. The activation of autodegradative
pathways appears to act in parallel with loss of the mature gene regulatory network, as forcing
expression of key mature‐cell‐promoting transcription factors like MIST1 (BHLHA15) impairs
the injury/repair process (Direnzo et al, 2012; Lo et al, 2017). MIST1 controls a cassette of genes
that help direct a cell's energy toward secretion and away from lysosomal activation and
autophagy (Mills & Taghert, 2012). We reason, as did Adami over a century ago, that to convert
from the differentiated state (structurally complex, energetically active) to the replicative state
(structurally simple, energetically active), cellular energy use must be repurposed as an
autodegradative program is activated to convert differentiated cell structure into building blocks
for replication. The release of nutrients through the lysosome is sensed in cells during the
autodegradative phase, resulting in reactivation of mTORC1, which, once the cell has reached
sufficient energy levels, subsequently facilitates cell cycle progression and growth to replace
cells lost during the injury.
Pancreatic adenocarcinoma and—to a lesser extent—gastric adenocarcinoma are commonly
driven by oncogenic mutations in Kras. In mouse models in both the pancreas (Hingorani et al,
2005) and stomach (Choi et al, 2016), KrasG12D mutations, in concert with tissue inflammation,
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promote changes in gene expression and cell phenotypes resembling injury‐induced metaplasia.
In the pancreas, genetically disabling autophagy in the context of K‐Ras mutations prevents
K‐Ras from driving high‐grade lesions (Rosenfeldt et al, 2013). Furthermore, cells unable to
phosphorylate S6 in the context of activating K‐Ras mutations also exhibit less pancreatic cancer
progression (Khalaileh et al, 2013). A similar critical role for mTORC1 downstream of another
key driver oncogene pathway, Wnt activation mediated by APC mutation, has been described in
intestinal carcinogenesis (Morran et al, 2014). Thus, tumorigenesis in diverse tissues may also
involve modulating lysosomal activity and mTORC1, similar to what we observe in our injury
models here. Other pathways downstream of K‐Ras, such as PI3K/Rac1 signaling (Heid et al,
2011; Wu et al, 2014), also play similar roles in injury‐induced metaplasia.
If there truly is a shared cellular program, paligenosis, underlying the process of recruiting
mature cells to become regenerative cells, we would expect the general features we have
described here in stomach and pancreas to be recapitulated in many other tissues and species.
Obviously, it will be important to conduct new studies in other systems to begin to support that
assertion; however, we can at this point re‐examine the extant literature to determine whether
roles for lysosomes/autophagy and/or mTORC1 in the process of cellular reprogramming to a
regenerative state have previously been described. One such previous study, using a different
injury protocol, with the endpoint to determine the role of mTORC1 and autophagy in severity of
pancreatitis, similarly showed a pattern of early autodegradation followed by mTORC1
activation (Hu et al, 2015). The authors also found that rapamycin worsened severity of
pancreatitis. In liver, it has long been known that the earliest phase of hepatocyte response to
partial hepatectomy is massive activation of autophagy/lysosomes (Becker & Lane, 1965).
mTORC1 is required for the later stages of the process, when proliferation is maximal, consistent
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with observations we make in the current manuscript (Jiang et al, 2001; Nelsen et al, 2003;
Buitrago‐Molina et al, 2009; Espeillac et al, 2011). In kidney, the reprogramming process
involves mTORC1 (Kato et al, 2012), and we show here that mTORC1 activity is increased
specifically in the tubular cells, which are the cell population called back into the cell cycle to
regenerate damaged tissue. To our knowledge, lysosomes/autophagy has not been examined in
regenerating kidney. In mature glial cells that dedifferentiate following axonal injury, activation
of autophagy/lysosomes is a well‐established early event (Jessen & Mirsky, 2016). To our
knowledge, mTORC1 activity has not been examined in the process. Furthermore, in tissue
culture cellular reprogramming models to generate induced pluripotent stem cells, there is an
emerging literature that an early autophagy phase is followed eventually by mTORC1 activation.
Inhibition of either autophagy or prolonged inhibition of mTORC1 reduces reprogramming
efficiency (He et al, 2012; Wang et al, 2013; Wu et al, 2015). Hence, the stages and checkpoints
appear to be the same as the ones we examine in the current manuscript.
Thus, there are numerous reports indicating that the pattern we show here systematically of
autodegradation first, then mTORC1 activation may be universal. Moreover, teleologically, it
makes sense that a mature cell would first recycle cellular components required for physiological
function to use them as substrates for subsequent synthesis of components needed for
proliferation. In organs like the vertebrate pancreas or liver, where there are no constitutively
active stem cells, repair would likely depend in large part on paligenosis. In tissues with
constitutive stem cells, like stomach and intestines, the tissues would have the choice of
regenerating with either constitutive stem cells or paligenotic cells, depending potentially on
type, extent, and location of injury.
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Not all differentiated cells are likely to be able to undergo paligenosis. In the stomach, for
example, we have never observed this phenomenon in mature parietal cells (Huh et al, 2012;
Mills & Sansom, 2015). Cells that are constitutively undifferentiated and replicative like those of
the isthmus of the stomach or LGR5+ crypt‐base columnar cells should not need any stage of
paligenosis (Figure A4.19). They may acquire the building block nucleotides and amino acids
from the blood and/or extracellular environment, given that, by definition, their lack of
differentiation means they contain limited non‐nuclear components to recycle. Other cells, such
as mucous neck cells in the stomach or +4 cells in the intestine (van Es et al, 2012; Roth et al,
2012; Buczacki et al, 2013), may be able to respond to injury but are less well differentiated and
thus may be able to skip the autodegradative phase and go directly to the activating mTORC1
and cell division phase of paligenosis.
Paligenosis may be beneficial for its potential to provide lifelong tissue repair in adult organs,
but this capacity also seems inherently tied to increased risk for tumorigenesis. Chronic injury of
the type that repetitively induces paligenotic/metaplastic events has long been known to increase
risk for acquisition of mutations and progression to neoplasm. We have proposed that the reason
that risk increases with age is that cycles of paligenosis and subsequent redifferentiation allow
accumulation of mutations that may be stored in long‐lived, differentiated cells. Eventually, a
critical mutation may be unmasked during paligenosis, and a clone of cells that is unable to
redifferentiate arises. We have termed this the “cyclical hit” model of tumorigenesis (Mills &
Sansom, 2015; Saenz & Mills, 2018).
There are numerous questions that our current study prompts. What molecular events underlie
the competence to pass through each stage of paligenosis? What is the relationship between
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paligenosis and chronic injury, and what causes the increased risk for cancer? Why are some
cells able to undergo paligenosis, whereas others are not? We expect that the framework of
sequential phases of paligenosis that we introduce here, along with the potential checkpoints that
serve as molecular barriers between each stage of the process, can serve as a starting point for
future questions.

A4.10 Materials and Methods
Animal studies and reagents
All experiments using animals followed protocols were approved by the Washington University
School of Medicine Animal Studies Committee. WT C57BL/6 mice were purchased from
Jackson Laboratories (Bar Harbor, ME). Tg(Atp4b‐cre)1Jig/JcmiJ (Atp4b‐Cre) (Syder et al,
2004), Gt(ROSA)26Sortm4(ACTB‐tdTomato,‐EGFP)Luo/J (ROSA26mtmg) (Muzumdar et al,
2007), Gnptab (Gelfman et al, 2007),and LC3‐GFP (Mizushima et al, 2004) mice were
previously described. Gnptab mice were a kind gift from Dr. Stuart Kornfeld of Washington
University. Tamoxifen (5 mg/20 g body weight; Toronto Research Chemicals) was injected
intraperitoneally (IP) daily for 2–3 days to induce maximal gastric injury (Huh et al, 2012; Saenz
et al, 2016). Tamoxifen was prepared by first dispersing in 100% ethanol by sonication and then
emulsifying in sunflower oil (Sigma‐Aldrich) 9:1 (oil:ethanol). Pancreatitis was induced by 6
hourly IP injections of 50 μg/kg (in 0.9% saline) cerulein (Sigma‐Aldrich) given every other day
for up to 2 weeks. Mice were sacrificed 24 h after the final cerulein injection. Rapamycin (60
μg/20 g body weight; LC Laboratories) was injected IP in 0.25% Tween‐20, 0.25% polyethylene
glycol in PBS for 3–7 days prior to starting and throughout injury time course. Tunicamycin
213

(Carlisle et al, 2014) and two‐thirds partial hepatectomy (Blanc et al, 2010) injuries were
performed as previously described. Mice were given an IP injection containing
5‐bromo‐2′‐deoxyuridine (BrdU; 120 mg/kg) and 5‐fluoro‐2′‐deoxyuridine (12 mg/kg) in sterile
water 90 min before sacrifice for all BrdU labeling experiments.
For parietal cell isolation, stomachs were harvested and washed several times with PBS. The
forestomach and antrum were carefully removed and the remaining corpus minced with a razor
blade. The tissue was mechanically dissociated using a 50 μm Medicon (Beckman) for two 30‐s
pulses. Chunks of tissue were further dissociated by incubating in 10 ml HBSS with 5 mM
EDTA and 1 mM DTT with vigorous shaking for 1 h at 37°C, and then, the solution was run
through a 100‐μm filter. Single cells were allowed to rest at 37°C, while filtered chunks were
incubated in 10 ml RPMI 1640 with 5% BSA (Sigma) and 1.5 mg/ml Dispase II (Stem Cell
Technologies) with vigorous shaking for 1.5 h at 37°C and then filtered again. Dissociated cells
were pelleted and washed with cold HBSS three times and then resuspended in PBS with 1%
BSA and 5 mM EDTA. Cells were sorted into a parietal cell population (GFP) and all remaining
cells (tdTomato) using a MoFlo FACS machine (Dako/Cytomation)
Imaging and tissue analysis
Mouse tissues were immediately excised and flushed with phosphate‐buffered saline and fixed
overnight in 4% paraformaldehyde in PBS. Tissues were washed, embedded in 3% agar, and
then underwent routine paraffin processing. Sections prepared for immunofluorescence or
immunohistochemistry underwent standard deparaffinization and rehydration protocols, were
blocked in 5% normal serum, and left overnight with primary antibodies. Sections were washed
in phosphate‐buffered saline and incubated for 1 h with secondary antibodies and then washed
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prior to mounting. For antibodies used in this study, see Appendix Table S2.
Immunofluorescence images were taken on a Zeiss Apotome or LSM710 confocal (Zeiss).
Bright field images were taken on a Nanozoomer (Hamamatsu) whole slide scanner or DP70
microscope (Olympus). Counting of stomach cell populations and proliferation was done as
previously described (Burclaff et al, 2017), except for analysis of Gnptab−/− mice. To account
for frequent gland loss in the base of these mice, a different approach was taken. For chief cell
quantification (SOX9+ and BrdU+), 10 random, 20× fields were chosen in three Gnptab−/− and
three control animals, and chief cells scored in slides from SOX9 or BrdU immunostained
sections. For BrdU, distribution, the 10 fields were further subdivided into two rectangular
regions: a basal one 100 μm perpendicular and 450 μm parallel to the muscularis mucosa and a
region of the same size immediately adjacent and encompassing the neck of the gastric unit. All
BrdU+ cells were scored and the proportion in each zone calculated. Quantification of
proliferation in the pancreas was done by counting 10 randomly sampled whole 20× fields per
condition. Cathepsin D+ area was calculated by generating a region of interest around PGC+
zymogenic cell cytoplasms and using particle counting analysis in ImageJ (NIH) to calculate
Cathepsin D+ area relative to total cytoplasmic area. Tissue preparation and imaging for electron
microscopy was done as previously described (Ramsey et al, 2007).
Human tissue studies
Human gastric pathological tissue specimens were obtained with approval by the Institutional
Review Board of Washington University School of Medicine. Figure 3A is a representative
image from a qualitative analysis of 44 separate curated gastric clinical samples that have been
previously described (Lennerz et al, 2010; Radyk et al, 2017). The study of tissue microarray
cases included in this paper was also approved by the China Medical University First Hospital
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Institutional Review Board and Ethics Committee. This patient cohort was initially treated at the
China First Medical University, and routine standard of care specimens was obtained from
patients treated between 2005 and 2009. Tumor, metaplastic, and uninvolved normal tissue from
each patient was formalin‐fixed and paraffin‐embedded. Staining was scored on the following
scale: 0, no staining; 1, minimal staining; 2, moderate to strong staining in at least 20% of cells;
3, strong staining in at least 50% of cells. The scoring system was designed, and independently
verified, by a human pathologist.
Bioinformatics, microarray, qRT–PCR, and statistical analyses
For qRT–PCR and microarray analyses of mouse stomach ±rapamycin, two independent
experiments were run and a total of two to three separate mice and corresponding microarrays
were generated for each condition. All mice were harvested 3 days after first injection and
treated as per protocol in (Figure A4.1). Conditions were Veh‐Veh (rapamycin vehicle regimen +
3 days of tamoxifen vehicle), Veh‐Tam (3 days of rapamycin vehicle regimen + 3 days of
HD‐Tam), Rap‐Veh (rapamycin regimen, 3 days of tamoxifen vehicle); Rap‐Tam (rapamycin
regimen + 3 days of HD‐Tam). RNA for microarray and qRT–PCR analysis was isolated as
previously described (Lo et al, 2017). For microarray, samples were processed and hybridized to
Affymetrix Mouse Gene 2.0 ST per the manufacturer's instructions by the Washington
University Genome Technology Access Core (GTAC). GeneChips were analyzed with Partek
Genomic Suite 6.6 (Partek, Inc.) analysis software using default settings (Lo et al, 2017).
Mapping to Gene Symbols was done either via GSEA (Subramanian et al, 2005) or GenePattern
software (Reich et al, 2006). GSEA was done using default 3.0 settings. GMX files were made
using previously published microarray data in the case of laser‐capture micro‐dissected chief
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cells (Capoccia et al, 2013), generated de novo or acquired from GSEA molecular signatures
database. For the list of parietal cell‐specific genes generated de novo for the current manuscript,
flow cytometry was used to sort parietal cells and control cells into 500 μl RNA protect reagent
(Qiagen). RNA was isolated using the RNeasy Micro Kit (Qiagen) following the manufacturer's
instructions. Mouse Gene 2.0 ST Array (Affymetrix) was used to analyze gene expression, and
the gene set whose expression was enhanced at least eightfold (96 separate genes) in parietal
cells vs. control was determined by Partek. For primers used in qRT–PCR, see Appendix Table
S3. Statistics for cell counts and qRT–PCR were done by Student's t‐test (in the case of pair‐wise
analysis of significance) or ANOVA (if multiple conditions were compared). For determining
statistically significant differences among various conditions in ANOVA, the post hoc tests were
either Tukey's (for multiple crosswise comparisons of means) or Dunnett's (for comparisons of
multiple experimental samples to a single control). For the tissue microarray, a χ2 analysis was
performed.
Western blot
Approximately 100 mg mouse corpus stomach tissue was lysed in urea buffer (8 M urea, 1%
SDS, 150 mM Tris–HCl, pH = 7.0) with 1× protease/phosphatase inhibitor cocktail (Thermo).
Protein concentration was determined using the DC protein assay (Bio‐Rad). Protein (30 μg) was
separated using a 10% SDS–PAGE gel and transferred to PVDF membranes (Millipore).
Membranes were incubated overnight at 4°C with Rabbit polyclonal pS6 240/244 or 235/236
(1:1,000 diluted, CST) and Rabbit polyclonal beta‐tubulin antibody (1:1,000 diluted, CST) and
then incubated with infrared fluorescent dye‐conjugated secondary antibodies (LI‐COR
Biosciences). Protein signal intensities were normalized against a tubulin loading control for
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each sample. Fluorescent intensity values were determined and quantified on Western blots at
non‐saturating exposures using the ImageJ software. Statistical analysis with both antibodies was
done using ANOVA with a post hoc Dunnett's test.
Data availability
All analyzed microarray data have been deposited in NCBI GEO under accession GSE103570.
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